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A B S T R A C T
Manuka honey (Leptospermum scoparium) produced in New Zealand has
been shown to exhibit substantial antibacterial activity against a broad
range of pathogens causing wound infection, and is being used in wound
management with excellent results. This activity is due to both hydrogen
peroxide and non-peroxide components. Manuka honey, however, may not
be useful for treating bacterial gastroenteritis because the gastrointestinal
environment may be unfavourable to the antibacterial action, and because
a sufficiently high concentration for effectiveness may not be achieved.
The research in this thesis is set out to evaluate in vitro the efficacy of
manuka honey as an antibacterial agent against enterobacteria, taking into
consideration some factors that may be involved in the gastrointestinal
environment.
Because some gastrointestinal bacteria (Campylobacter spp., Helicobacter
pylori, Lactobacillus spp. and Bifidobacterium animalis subsp. lactis) are not
aerophilic, a cheap yet acceptable gas generating system alternative to the
commercial gaspack counterpart was sought for use in this study. Various
alternatives were compared for their performance. The spirits burn method
was chosen for cultivating microaerobes and some anaerobes because of
its comparable performance to that of commercial systems in terms of the
growth of bacterial species, and because of the ease of use and the low cost.
In the first part of this thesis, the susceptibility of gastrointestinal bacte-
ria against manuka honey was investigated by determining the minimum
inhibitory concentration (MIC) and minimum bactericidal concentration
(MBC) using a standardised manuka honey. Throughout the research, a
manuka honey with median level non-peroxide antibacterial activity (equiv-
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alent to that of 16.5% phenol) was used, except that Campylobacter spp.
were assayed with a more potent manuka honey equivalent to 29.4% phe-
nol. The measured sensitivity of bacteria showed that manuka honey is
significantly more effective than artificial honey (a mixture sugars as in
honey), indicating that osmolarity is not the only factor that is responsible
for the antibacterial activity of the honey. It was found that some species
of bacteria e. g. Campylobacter spp. are exceptionally sensitive to manuka
honey (both MIC and MBC are about 1% honey solution), whereas most
other gastrointestinal pathogens have MIC and MBC values in the range
5–10% honey other than Enterobacter and Pseudomonas which were in the
range 10–17%. Bifidobacterium, lactobacilli and enterococci appear to be
more tolerant to the honey (MIC: 9.36–14.29%; MBC: ≥13.3%) than most
other species are. The difference in efficacy between the honey with and
without hydrogen peroxide removed was also studied, and it was found
that both hydrogen peroxide and the non-peroxide components contribute
to the bacteriostatic and bactericidal activity of the honey.
Because oxygen is required for hydrogen peroxide to be produced in
honey, the role that oxygen plays in the antibacterial activity of manuka
honey was investigated by analysing the susceptibility data obtained under
both aerobic and anaerobic conditions using facultative anaerobes. Manuka
honey appeared to be a more potent bacteriostatic agent against most
species of bacteria in the absence of oxygen, whereas a relatively higher
concentration of manuka honey solution was required to kill some bacteria
under anaerobic conditions. This may partially be due to the atmosphere
having also affected the metabolism, and hence the growth, of bacteria.
Therefore, the activity of manuka honey would not necessary decline in the
intestinal environmental atmosphere.
To investigate how long it takes for manuka honey to kill bacteria,
time-to-kill studies were conducted by monitoring the survival of bacteria
iii
in manuka honey. It is found that it takes a 20% solution of manuka honey
with a medium-level activity more than 6 h to kill 90% of the cells of most
of the species tested if the bacterial cells are kept in contact with the honey.
This suggests that manuka honey is not rapidly bactericidal, and that it
is unlikely to be possible to fully eradicate a bacterial gut infection by
ingesting a small amount of manuka honey for a short period. It was found
that probiotics can survive in the 20% honey solution for more than 12 h.
The pharmacodynamics of the antibacterial activity of manuka honey
were studied to investigate the survival and the re-growth of bacteria after
they had been treated with honey. It was revealed that after being exposed
to manuka honey for a short term (1 h), the growth of most enteropathogens
is slowed for approximately 2–4 h before it gets back to a full rate. The
assays of this postantibiotic effect also showed that the latency in the re-
growth after being exposed to honey is not proportional to the MIC, MBC
or time-to-kill profiles.
Finally, the efficacy of manuka honey on bacteria was studied under
conditions simulating the environment in the stomach and intestines. The
tested bacteria were unable to grow under the acidic conditions as in
the stomach, so whether or not the honey had any antibacterial activity
under these conditions could not be determined. Under the conditions
simulating the intestinal environment, the results demonstrated that the
antibacterial activity of manuka honey is slightly decreased in the mildly
alkaline conditions of the intestine (pH 7.5). In the presence of pancreatin
and bile at the same pH, the activity of manuka honey was found to decrease
by more than 50%. This suggests that pancreatin and bile in the gut may
negatively affect the efficacy of the antibacterial activity of manuka honey
in vivo. This indicates that although ingested manuka honey may still have
some antibacterial action when in the gut, the antibacterial activity would
iv
be different from that which is usually examined with sensitivity studies
in vitro.
Gastroenteritis has generally been treated with oral rehydration solution
(ORS) that consists of carbohydrates and electrolytes. Manuka honey could
be used instead of the usual carbohydrate component of ORS and would
provide additional bioactivities such as antibacterial activity and stimulation
of growth of probiotics, which would make the honey rehydration solution
more beneficial to patients with gastroenteritis than is the traditional ORS.
After some initial investigation to find the most appropriate dosage and
frequency of doses, a clinical trial may be warranted.
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I N T R O D U C T I O N A N D L I T E R AT U R E R E V I E W S
This chapter first gives a general introduction to gastroenteritis, followed
by giving four parts of literature review - the human digestive system,
gastroenteritis and its associated bacteria, commonly used therapies and
their limitations, and the medical use of honey. The possibility is also
discussed that the gastro-intestinal environment may affect the antibacterial
activity of manuka honey, and therefore the in vitro activity may not reflect
the actual efficacy in gastro-intestinal infection.
Lastly, the intentions of this thesis, that the assessment of the sensitivity
of enteropathogenic bacteria to the antibacterial activity of manuka honey,
and the assessment of the effect of gastro-intestinal environmental factors
on the antibacterial activity of manuka honey, are introduced.
1
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Gastroenteritis is an inflammation in the gastrointestinal tract that
results in acute diarrhoea. In the world, millions of people are killed by
improperly treated gastroenteritis each year (Kasper et al., 2005), and it is
the leading cause of death among infants and children due to their impaired
immunity (King et al., 2003). Most infectious gastro-intestinal diseases are
known to be food-borne, i. e. invoked by ingesting “unfavoured” substances
by the host along with food or drink water. Generally these “intruders” may
not be able to cause disease as they would have to pass through a series of
defensive barriers provided by the digestive system before any symptom
can result.
1.1 The digestive system
This section first approaches an overview of the human digestive system,
then the symptoms of gastrointestinal diseases frequently reported are
reviewed. The content of this section is largely from Kasper et al. (2005) and
Pocock and Richards (2006).
The digestive system consists mainly of the mouth, pharynx, oesopha-
gus, stomach and intestines, with the accessory organs including the teeth,
salivary glands, liver, gallbladder and pancreas. The system assists the
movement of the ingested food, and at the same time secretes mucus and
digestive juices to digest the food into small molecules that can be absorbed
by the digestive tract into the bloodstream. Because of the chemical and en-
zymatic properties of the digestive juice, the digestive system also functions
as a part of the defensive system against the microorganisms in food.
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1.1.1 The mouth
The mouth is the entry for food and drink as well as for most microorgan-
isms. When a person is ingesting food, the salivary glands secrete saliva,
which mainly serves as a lubricant and also contains salivary α-amylase
(ptyalin), that starts digesting complex polysaccharides (e. g. starch and
glycogen) into glucose, maltose, maltotriose and dextrins. Saliva also con-
tains immunoglobulin A (IgA) and lysozyme. The latter acts on the cell walls
of some bacteria to cause bacteriolysis or death of the cells. Individuals who
lack functional salivary glands or in whom salivary secretion is impaired
due to medication or therapy may suffer from dental caries or some diseases
such as xerostomia. Approximately 1 500 ml of saliva is produced by the
salivary glands each day.
1.1.2 The stomach
After food is swallowed, it passes through the pharynx and oesophagus into
the stomach, where the food is temporarily stored and mechanically broken
down to small particles.
The stomach secretes gastric juice which begins the digestive process
of food in the body. Gastric juice is a mixture of salts, water, hydrochloric
acid, pepsinogen (pepsin) and an intrinsic factors that is essential for the
absorption of vitamin B12 (cobalamin) by the mucosal epithelial cells of the
lower ileum. In the stomach food is partially digested and most bacteria are
considered to be eliminated. Clinical trials have shown that the secretion
of gastric juice and its composition are related to the time that has elapsed
since the ingestion of food. There is little or no fluid in the stomach during
fasting whereas following meals, secretion of the constituents of gastric juice
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increases progressively over the next 90 min or so. Approximately 2–3 l of
gastric juice is secreted by gastric glands in adults each day.
The generation of gastric acid is driven by the H+/K+-ATPase pro-
ton pump system. It pumps hydrogen ions out of parietal cells by using
energy derived from the hydrolysis of ATP, whereas chloride ions leave
the cells either through a chloride channel in the secretory canaliculi, a
tubular structure formed on parietal cell when food enter the stomach, or
through a potassium-chloride symporter which transfers chloride through
the membrane.
The pH of gastric acid is about 1–3. The highly acidic environment
not only breaks down ingested food but also activates inactive pepsinogen
into pepsin, an endopeptidase which shows greatest proteolytic activity at
pH values below 3. HCl also aids the absorption of calcium and iron by
dissolving insoluble salts of these minerals.
The stomach is fairly elastic due to its smooth muscle on the fundus
and body of the stomach, and therefore is capable of accommodating a large
volume of food. It has a volume of about 50 ml when empty whereas this
can expand by approximately 80 times when it is fully distended.
To protect the stomach itself, the stomach creates a mucosal barrier
which is contributed to by several factors. Firstly, the mucosal epithelial
cells are tightly linked to each other, which prevent the gastric juice from
leaking into the underlying layers of the tissue. Secondly, the epithelial cells
and neck cells on gastric glands produce mucus that forms a thin layer of
protective barrier. This mucus is alkaline because it contains bicarbonate
and potassium secreted by the epithelial cells. Lastly, prostaglandin appears
to play an important role on the protection by means of increasing the
thickness of the mucus layer, stimulating the production of bicarbonate
and improving the supply of nutrients to any damaged mucosal area. It is
because of the viscous mucus that the lining of the stomach is not directly
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contacted by the corrosive gastric juice, and only limited components such
as alcohol and some drugs can pass through the mucus and be absorbed by
the stomach.
On the other hand, direct contact of gastric juice with the stomach
can result in inflammation of the underlying tissue, a condition known
as gastritis which may lead to gastric ulcers. This is mainly caused by
hypersecretion of hydrochloric acid or hyposecretion of the protective mucus.
Many chemicals including caffeine, nicotine and some anti-inflammatory
drugs alter the rate of acid and mucus production and this results in the
stimulation of ulceration. The detergent actions of regurgitated bile acids
or intestinal fluid may also break down the protective mucosal barrier. It
is now also known that Helicobacter pylori, an acid-resistant bacterium, can
adhere to gastric epithelial cells, destroy the mucus layer and thus cause
peptic ulcers.
1.1.3 The intestines
Chyme, the food partially digested in the stomach, enters the intestines,
which can be divided into the the small intestine and the large intestine,
or colon. The small intestine, a tube of about 4 metres long and 2.5 cm in
diameter, can be sub-divided into the upper, mid and lower area which
are called the duodenum (about 25 cm long), jejunum (1.5 metres long)
and ileum (2.5 metres long) respectively whereas the large intestine is sub-
divided into the ascending colon, transverse colon, descending colon, and
sigmoid colon. The ileum locates at the lower end of the small intestine
and it contains lymphoid tissue that protects the small intestine from the
invasion of microorganisms from the large intestine.
The small intestine is the major site of digestion and absorption. The
intestine has an extensive internal surface area due to numerous villi, 0.5–1.5
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mm high finger-like projections, in the wall and microvilli (roughly 1.0 µm
long and 0.1 µm in diameter) in the membranes of mucosal cells. Digestion
is completed in the small intestine, and water-soluble materials such as
simple sugars and amino acids are absorbed into the blood vessels in villi
whereas fats are absorbed into the lymph vessels.
The small intestine secretes intestinal juice (succus entericus) sponta-
neously when acidic or hypotonic chyme enters the duodenum. The juice
contains bicarbonate and mucus which neutralise the chyme and prevent
the acid and pepsin from damaging the duodenal mucosa. A decrease in
the secretion of mucus in the duodenum can result in the exposure of the
duodenal tissue to the erosive substances, and because the stimulation of
sympathetic nerve activity remarkably reduces the production of mucus, a
large proportion of peptic ulcers emerge in this site of the gut. The intestinal
juice also contains disaccharidases, peptidases and phosphatase that are
secreted by the small intestine itself, bile (containing bile salts, bile pigments,
cholesterol, lecithin, bicarbonate and mucus) from the liver, and digestive
enzymes (trypsin, chymotrypsin, elastase, carboxypeptidase, amylase, li-
pase, phospholipase A2, cholesterol esterase, DNAse and RNAse) from the
pancreas.
Depending on the constituents of chyme, the time chyme takes to pass
through the small intestine may vary from 3 hours to 10 hours. Meanwhile
the small intestine mixes chyme with digestive enzymes, absorbs the di-
gested products and moves the unabsorbed remains to the large intestine
by means of segmentation, peristalsis and the movements of villi. Besides
these actions, the small intestine also absorbs a large amount of fluid that
has been secreted by the salivary glands, gastric glands, liver (bile) and
pancreas (Figure 1.1).
The large intestine is approximately 1.3 metres long in adults and has
a greater diameter than that of the small intestine. It has several functions,
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Saliva
1.5 L/day
pH 6.8-7.0
Gastric secretion
2 L/day
pH 1.5-3.0
Intestinal secretion 
1.5 L/day
pH 7.0-7.4
Bile
0.5 L/day
pH 7.8-8.0
Pancreatic juice
1.5 L/day
pH 8.0-8.4
Ingest
(water/food)
~ 2 L/day
Small intestine
absorbs ~ 8 L/day
Colon absorbs
0.4-1.0 L/day
0.1 L/day
water excreted
Figure 1.1: The overall secretion and absorption of fluid in the gastrointestinal tract
(Modified from Pocock and Richards, 2006).
which include temporary storage of the semi-solid waste (faeces), secreting
mucus for lubricating the passage of faeces, and also absorbing most of the
remaining fluid and electrolytes. Albeit most water in chyme is absorbed in
the small intestine, there still remain a considerable amount of fluid in the
chyme that the colon may absorb by osmosis, and failure to do this results
in severe diarrhoea (Figure 1.1).
The caecum is a 7 cm-long blind-ended tube which is essential for
cellulose digestion in herbivores yet is not functioning in humans. Attached
to the caecum is the appendix which has the size of a finger. Again, this
has no known function in humans as the caecum. However, appendicitis,
the inflammation of the appendix, can be critical as its rupture may cause
peritonitis because of the presence of bacteria in the faeces. The colon is
about 1.2 metres long and from which most of the residue of digestion
would be eliminated within 72 hours, although the remainder of the waste
may stay in the colon for a longer term. As faeces are stored in the large
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intestine until excretion, and also because the anus is another entry point for
organisms, the large intestine is an important reservoir of both microflora
and pathogens.
Digestion in the large intestine is largely carried out by the microflora.
There exist a large number of bacteria that symbiotically colonise the large
intestine. Some bacteria synthesise certain vitamins such as B and K, while
some other microflora can ferment indigestible carbohydrates such as cellu-
lose and lipids. Short-chain fatty acids (SCFA) are amongst the by-products
of the fermentative metabolism and can be readily absorbed by the colon.
Short-chain fatty acid also appears to be an energy source of colonocytes.
Microflora in the large intestine also provide protection from gastrointesti-
nal infections by competing with pathogens or commensal microbiota and
prevent them from growth or reproduction in the colon (see Section 1.4.2).
Gastrointestinal diseases, however, may occur when the microbial ecology
is disturbed by the overgrowth of pathogenic organisms or by other factors
such as drugs and life style.
1.2 Gastrointestinal diseases
The main symptoms of gastrointestinal diseases are alteration in gastroin-
testinal function, including abdominal pain (e. g. heartburn and dyspepsia),
nausea and vomiting, indigestion and weight loss, diarrhoea, and gastroin-
testinal bleeding (Hasler and Owyang, 2005). Heartburn results from gastroe-
sophageal reflux of acid and causes a burning sensation in the oesophagus.
Dyspepsia refers to upper abdominal discomfort or pain. Some dyspepsia
patients experience ulcer-like symptoms such as epigastric burning or gnaw-
ing discomfort (Hasler and Owyang, 2005). Nausea is a subjective feeling of
a need to vomit, which is the oral expulsion of the upper gastrointestinal
contents. Diarrhoea is a frequent passage of watery stools. Its diagnosis
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is broad and its symptoms usually includes infection, inflammation and
malabsorption. Some diarrhoea or vomiting cause dehydration that may
be lethal if rehydration is not immediately accomplished. Gastrointestinal
bleeding may happen in any gut organ. Most upper gastrointestinal bleed-
ing is caused by ulcer disease, gastroduodentis and esophagitis whereas
the most prevalent cause of lower gastrointestinal bleeding is haemorrhoid,
inflammatory bowel disease or infectious colitis. The taking of non steroid
anti-inflammatory drugs (NSAIDs) is also a common cause of gstrointesti-
nal bleeding. Other non-specific symptoms include weight loss, chest pain,
fatigue and fever.
Any factors that may cause the digestive system to malfunction are likely
to trigger gastroenteritis, and these factors may be divided into biological
factors (bacterial, viral and parasite infections) and non-biological factors
(drugs, chemicals, toxins secreted by bacteria, improperly prepared food,
life styles etc.)
Bacterial gastroenteritis has a high incidence rate worldwide, and will
be reviewed in details in the next section (Section 1.3).
Viruses are another common source of the illness that results in acute
gastroenteritis. Viral infections among humans include rotavirus , norovirus,
sapovirus, astrovirus and adenovirus, rotavirus and norovirus being the
prominent cause of viral gastroenteritis (Parashar and Glass, 2005). The
infectious dose can be as low as 10–100 viral particles and the virus can
be found even in vomit. Although fever, vomiting and diarrhoea can last
1–8 days depending on the causal virus, and no specific antiviral agent
is available at this point, treatment is generally not required because the
disease is usually self-limited, and oral or intravenous fluid therapy is
usually advised if severe dehydration symptom occurs (Parashar and Glass,
2005).
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Whichever the cause is, the mechanism of gastrointestinal disease is
largely related to host-pathogen interactions (Asakura et al., 2007). In this
review only bacterial factors are considered.
1.3 Gastrointestinal pathogens
Bacterial gastrointestinal diseases are usually caused by, but not limited to,
infection by Gram-negative bacilli e. g. Enterobacteriacea, Campylobacter spp.,
Helicobacter spp. and related organisms, and Clostridium spp.
1.3.1 Salmonella spp.
The genus Salmonella is a Gram negative rod-like facultative anaerobe, and
is one of the most common food borne gastrointestinal pathogens. There are
three species of Salmonella (S. choleraesuis, S. typhi and S. enteritidis) and 1 700
serotypes and the nomenclature is complicated. Of the numerous serotypes,
DT104 is the most unusual one in that multiple antibiotic resistance is the
common characteristic of the strain (Poppe et al., 1998). The isolation of
DT104 has been rapidly increasing since 1990 in Britain (Gresham, 1996)
and is now commonly isolated worldwide (Ben Aissa and Al-Gallas, 2008;
Ethelberg et al., 2007; Fekete and Nagy, 2008; Kishima et al., 2008; Lee and
Lee, 2007; Little et al., 2008; Majtán et al., 2008; Molla et al., 2007; Murphy
et al., 2008; Notermans et al., 2005; Valdezate et al., 2007; Wasyl et al., 2006;
Weill et al., 2006). The generation of the resistant strain is thought to be due
to the increasing use of antibiotics in veterinary practice (Davis et al., 2002).
The symptoms and severity vary widely, but generally Salmonella can
cause gastrointestinal upset, enteric fever, specific localised infection, nausea,
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crampy abdominal pain, diarrhoea and sometimes vomiting (Balows et al.,
1991).
1.3.2 Enterobacteriacea
Enterobacteriacea includes Escherichia coli, Yersinia spp., Enterobacter spp. and
Shigella spp.
1.3.2.1 E. coli
There are numerous classes of diarrhoeagenic E. coli (Clarke, 2001). Accord-
ing to the pathogenic mechanisms, these can be classified into enterotoxi-
genic E. coli (ETEC), enterohaemorrhagic E. coli (EHEC), enteropathogenic E.
coli (EPEC), enteroinvasive E. coli (EIEC) and enteroadherent E. coli (EAEC).
ETEC may colonize the small intestine and produces a heat-labile (LT) and
heat-stable (ST) enterotoxin (Qadri et al., 2005). EIEC penetrates and multi-
plies within the intestinal epithelial cells and may resemble the symptom
caused by Shigellae (Blakelock and Beasley, 2003). EPEC causes diarrhoea
by adhering to the brush border of the small intestine but does not produce
LT or ST (Goosney et al., 2000). EHEC produces several toxins including
one that is related to Shiga toxin. E. coli O157:H7, having caused several
outbreaks, is the most common serotype of EHEC (Manning et al., 2008;
Nauschuetz, 1998). EAEC may adhere to HEp-2 cells, but its aetiology
is not well known yet (Blakelock and Beasley, 2003). Diarrhoeagenic E.
coli, particularly ETEC, may cause profuse watery diarrhoea, dehydration,
malnutrition, haemorrhagic colitis or haemolytic uraemic syndrome (HUS)
(Karmali, 2004).
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1.3.2.2 Yersinia spp.
Yersinia spp., especially Y. enterocolitica, usually cause diarrhoea and some-
times it may be difficult to distinguish from appendicitis until surgery or
ultrasonography is carried out, as it produces pain in the ileocecal area
(Balows et al., 1991). Because Yersinia can multiply within a wide range of
temperature (−1 to 45 °C) (Lake et al., 2004), yersinial enteritis can be caused
by oral transmission through raw milk or contaminated pasteurised milk,
raw meat or fish. Although rare, the ability to multiply at low temperature
has also caused transfusion-associated septicaemia (Roussos et al., 2001;
Tipple et al., 1990).
1.3.2.3 Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative aerobe that is a common cause of topical
wound infection. Gastrointestinal infection caused by the species has been
usually under-estimated (Qarah et al., 2008) but, in fact, it has caused several
diarrhoea outbreaks (Falcão et al., 1972; Kienitz, 1979; Porco and Visconte,
1999).
1.3.2.4 Enterobacter spp.
Enterobacter spp. rarely infect healthy bodies but cause diseases in hospi-
talised persons (Kasper et al., 2005). E. cloacae and E. aerogenes are the major
causes of Enterobacter infections, but Enterobacter sakazakii (now has been
re-classified as a new genus, Cronobacter; Iversen et al., 2008) emergence
through paediatric nutrition is occasionally reported (Friedmann, 2007;
Giovannini et al., 2008).
1.3.2.5 Shigella spp.
There are three major species of Shigella (S. sonnei, S. flexneri, Shigella dysente-
riae) and one minor species (Shigella boydii) that are relevant to Shigellosis,
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in which S. sonnei is the species that is responsible for most clinical cases.
There are four groups of Shigella spp. - group A, B, Q and D - that can be
distinguished by biochemical or serological criteria. Group D accounts for
most cases of Shigellosis, but all Shigella may produce heat-stable and heat-
labile enterotoxins, and mortality usually results from severe dehydration
(Blakelock and Beasley, 2003). The common symptoms include diarrhoea,
dysentery, bloody or mucoid stools, abdominal cramps, tenesmus, ulcera-
tion, inflammation and bleeding.
1.3.3 Campylobacter spp.
The genus Campylobacter is a curved or spiral rod-shaped gram-negative or-
ganism. This is a widespread zoonotic pathogen and has been recognized as
a leading cause of gastroenteritis worldwide. The prevalence of campylobac-
teriosis has been reported to outnumber that of enteritis caused by other
common food-borne pathogens such as Salmonella spp. or E. coli in several
developed and developing countries (Allos, 2001; Meldrum et al., 2006).
According to an annual report published by the Institute of Environmental
Science and Research (ESR) in 2008, New Zealand has the highest prevalence
of campylobacteriosis in the developed world (Institute of Environmental
Science and Research, 2008).
Campylobacter has an extremely low infectious dose, which may par-
tially explain the high incidence of food borne diseases despite the bacterium
being fastidious in respect of nutrition and atmosphere. Robinson (1981)
swallowed 500 cells of Campylobacter jejuni in 180 ml of pasteurised milk,
and the count of the organisms in faeces was examined to be at least 106
/g within two days. Abdominal cramp and diarrhoea containing mucus
also appeared on day 4 and lasted for the next three days in the trial. Wallis
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(1994) suggested a similar infective dose which can be as low as 800 cells to
initiate infection.
Another possible explanation for the high prevalence regardless of it
being fastidious is that the species may either form a protective biofilm on
its own, or colonise in biofilms formed by other microorganisms. Bacteria,
including Campylobacter spp., are known to form biofilms that provide supe-
rior protection from lethal or undesirable environment (Buswell et al., 1998;
Costerton et al., 1995). Campylobacter has been reported to show difference
in the potential to form biofilm from strain to strain (Gunther and Chen,
2009). Also, the persistence of Campylobacter spp. under environmental stress
varies among the types of biofilm formed (Joshua et al., 2006). Although not
well demonstrated with Campylobacter spp. yet, it is also possible that other
bacteria may promote the biofilm formation of the species, as has been seen
with other bacteria (Sasahara and Zottola, 1993).
Mostly campylobacteriosis is self-limited, and it can be treated with
fluoroquinolones if antimicrobial therapy is necessary. However, deaths have
been reported occasionally (Meyer et al., 1997; Peetermans et al., 2000) and
its linkage with Guillain-Barré syndrome (Ang et al., 2004) and abortion
(Smith, 2002) is also of great concern. Furthermore, although not having
been isolated yet in New Zealand (Institute of Environmental Science and
Research, 2008), antibiotic-resistant strains have been reported in developed
and developing countries (Delsol et al., 2004; Padungton and Kaneene, 2003;
Takayama et al., 2005). The increasing rate of resistance to antibiotics is
thought to be due to the over-use of antibiotics in veterinary treatment (van
Boven et al., 2003).
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1.3.4 Helicobacter spp.
Helicobacter pylori, or formerly Campylobacter pyloridis, is a Gram-negative
microaerobe that predominates in the stomach mucosa. This species was
originally reported by Warren and Marshall (1983) and was found to be
helical S-shaped. This organism is commonly found in gastric biopsy where
most organisms are unlikely to survive due to the acidic gastric juice. Re-
search has shown that Helicobacter pylori produces a urease enzyme which
metabolises urea into CO2 and ammonia which neutralises the acidity
around the cell so that it is not affected by the gastric acid (Dunn et al.,
1997). H. pylori induces a strong inflammatory response. Because of this
characteristic, H. pylori has been implied by the World Health Organization
(WHO) as a Group 1 carcinogen of gastric carcinoma (World Health Organi-
zation and International Agency for Research on Cancer, 1994) and is now
largely known as the major cause of peptic ulcer by the public.
Combinations of amoxicillin, clarithromycin, lansoprazole, metronida-
zole, tinidazole or bismuth are usually used for H. pylori eradication therapy
(Dunn et al., 1997; Erah et al., 1997). Nowadays triple therapy (amoxicillin,
clarithromycin and lansoprazole or bismuth) is approved by FDA due to
its high cure rate (of about 85%) and low relapse rate, albeit diarrhoea and
minor side-effects have also been reported (Dunn et al., 1997).
However the treatment of H. pylori with antibiotics is increasingly facing
complication lately. Some patients revealed symptoms of reactive arthritis
(Söderlin et al., 1999) or pseudomembranous colitis that are triggered by C.
difficile after the H. pylori eradication therapy (Kubo et al., 2006; Rai and Rai,
2002; Archimandritis et al., 1998; Nawaz et al., 1998; Teare et al., 1995; Lau
et al., 2001; Harsch et al., 2001; Roseveare et al., 1998; Awad et al., 1994).
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1.3.5 Clostridium difficile
Clostridium difficile is a commensal, endospore-forming Gram positive anaer-
obic bacterium that exists in the human intestine.
Despite the recent worldwide outbreaks of C. difficile colitis reported
(Canada (Eggertson, 2004; Loo et al., 2005; Pindera, 2007), North America
(Cookson, 2007), Europe (England (Anonymous, 2005; Katikireddi, 2005;
Smith, 2005), Belgium (Joseph et al., 2005), the Netherlands (van Steenbergen
et al., 2005; Kuijper et al., 2005, 2006) and Northern France (Tachon et al.,
2006)) and Japan (Komatsu et al., 2003)), this is actually not a new epidemic
enteropathogen. In fact C. difficile was first isolated in 1935 by Hall and
O’Toole (1935) who termed it “difficile” as it was difficult to cultivate and
isolate the species. It has been reported as the agent of antibiotic-associated
diarrhoea in humans in 1978 (Bartlett et al., 1978). Until the late 1900s it was
considered that antibiotic exposure, advanced age and long hospitalization
are the major factor of infection with C. difficile (Gerding, 1989; Fekety and
Shah, 1993; Kelly et al., 1994).
This organism is found resistant to most antibiotics used nowadays in-
cluding fluoroquinolones (Bartlett, 2006), primarily because of its endospore,
therefore humans that have been staying in hospital for long term are highly
likely to be colonised by the organism. With small number of the cells no
significant symptom or disease would be caused, but once the normal in-
testinal flora is disrupted by broad spectrum antibiotic therapy it overgrows
in the colon and produces toxin A (TcdA) and toxin B (TcdB). TcdA is an
enterotoxin and causes fluid accumulation in the bowel. TcdB, on the other
hand, is a cytotoxin and is extremely cytopathic (Poxton et al., 2001; Knoop
et al., 1993; Voth and Ballard, 2005).
Interestingly, the outbreaks after 2000 were found to be more frequent,
more severe and have higher rates of relapse than those reported in the late
chapter 1 introduction and literature reviews 17
1900s (Bartlett, 2006), and a highly virulent strain, designated BI/NAP1 or
serotype O27 (BI by restriction endonuclease analysis, NAP1 by pulsed-field
gel electrophoresis and O27 by polymerase chain reaction), was found to be
responsible for the majority of the outbreaks (Åkerlund et al., 2008). This
strain produces substantially more TcdA and TcdB than the usual strains
in vitro (Bartlett, 2006). It also produces a binary toxin which is an iota-like
toxin similar to that produced by Clostridium perfringens type E but the role
of the binary toxin in the pathogenesis is unknown (Voth and Ballard, 2005).
The disease is almost always restricted to the colon and the symptoms
vary in severity, from mild (diarrhoea, fever, decreased gut motility) to
extremely severe (fever, pain, toxic megacolon, leukemoid reactions, septic
shock, pseudomembranous colitis, hypoalbuminemia, leukocytosis, require-
ment of coloctomy or sometimes death) (Bartlett, 2006).
The emergence of C. difficile has potentially complicated the gastroin-
testinal disease treatment. To control the disease, patient isolation, contact
precautions, handwashing with soap and water rather than alcohol-based
hygiene and avoidance of the implicated antimicrobial agent(s) are sug-
gested (Bartlett, 2006). If antibiotic treatment is necessary, antimicrobial
agents with a low probability of causing C. difficile-associated diarrhoea
(CDAD) such as tetracycline, narrow-spectrum β-lactams, macrolides, sul-
fonamides, or if the symptoms are severe, oral vancomycin or metronidazole
are recommended (Bartlett, 2006). However, the antibiotic treatment of C.
difficile had been reported to have a high relapse rate of about 20%. Also
metronidazole and vancomycin would cause the overgrowth of vancomycin-
resistant enterococci (Al-Nassir et al., 2008) or metronidazole-resistant C.
difficile strain (Pépin et al., 2005; Musher et al., 2005), therefore an alternative
treatment may be urgently required to be developed.
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1.4 Gastroenteritis treatments
1.4.1 Oral rehydration solution
Generally, dehydration is the major risk factor for gastroenteritis, and it
is recommended to replace lost fluid and electrolytes promptly. WHO
recommends a simple oral rehydration solution (ORS) formula, which
consists of Na+ 75 mmol/l, K+ 20 mmol/l, Cl− 65 mmol/l, citrate 10 mmol/l
and glucose 75 mmol/l. Glucose assists the absorption of sodium (and
therefore water) in the small intestine; potassium and chloride replace the
lost ions due to diarrhoea and vomiting, and citrate balances the acidosis
due to diarrhoea and dehydration (World Health Organisation, 2006).
1.4.2 Probiotics
Although complementary and alternative medicines (CAM) are generally
not accepted or regularly used in mainstream medicine (Kasper et al., 2005),
some of them such as probiotics are actually relatively well researched and
increasingly used for internal disease control or prevention. Probiotics refer
to ‘live microorganisms which when administered in adequate amounts
confer a health benefit on the host’ (Food and Agriculture Organization
and World Health Organization, 2002). These gastrointestinal commensal
microflora have been suggested to accomplish beneficial effects to human
health by several mechanisms, although some are not well established yet.
Some suggested mechanisms include producing trace elements or antimi-
crobial agents, excluding the pathogenic organisms from colonising the gut
by competing for attachment sites or strengthening the barrier function,
restoring gastrointestinal barrier function, modulating the immune system
chapter 1 introduction and literature reviews 19
in the host, producing fermentation end products butyrate and propionate
that change intestinal pH, facilitating the conversion and uptake of dietary
components (vitamins) as well as transforming or excreting toxic substances
(bile acids, nitroseamines), and generating faecal bulk to reduce the expo-
sure time of the intestinal lumen to the toxic substances. (Louis et al., 2007;
Saxelin et al., 2005; Servin, 2004; Sullivan and Nord, 2002, 2005; Surawicz,
2003).
It is estimated that there are trillions of microbial cells with high di-
versity in the human gut (Ley et al., 2006), most of which are unable to
be successfully cultivated in vitro, and Bifidobacterium spp. and Lactobacillus
spp. are the most popularly used microorganisms for health promotion.
Bifidobacterium is an irregular non-sporing Gram-positive anaerobe and was
first isolated from human infants’ faeces (György, 1953). Pathogenicity is
rare among the genus Bifidobacterium and only Bifidobacterium dentium seems
to have pathogenic potential (Hillier and Moncla, 1991). Lactobacillus spp. is
a regular non-sporing Gram-positive facultative anaerobe and can usually
be found in wide range of food such as dairy products, meat, fish, grain,
sour dough, fruits, wine and fruits (Sneath and Holt, 1986). Like the genus
Bifidobacterium, this is a part of normal flora in the mouth, intestinal tract
and vagina of humans (Sneath and Holt, 1986). Some beneficial bacteria
have been used in the food industry for preventing the growth of spoilage
pathogens for centuries, and some bacteriocins such as nisin have also been
approved by FDA (Food and Drug Administration, 2001). McAuliffe and
Hill (2001) gave a thorough review regarding the properties of bacteriocin.
However, the utility of probiotics in treating gastroenteritis may some-
times be limited. Firstly probiotics may not survive the acidic gastric juice or
enzymatic intestinal juice if intaken orally, and consequently the probiotics
may have lost their viability to provide any bioactivity in the gastro-intestinal
tract. An increasing number of reports also shows that the use of antibiotics
chapter 1 introduction and literature reviews 20
usually eliminates the beneficial bacteria too and the ecological impacts can
last for up to 2 years (Bühling et al., 2001; Jernberg et al., 2007; Sullivan
et al., 2001; Witte, 2000). Once the microbiological ecology in the gut is
disturbed by external factors such as antibiotics, drugs or even stress, some
of the organisms may cause a bacterial gastrointestinal disorder which is
known as the antibiotic associated diarrhoea (AAD). One significant exam-
ple of antibiotic associated diarrhoea is C. difficile associated diarrhoea that
was described above (Section 1.3.5). Some antibiotics are also known to be
antagonistic to the action of bacteriocins (for example chloramphenicol is
antagonistic to nisin; Brumfitt et al., 2002).
Recent reports also show that probiotics are not free from risk and
some clinical studies even suggest that probiotics may be fatal. One of the
most significant reports was a well-designed randomised controlled trial
(RCT) held in the Netherlands in which Besselink et al. (2008) reported
a significantly higher mortality in the probiotics group than the placebo
group (24/152 cf. 9/144, p = 0.01). In the same report the investigators also
noted that there were 9 patients in the probiotics group who suffered bowel
ischaemia (8 of which were fatal) whereas there were none in the placebo
group. Probiotics septicaemia has also been reported in diabetic patients
(Rautio et al., 1999; Zein et al., 2008), short gut syndrome infants (De Groote
et al., 2005; Kunz et al., 2004) and a patient with ulcerative colitis (Farina
et al., 2001). Numerous examples are also given in a review by Boyle et al.
(2006). Interestingly, all reported probiotic bacteraemia occurred only in
immunocompromised individuals and sepsis associated with probiotics has
not been observed in healthy humans. One possibility is that adherence of
probiotics to the intestinal mucosa provokes a higher chance of translocation
and virulence in immunocompromised individuals than in healthy ones.
That is to say, the use of probiotics on some gastroenteritis patients may
adversely lead to or increase gastrointestinal damage.
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1.4.3 Antibiotics
As the symptoms of gastroenteritis are generally self-limited, and also that
the disease is also commonly caused by viruses against which antibacterials
are of no use, generally administration of antibiotics is neither necessary nor
recommended (King et al., 2003). Although in some severe cases antibiotics
may be considered for use to shorten the duration of infections (Kasper
et al., 2005), numbers of issues on the use of antibiotics, including wasting
resources on non-bacterial infection, have arisen during the last few decades.
One of the biggest issues is that the use of antimicrobial agents has
been largely associated with development of strains of bacteria resistant to
antimicrobial agents. Whilst MRSA and VRE are the resistant bacteria most
widely known by the public, there have been countless reports concerning
the emerging of the resistant strains of Salmonella, Campylobacter, Enterococci,
E. coli, Enterobacter and other bacteria (Dowell, 2004; Sharma et al., 2005;
Thakur and Gebreyes, 2005). This is especially of alarm to hospitalised
patients whose immune systems are usually in a weakened state and are
susceptible to nosocomial pathogens. The spread of antibiotic-resistant
organisms which results in outbreaks of nosocomial infections as well as
antibiotic associated diarrhoea has been repeatedly reported and reviewed
(Jones, 2001; Komatsu et al., 2003; Loo et al., 2005; McMullin et al., 2005;
Pong and Bradley, 2004).
The possible ecological impact of antibiotics therapy on the normal flora
in the gut is another concern, because antibiotics can cause disturbances in
the ecological balance between the host and microorganisms. Traditionally
the study of the ecological composition in faeces as well as on the effect of
antimicrobial agents on microorganisms have largely relied on cultivation-
based techniques, which are laborious and provide few information on
or poor view of the community. The recent advent of several molecular
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techniques based on 16S rRNA genes, on the other hand, have made the
investigation on the ecological impact of antibiotics on the human gastroin-
testinal microbiota in detail possible. Sjölund et al. (2003) found that all
enterococci isolated from patients who had received H. pylori eradication
therapy (clarithromycin, metronidazole and omeprazole) showed high-level
clarithromycin resistance due to the erm (erythromycin resistance methy-
lases) gene which persisted for 3 years after the treatment. Jernberg et al.
(2007) also investigated the long-term ecological impacts of clindamycin on
Bacteroides spp. by detecting the erm gene family in the faecal samples of
volunteers after 7-day clindamycin administration using rep-PCR (repetitive
sequenced based-PCR), real-time PCR and T-RFLP (terminal restriction
fragment length polymorphism), and found the antibiotic selective pressure
to be persisting for as long as 2 years after the termination of treatment.
However the effects of antibiotics on the gut microflora appear to be de-
pendent on several factors including the spectrum of the drugs, microbial
taxa, degree of absorption of the drugs, enzymatic/chemical inactivation
or interaction between gastrointestinal materials. Indeed, Dethlefsen et al.
(2008) reported that some microbial communities recovered to their pretreat-
ment state by four weeks after the end of ciprofloxacin treatment, whereas
others failed within six months. It also appeared that many antimicrobial
agents may suppress the growth of a part of microorganisms and increase
others during therapy (reviewed by Sullivan et al., 2001). In short, antibiotic
therapy can disturb the ecological balance in the gastrointestinal tract, and
either the positive or negative effect can remain for months to years.
Another controversial aspect of antibiotic usage to treat gastroenteritis
is that, to protect drugs from digestive gastric juice, proton pump inhibitors
(PPIs) e. g. omeprazole, lansoprazole, pantoprazole, rabeprazole and es-
omeprazole are usually given along with antibiotics (Robinson and Horn,
2003). All proton pump inhibitors suppress gastric acid secretion by blocking
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the gastric acid pump (H+/K+-ATPase). Although proton pump inhibitors
are widely used for the treatment of acid-related disorders e. g. peptic ulcers,
a few reports pointed out that the acid suppression would inadvertently
cause side-effects on the digestive system (Leonard et al., 2007). As reviewed
above (Section 1.1.2), gastric acid plays an important defensive role in the
digestion system, and therefore 5suppressing the acid secretion by adminis-
tering proton pump inhibitors may adversely increase the risk of bacterial
invasion in the gut.
To demonstrate the importance of gastric acid secretion, several studies
have been conducted to compare the viability of several bacteria in normal
and achlorhydric/hypochlorhydric stomachs. Giannella et al. (1972) noted
that bacteria in the normal human stomach were promptly killed within 15
min whereas they remained viable in the achlorhydric stomach for longer
than 1 hour. Gray and Trueman (1971) reported that patients with gastric
surgery had much more severe salmonellosis than those that did not have
gastrectomy. Similarly, Hornick et al. (1971) demonstrated that a much
higher threshold dose of Vibrio cholerae was required to induce diarrhoea in
healthy volunteers than the control group that was given sodium bicarbonate
to neutralise the gastric acid. In this study the threshold dose differed by
10 000 times. Dial et al. (2004) and Dial et al. (2006) also noted that the
use of proton pump inhibitors, which resulted in the lack of gastric acid,
may increase the risk of C. difficile associated diarrhoea. A meta-analysis
done by Leonard et al. (2007) showed that acid suppresion associated with
the increased risk of enteric infection caused by C. difficile, Salmonella spp.,
Campylobacter spp. and other microbes. The possibility of association of
suppression of acid secretion in the stomach with an increased risk of acute
gastroenteritis and community-acquired pneumonia was also suggested
(Canani et al., 2006; García Rodríguez et al., 2007). Additionally, Youssef et al.
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(2005) reported a rare side-effect, acute pancreatitis, occurring in a patient
after being treated with omeprazole to decrease acidity in the stomach.
Given that antibiotic therapy reveals several shortcomings, it is necessary
to seek alternative therapy for treatment of gastrointestinal infection.
1.5 Honey - a “re-discovered” therapy
This section reviews the use of honey, now considered to be an “alternative
medicine” but which has been used since the time of the ancient Egyptian,
the Hebrew kingdoms, and historically in China, India, Greece, Rome and
many other nations (Crane, 1979). Emphasis in this section is placed on the
antibacterial properties of honey.
The use of honey for treating gastroenteritis, peptic ulcers or gastritis
can be traced back to the ancient era. The Muslim prophet Mohammed
(Al-Bukhari, 1976) and the Roman physician Celsus (Celsus, (c.25 A.D.)
1935) used honey as a cure for diarrhoea. The use of honey on treating gas-
troenteritis was also recorded in ancient China. Other countries, especially
Russia and Arabic countries, also have been traditionally using honey as an
elixir for treating upper intestinal dyspepsia (Molan, 1999).
Honey is produced by bees from the nectars they collect from flowers.
When a bee collects nectar from flowers, it secretes into it enzymes from
its pharyngeal gland. The nectar is then dehydrated and matured in the
honey combs as the stored dietary energy source of the bees. Various kinds
of honey have been produced in the world and the property of the honey
usually reflects that of the floral source. Crane (1979) produced a thorough
review on honey in which she noted that the medical literature of honey may
be traced back to as far as 2000 BC. Crane (1979) also noted that in England
and the Soviet Union honey by itself was used as a surgical dressing for
open wounds, burns, and septic infections in the mid-20th century. It is also
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of interest to note that a clinical trial in Switzerland revealed that honey
was useful for easing the sickness after radiation treatment (Buman, 1953).
In the Chinese Encyclopaedia (1727) it is recorded that honey is also used in
ancient China for various diseases (Crane, 1979).
1.5.1 Composition and properties of honey
Honey is a complex material but is primarily a saturated or super-saturated
solution of sugars which largely consists of glucose and fructose (84%)
and the high percentage of sugars makes it of high osmolarity. Although
present in much lesser quantities than glucose and fructose, honey also
contains other carbohydrates including disaccharides (sucrose and maltose)
and oligosaccharides which seem to be vary depending on the floral source
of the honey (Molan, 1996).
Besides carbohydrates honey also contains a number of enzymes. Some
of the most significant enzymes in honey are glucose oxidase, amylase
and invertase, which appear to originate from honeybees (Molan, 1992a).
Glucose oxidase has been of particular significance as this is responsible for
the generation of gluconic acid and hydrogen peroxide, which are mainly
responsible for the antimicrobial activity of honey (see Section 1.5.2). Other
minor enzymes including catalase (Dustmann, 1971) and acid phosphatase
(White, 1975) are also found in some honeys but these are likely to be
derived from the pollens and nectar of plants.
Honey contains other constituents (White, 1975). These include vitamins
A, the B group of vitamins, and vitamins C, D, and E, mineral salts, organic
acids, proteins, amino acids, lipids, hydroxymethylfurfuraldehyde (HMF)
and other minor substances that contribute to honey colour, aroma and
flavour, although these are relatively less in significance in the daily diet
because of their low concentrations. Interestingly, hydroxymethylfurfuralde-
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hyde may be formed by the decomposition of fructose in the presence of
acid and this was usually taken as the evidence of the addition of invert
sugar. Research showed that even fresh honey contains a small amount of
hydroxymethylfurfuraldehyde, which increases with time when the honey is
stored at room temperature. The increase in hydroxymethylfurfuraldehyde
level is retarded when stored in a cool environment (White et al., 1964).
1.5.2 The antibacterial activity of honey
Honey has been used in medical treatment as an antiseptic since ancient
times until antibiotics were invented. However, the nearly unlimited use of
antibiotics has led to the emergence of antibiotic-resistant microorganisms
that have made the treatments more difficult than ever, and this has also
made humans to seek alternative therapies such as honey to treat the
diseases. Numerous research studies have shown that honey is effective
against a wide range of microorganisms including MRSA and VRE (Molan,
2008b).
Several mechanisms of antimicrobial activity in honey are discussed
below.
1.5.2.1 Osmolarity and water activity
As described previously, the process by which bees make honey and the
high content of sugars make it highly osmotic. Most water molecules in
honey interact with the sugars and the proportion of “free water”, described
as the water activity (aw), is too low for microorganisms to utilise when
honey is not diluted. Generally honey is reported to have aw of 0.56–0.62
(Bogdanov et al., 1987; Rüegg and Blanc, 1981; Tysset et al., 1980) while
most organisms have a minimum aw of 0.9–1.0 (Rizvi, 2005) for growth and
can not survive in the lower aw environment. To reach the aw above which
chapter 1 introduction and literature reviews 27
most microorganisms can survive, a typical honey would need to be diluted
down to about 2–12% (based on the reasoning that the concentration is
proportional to −log aw; Scott, 1957). Although a few microorganisms such
as osmophilic yeasts can live in honey with an unusually high water content
and result in spoilage of the honey, undiluted ripened honeys generally
have an aw which is too low for any species to survive (see Table 1.1).
Table 1.1: Water activity and growth of microorganisms in food. Source: Adopted
from Rizvi (2005).
Range of aw Microorganisms generally inhibited by lowest aw in
this range
0.20–0.50 No microbial proliferation
0.60–0.65 Osmophilic yeasts (Saccharomyces rouxii), a few
moulds (Aspergillus echinulatus, Monoascus bisporus)
0.65–0.75 Xerophilic moulds (Aspergillus chevalieri, Aspergillus
candidus, Sallemia sebi), Saccharomyces bisporus
0.75–0.80 Most halophilic bacteria, mycotoxigenic aspergilli
0.80–0.87 Most moulds (mycotoxigenic penicillia), Staphylococ-
cus aureus, most Saccharomyces (bailli) spp., Debary-
omyces
0.87–0.91 Many yeasts (Candida, Torulopsis, Hansenula), Micrococ-
cus
0.91–0.95 Salmonella, Vibrio parahaemolyticus, Clostridium bo-
tulinum, Serratia, Lactobacillus, Pediococcus, some
moulds, yeasts, (Rhodotorula, Pichia)
0.95–1.00 Pseudomonas, Escherichia, Proteus, Shigella, Klebsiella,
Bacillus, Clostridium perfringens, some yeasts
However, osmolarity may not be useful from an antimicrobial viewpoint
as the sugar component would readily be diluted by body fluid if ingested
or by exudate if used as a wound dressing. Also the sugar content in honey
can be rapidly absorbed in the gastrointestinal tract. Once honey is diluted,
the water activity rises and the osmolarity is no longer inhibitory to the
microorganisms.
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1.5.2.2 Acidity
Honey is characteristically acidic, with an average pH between 3.2 and 4.5
(White, 1975) which is too low for most organisms to survive as the optimal
pH for most organisms is between 7.2–7.4 (Sneath and Holt, 1986) and the
viability largely declines as the acidity rises. Although several organisms
can survive in relatively acidic conditions (e. g. E. coli at pH 4.3, P. aeruginosa
at pH 4.4 and Salmonella spp. at pH 4.0; Thimann, 1963, the pH of undiluted
honey is usually too low for the microorganisms to survive. The acidity of
honey is largely due to the gluconic acid that exists in honey as shown in
the reaction equation 1.1.
However, like the osmolarity described previously, acidity is unlikely to
be a key factor that is responsible for the antimicrobial activity. The quantity
of gluconic acid is quite low and the pH would be raised by dilution of honey
with body fluid which contains buffers (0.17–1.17%; White, 1975). Research
has shown that a buffered gluconolactone/gluconic acid solution that was
equivalent to 25% honey solution did not reveal detectable antibacterial
activity against Staphylococcus aureus in an agar diffustion assay whereas
12.5% honey solution gave much higher activity (Molan and Russell, 1988).
Other research studies have shown that a remarkable antibacterial activity
can be detected even after honey has been neutralised, which suggests that
the level of antimicrobial activity is not linearly correlative to the pH (Molan,
2008b).
1.5.2.3 Phytochemical compounds
Several phytochemical compounds have been isolated from honey by many
researchers. These include benzyl alcohol, pinocembrin, terpenes, 3,5 -
dimethoxy - 4 - hydroxybenzoate (syringic acid), methyl 3,5-dimethoxy-
4-hydroxybenzoate (methyl syringate), 3,4,5-trimethoxybenzoic acid, 2-
hydroxy-3-phenylpropionate, 2-hydroxybenzoate and 1,4-dihydroxybenzene
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(Russell et al., 1990). However, the quantity of these compounds in honey is
too low to account for the significant antimicrobial activity.
1.5.2.4 Hydrogen peroxide
Hydrogen peroxide is one of the dominant antibacterial substances that exist
in honey. When a bee collects nectar from flower, it secretes glucose oxidase
from its hypopharyngeal gland into the nectar to assist the formation of
honey from the nectar. Through the activity of this enzyme, glucose in the
honey is transformed into gluconic acid and hydrogen peroxide as shown
in the reaction equation below (Molan, 1995):
Glucose+H2O Glucose oxidase−−−−−−−−−→
O2
Gluconic acid+H2O2 (1.1)
Hydrogen peroxide is an effective antimicrobial against a number of
microorganisms, and is commonly used as an antiseptic. It is reported that
some microorganisms, mainly Lactobacillus spp., produce hydrogen peroxide
for help competing against other microorganisms (Chaveerach et al., 2004;
Voravuthikunchai et al., 2006).
There are several drawbacks when hydrogen peroxide is used as an
antiseptic. First, hydrogen peroxide is readily degraded into oxygen and
water when catalase exists. As catalase exists in plasma and in body tissues,
which would destroy hydrogen peroxide, the efficacy of the antiseptic may
be lost in a short time. Second, hydrogen peroxide is an irritant to body
tissues and the patients may feel uncomfortable. Third, reactive oxygen
species (ROS) derived can do harm not only to bacterial cells but to tissue by
breaking down proteins, nucleic acids and cell membrane lipids, and also
by activating proteases in the wound tissues (Ossanna et al., 1986; Peppin
and Weiss, 1986; Turner, 1983; Weiss et al., 1985). Therefore using hydrogen
peroxide as an antiseptic is unfavourable.
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It is interesting to note that undiluted honey has a negligible level
of hydrogen peroxide, and even if honey is diluted the concentration of
hydrogen peroxide generated is still far lower than the 3% solution of
hydrogen peroxide typically used as an antiseptic (Lineaweaver et al., 1985).
An explanatin to this is that the glucose oxidase in honey is inactive when
the honey is undiluted. The enzyme reveals highest activity at pH 6.1 and
a good activity between pH 5.5–8, low activity at below pH 5.5 and zero
at pH 4 (Schepartz and Subers, 1964). Indeed, Bang et al. (2003) reported
that the concentration of hydrogen peroxide in honey increased once it was
diluted, and reached a maximum level of 3.65 mM when the honey was
diluted down to 50% (v/v), but this was still far lower (242-fold) than in
the 3% hydrogen peroxide solution used as an antiseptic. Interestingly yet,
it has been found that low levels of hydrogen peroxide is more effective
when expose continuously to bacteria than when applied as a bolus (Pruitt
and Reiter, 1985), which suggests that the continuously generated hydrogen
peroxide caused by glucose oxidase in honey is in fact more antibacterial
than the low concentration could have suggested.
It must be noted that hydrogen peroxide in honey seems to reveal higher
antibacterial activity than hydrogen peroxide alone, which suggests that
some indigenous substances in honey would raise its activity. Miller (1969)
and Roos and Balm (1980) added 0.1 mM ascorbic acid and metal ions in
a hydrogen peroxide solution and found that the bactericidal potency of
hydrogen peroxide increased. In another study done by Waites et al. (1979)
it was shown that hydrogen peroxide was more sporicidal when 10 mM
copper was added. McCulloch (1945) also showed that 0.83 mM iron, copper,
chromium, cobalt or manganese increased the potency of hydrogen peroxide
10-fold. As the antibacterial action of hydrogen peroxide is largely achieved
via oxygen free radicals rather than by hydrogen peroxide itself (Turner,
1983), it is possible that the synergistically enhanced antimicrobial potency
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of hydrogen peroxide being reported is due to the catalytic action of the
ions that potentialised the production of the damagingly reactive hydroxyl
free radical species.
Equation 1.1, however, also suggests that the gastrointestinal environ-
ment may be unfavourable to the antibacterial activity in honey that is
due to hydrogen peroxide. Oxygen is needed for hydrogen peroxide to be
produced by glucose oxidase activity, whereas oxygen is not available in the
intestines. Although glucose oxidase is stable against digestion by protease
activity in the gut and intestine (Stecher et al., 1968), it may be denatured by
the low pH in the stomach (Keilin and Hartree, 1948). That is, it is possible
that the actual antibacterial activity of honey in the gut might not be as
significant as that observed at the bench (Adebolu, 2005; Al-Waili et al., 2005;
Mundo et al., 2004) because hydrogen peroxide production could have been
at least impaired (although hydrogen peroxide having been accumulated in
diluted honey before it entered the gut could be of some effect).
1.5.2.5 Non-peroxide component
Several researchers have shown that beside hydrogen peroxide there exists
non-peroxide antibacterial activity in some honeys. In these studies the
authors noticed that some honeys exhibited antibacterial activity even if
the honeys were heated to inactivate glucose oxidase (Gonnet and Lavie,
1960; James et al., 1972; Molan and Russell, 1988; Roth et al., 1986) or treated
with catalase (Adcock, 1962; Allen et al., 1991a,b; Hodgson, 1989; Molan
and Russell, 1988; Roth et al., 1986) to destroy the hydrogen peroxide in the
honeys.
Specifically in some manuka honey (Leptospermum scoparium) produced
in New Zealand there exists a substantial antimicrobial activity that is
not destroyed by catalase (Allen et al., 1991a,b). Much research has been
done on the non-peroxide antibacterial activity of manuka honey and it has
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been found that the activity is more stable than is the antibacterial activity
due to hydrogen peroxide (not destroyed by light and heat). It actually
increases with time at room temperature (Peter Molan; personal commu-
nication). However, it is rapidly inactivated in an alkaline environment.
As this unusual non-peroxide activity only exists in manuka honey, Prof.
Peter Molan at the University of Waikato termed this activity as the Unique
Manuka Factor (UMF). The non-peroxide activity of manuka honey has
revealed siginificant efficacy against wide range of organisms, including the
antibiotic-resistant organisms MRSA and VRE that are otherwise difficult to
eradicate (Cooper et al., 2002a; Natarajan et al., 2001).
It should be noted that this non-peroxide antibacterial activity exists
only in some manuka honey. Several possibilities have been suggested to
explain the variation in the activity of manuka honey, and these theories have
recently been thoroughly examined by Stephens (2006). After investigating
several possible biological factors (animal, plant and fungal associations)
and non-biological factors (location of sites and climate), he concluded that
some manuka honey had been diluted by nectar collected from other flora
species by honeybees. In some manuka honey samples it was estimated by
measurement of thixotropy that they contained less than 30% Leptospermum
nectar, which renders the non-peroxide antibacterial activity too low to be
measured in the agar diffusion assay of Allen et al. (1991a).
1.5.2.6 Methylglyoxal in manuka honey
While this project was progressing, Mavric et al. (2008) published the pro-
posal that methylglyoxal (MGO) is the substance responsible for the non-
peroxide antibacterial activity of manuka honey. At the same time Adams
et al. (2008) used HPLC to isolate the non-peroxide antibacterial activity in
manuka honey and proved that it was methylglyoxal.
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Surprisingly, Adams et al. (2009) found that methylglyoxal does not
dominate in freshly produced manuka honey, nor does it exist in the nectar
of manuka flower at a detectable level. Adams et al. reported that the nectar
of manuka flower contained a high level of dihydroxyacetone (DHA), and
storage at 37°C led to a decrease in the level of the dihydroxyacetone in the
honey and a related increase in that of methylglyoxal. This finding, that the
methylglyoxal in manuka honey is formed with time from the dihydroxy-
acetone in the nectar of manuka flower, is in agreement with the observation
that the non-peroxide antibacterial activity of manuka honey continuously
increases during storage (Peter Molan; personal communication).
Whilst the finding that methylglyoxal is the major antibacterial factor of
manuka honey is of interest, it may be still too early to draw conclusion that
methylglyoxal alone is the only factor that is responsible for the significant
non-peroxide activity in manuka honey. Molan (2008b) pointed out, using
the data published by Adams et al. (2008), that methylglyoxal alone did not
account fully for the antimicrobial activity that a manuka honey generally
has. To illustrate that methylglyoxal does not fully explain the non-peroxide
antimicrobial activity in manuka honey, Molan (2008a) also compared the
antimicrobial activity of methylglyoxal in honey with that of methylglyoxal
in water, and demonstrated that the antibacterial activity of the former was
more than 3–4 times higher than that of the latter. These results clearly
explain that methylglyoxal alone does not account for the antimicrobial
activity of manuka honey, and also suggest that some non-antimicrobial
components that exist in the honey must have acted as synergists with
methylglyoxal to provide the substantial antibacterial activity of manuka
honey. Additionally, in accordance with the regression analyses amongst the
scatter plots of methylglyoxal vs antibacterial activity given by Adams et al.
(2008) and Atrott and Henle (2009), there exists non-peroxide antibacterial
activity equivalent to that of around 7.5–10% phenol that is not accounted
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for by methylglyoxal alone if the linear regression plot is extrapolated back
to zero methylglyoxal. As honey has a very complex composition, and also
there are various interactions among the components that may influence
its activity, further research is needed to be done on the antimicrobial
components in manuka honey to understand the mechanism(s) of the honey
on microorganisms.
1.5.3 Reported use of honey for treating gastroenteritis
Honey has been used for the treatment of veterinary diarrhoea. An 8% (v/v)
solution of honey was reported to be effective for the treatment of chronic
diarrhoea in horses (Linnet, 1996). Kandil et al. (1987) also reported that
the number of ulcers caused by aspirin, a non-steroidal anti-inflammatory
drug (NSAID), in 10 rats was significantly decreased in the group treated
with floral honey (3 cf. 10), whereas it was less significantly decreased if
treated with honey from sugar-fed bees (8 cf. 10) or increased in those
given saline (15 cf. 10). Ali (1995) carried out a similar study, in which
the healing rate of honey against ulcers caused by another non-steroidal
anti-inflammatory drug, indomethacin, in the rats was reported to be 70%.
The same author also reported that honey prevented ulceration from being
caused by indomethacin (Ali et al., 1990). Badawy et al. (2004) reported that
mice infected with E. coli O157:H7 or S. typhimurium had a lower mortality
in the group injected with 7 month old Egyptian clover honey than in the
control group (E. coli: 0% cf. 86.6%; S. typhimurium: 40% cf. 93.3%), whereas
the reduction in the mortality was less significant in the honey being stored
over a long term. However, it must be noted that Badawy et al. did not
include oral rehydration solution as a control group in their animal trial,
therefore it is not known if the reduction in the mortality is due to the
antibacterial activity of honey or the effect of rehydration of the honey.
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A clinical trial in humans with a relatively large sample size was re-
ported by Haffejee and Moosa (1985). In this study 169 infants and children
admitted into hospital suffering from gastroenteritis were assigned into two
groups (in each group there were 18 patients with bacterial diarrhoea). One
group was treated with honey whilst the other was treated with the standard
oral rehydration therapy (ORT; a 2% solution of glucose and electrolyte).
The treatment with honey solution revealed a statistically significant reduc-
tion in the duration of bacterial diarrhoea (58 hours cf. 93 hours), and gave
no increase in the duration of non-bacterial diarrhoea. In another clinical
trial, reported by Salem (1981), 45 patients with dyspepsia were given no
treatment other than 30 ml of honey solution before meals three times
daily. After the treatment the number of patients passing blood into faeces
declined from 37 to 4, the number of patients with dyspepsia from 41 to 8,
the number of patients with gastritis or duodenitis from 24 to 15, and the
number of patients with duodenal ulcer from 7 to 2.
1.5.4 Honey and gastrointestinal pathogens
Comprehensive reviews of the large amount of research carried out on
the antimicrobial activity of honey against a large number of microbial
species have been published by Molan (1992a), Blair (2009) and Molan
(2009). Several in vitro research studies have also shown that honey may
reveal antimicrobial efficacy against a wide spectrum of gastrointestinal
pathogens. The findings from these are summarised in Table 1.2.
However, it must be noted that those reported results are usually not
comparable with each other. For instance, Mundo et al. (2004) tested the
sensitivity of gastrointestinal pathogens E. coli O157:H7, Listeria monocy-
togenes, S. typhimurium and S. aureus with 13 different honeys including
manuka, and reported that a high concentration of honey (50–100%) was
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required to inhibit all the bacteria. Relatively high concentrations of manuka
honey (25–50%) were required to inhibit the bacteria in that study, whereas
Lusby et al. (2005) reported that a concentration of 5% of all tested honeys,
including manuka honey, were effective against E. coli.
There are several factors that have made it difficult to compare the
results from the different reports. Some factors that are usually missed
out in the reports include the inoculum density and the state of the tested
microorganisms, the floral source and the storage of the honey, the media
and the method used in the test, and sometimes whether or not an artificial
honey is included in the assay as a control. One of the most important
parameters being missed out in most of the studies, however, is that the
authors failed to standardise the antibacterial activity of the tested honey
using a standard antiseptic, so that it is highly possible that the potency of
the antibacterial activity of the honeys used in the studies may have varied
many fold. This may have led to the different results when testing the same
bacterial species even if the honeys were from the same floral source. For
example, Lusby et al. (2005) commented that “the overall poor activity of
honeys against S. aureus was unexpected as previous reports (Cooper et al.,
1999) have shown that manuka honey has an excellent activity against this
organism”. The potency of the antimicrobial activity of honey can in fact
vary up to 100-fold (Molan, 1992b). Therefore, it is essential to have the
antimicrobial activity in a honey standardised when that honey sample a
honey sample is to be assessed against specific microorganisms or to be
compared with other types of honey.
Another example of variable results in the published reports is the
efficacy of honey against the genus Campylobacter, a widespread causative
pathogen of diarrhoea. To the author’s knowledge there have been very
few reports of testing this genus with honey (Adebolu, 2005; Obi et al.,
1994), and these tests were done on only one isolate of C. jejuni. In the
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study carried out by Obi et al. (1994), honey was found to have a significant
activity against the tested Campylobacter whereas Adebolu (2005) reported
that natural honeys did not show any antibacterial activity against the tested
C. jejuni strain, but did not discuss the reason. In fact, the research study
done by Adebolu (2005) is highly questionable. Beside the fact that the
activity of the tested honeys were not standardised, in this work the agar
diffusion method with nutrient media was used, which may not be suitable
for testing the sensitivity of slow-growing bacteria like Campylobacter spp.
against honey, as the honey may have diffused out into the agar and thus
had its concentration decreased to a level below the MIC by the time the
microorganism had grown. This dilution by the agar means that the MIC
values for any antimicrobial agent will be reported as being higher than the
true value when an agar diffusion method is used.
Yet another variable that is commonly missed out in studies that are in
the literature is the cell density of the bacteria being tested in the susceptibil-
ity assay. It is generally observed that the higher the cell number, the more
resistant the cells are to antimicrobial agents. Depending on the species of
bacteria or the antibacterial agents being tested, the MIC could rise 4 to
16-fold with as little as 0.5 log10 increase in inoculum density (Aldridge
and Schiro, 1994). Wiegand and Burak (2004) reported that the MIC of eight
tested antibiotics against P. shigelloides dramatically increased from ≤0.03
mg/l using 105 CFU/ml up to 16 mg/l using 106 CFU/ml. It has also been
observed that the influence of inoculum size substantially increased as the
inoculum exceeded 9×107 CFU/ml (Edwards et al., 1991). The influence
of inoculum density on sensitivity studies is understandable because an
increase in the inoculum would reduce the effective concentration or the per-
cell concentration of antibacterial agents (Udekwu et al., 2009). Therefore,
without the information on the cell density being given, it would be difficult
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to determine if the reported sensitivity of the microbes to the antibacterial
agents being tested is actually over-estimated or under-estimated.
In this thesis both the antibacterial potency and the cell density are
standardised, and this makes the findings from this thesis of greater value
than those from other similar work where this was not done.
1.5.5 Honey and probiotics
The gut microflora plays an important role in maintaining gastrointestinal
health. It is thought that by maintaining the beneficial microorganisms,
humans may decrease the chance of suffering from gastroenteritis.
Several researchers have shown that honey may reveal positive effects
on the normal flora, although some of the results may not always agree
with others due to several experimental factors such as the floral source of
the tested honey and the microbial flora examined. Ezz El-Arab et al. (2006)
demonstrated that the colon bifidobacteria and lactobacilli counts in male
Swiss albino mice were markedly increased in the group receiving food
supplemented with a monofloral (cotton) honey even when the mice had
administered ochratoxin A (10 ng/kg by weight/day) or aflatoxins (1 µg/kg
by weight/day), although the concentration of the honey in the diet was not
clearly noted. Kajiwara et al. (2002) compared the stimulative effect of 5%
honey on the growth of intestinal bifidobacteria with fructooligosaccharide
(FOS), galactooligosaccharide (GOS) and inulin, and found them to be
equivalently effective. Shamala et al. (2000) also noted that Lactobacillus
acidophilus and L. plantarum had higher viable counts in a medium with a
diluted honey (equivalent to 1% sugar concentration; floral source unknown)
than in a medium with sucrose (1%) or a mixture of glucose (0.5%) and
lactose (0.5%). An in vivo study conducted by the same authors also showed
that viable counts of lactic acid bacteria from both small and large intestines
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of rats fed with honey were markedly higher than those from rats fed with
sucrose (Shamala et al., 2000).
On the other hand, Varga (2006) reported that none of the 1%, 3% and
5% (w/v) acacia honeys added in yogurt had stimulatory or inhibitory effect
on Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus in
the yogurt. This was partly in agreement with a report by Chick et al. (2001)
in which L. acidophilus and Bifidobacterium bifidum in addition to the same
species (S. thermophilus and L. delbrueckii subsp. bulgaricus) were neither
positively nor negatively affected by 5% (w/w) clover honey added in skim
milk in comparison with other sweeteners, although the production of lactic
acid by bifidobacteria appeared to be significantly enhanced by the honey.
However, so far there is no report showing that honey is detrimental to the
normal flora, perhaps due in part to the antibacterial activity of the reported
honey not being as significant as that of manuka honey.
The antibacterial activity of manuka honey against gastrointestinal
organisms has been studied (Molan, 2009; Al Somal et al., 1994; Mundo
et al., 2004), however all these reports only considered the efficacy of the
honey against one or more specific enteropathogenic species but did not
take the possible impact of the antibacterial activity of manuka honey on
the normal flora into account. Since manuka honey revealed a significant
antimicrobial activity against a wide range of microorganisms, it is also
possible that the honey may be inhibitive to the probiotic gastrointestinal
microflora.
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1.5.6 Possible mechanisms that may be involved in the treatment
of gastroenteritis with honey
1.5.6.1 Rehydrating electrolytes
Oral rehydration therapy, with a solution of glucose and electrolytes, is
recommended when acute gastroenteritis occurs because the gastrointestinal
tract re-absorbs large amount of fluid daily to maintain the balance of
electrolytes in the body (Figure 1.1), and spontaneous dehydration due
to vomiting or diarrhoea can be more critical or fatal than infection itself
(World Health Organisation, 1976). In this aspect, honey can be useful
because it consists of sugars and also contains ions. Additionally, although
an electrolyte solution with glucose added (ORS) is recommended by the
World Health Organisation (2006), in the clinical trial approached by Haffejee
and Moosa (1985) an ORS in which glucose was replaced with honey (the
glucose concentration and electrolyte content being identical to those in
the ORS by WHO) seemed to be more effective than glucose-electrolyte
solution in re-hydrating patients. Fordtran (1975) suggested that fructose
may also promote the uptake of potassium, which is an extra advantage
when treating gastrointestinal disorders with honey.
1.5.6.2 Repairing damaged mucosa
The second possible mechanism for honey to alleviate gastroenteritis is
through repairing the damaged gastrointestinal mucosa, which may be
involved simultaneously with the anti-oxidative and anti-inflammatory
activity.
Inflammation and oxygen-derived free radicals have been thought to
be involved in gastroenteritis (Asakura et al., 2007), and honey has been
reported to contain a number of anti-inflammatory and antioxidant compo-
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nents (Al-Waili, 2003; Aysan et al., 2002; Bilsel et al., 2002; Duddukuri et al.,
1997; Nasuti et al., 2006. Also reviewed in Molan, 2001). These activities
are largely relevant to the topical treatment of wounds with honey (White
et al., 2006), and both these activities may also apply to the gastrointestinal
ulcers. Mahgoub et al. (2002) reported in an animal trial that honey (5 g/kg)
provided almost 100% protective effect on Wistar albino rats from acetic
acid-induced colitis, whereas a mixture of glucose, fructose, sucrose and
maltose did not provide any protection. The same research group also tested
several biochemical properties and found that honey prevented depletion
of the antioxidant enzymes, reduced glutathione and catalase. Bilsel et al.
(2002) also investigated the effect of honey on induced colonic inflammation
in rats and found that with honey there was a significantly lower percentage
in mucosal damage than with prednisolone, a drug commonly used to treat
inflammatory bowel disease (P=0.04).
1.5.6.3 Prebiotic effect of honey
Honey also appears to have a prebiotic effect, which improves the growth of
microflora that directly and/or indirectly help retard enteropathogenic infec-
tions. Ustunol and Gandhi (2001) reported that the growth of Bifidobacterium
spp. were significantly improved in 3–5% (w/v) honey solution. Kajiwara
et al. (2002) demonstrated similar results and also observed that the mean
doubling times decreased from 147–690 hours to 9.9–14.3 hours. Whilst
Astwood et al. (1998) and Sanz et al. (2005) demonstrated that some honeys
contained oligosaccharides, it is interesting to note that the effects of honey
stimulating the growth of microflora presented in Kajiwara et al. (2002) and
Ustunol and Gandhi (2001) were higher than those of fructooligosaccharide,
galactooligosaccharide and inulin.
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1.5.6.4 Antimicrobial actions
The indigenous antimicrobial properties in honey stated above may inhibit
the growth of enterobacteria. As demonstrated in the study of Haffejee and
Moosa (1985) in which the duration of the bacterial diarrhoea was halved
whereas the viral diarrhoea was not, it is possible that the effectiveness
of honey on treating diarrhoea is partially contributed by the antibacterial
activity, although this may also suggest that the antiviral activity in the
honey was also partially contributing to this, as otherwise the duration of
the viral diarrhoea in this trial could have increased as antibacterial agents
commonly do. Indeed, in vitro studies have shown that several honeys exhibit
significant inhibition on gastrointestinal pathogens including Bacteroides,
E. coli, H. pylori or Salmonella (Adebolu, 2005; Ali et al., 1991; Al Somal
et al., 1994; Al-Waili et al., 2005; Mundo et al., 2004; Obi et al., 1994; Osato
et al., 1999; Shin and Ustunol, 2005; Taormina et al., 2001). Interestingly, the
microbiological action may also be due to the prevention of organisms from
adhering to gastrointestinal epithelial cells (Alnaqdy et al., 2005; Breton and
Pineau, 1999; George et al., 1978b; Lerrer et al., 2007).
1.6 Intention of this research project
It must be noted that the study in this thesis does not intend to investigate
all possible factors that may exist in the gastrointestinal environment as
this would not be feasible. The aim of this study was primarily to evaluate
the antimicrobial effect of manuka honey on enterobacteria with regard
to several gastrointestinal factors that may potentially affect the efficacy
of the honey against the organisms. These factors include the less aerobic
atmosphere, the time required for the honey to inhibit the growth of enter-
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obacteria, the declining honey concentration to which the enterobacteria
may be exposed, and the acidity and digestive enzymes in the gut.
The aims of each chapter in this thesis are as follow:
• To evaluate a cost-effective cultivation method for studying gastroin-
testinal bacteria in a microaerobic environment. (Chapter 3)
• To investigate the efficacy of manuka honey against common gas-
trointestinal pathogens and probiotics dominant in the gastrointestinal
environment. (Chapter 4)
• To investigate the effect of oxygen on the production of peroxide
activity thereby the total antimicrobial activity of honey. (Chapter 5)
• To obtain information on the kinetics of the antibacterial effect of
manuka honey by measuring the “time to kill” and the postantibiotic
effect (PAE). (Chapter 6)
• To find the effect that the digestive enzymes would have on the activity
of the honey. (Chapter 7)
2
G E N E R A L M AT E R I A L S A N D M E T H O D S
This chapter describes the general materials and methods routinely used
in this study. Bacterial cultures and microbiological media used are listed,
and the reasons the particular media were used are explained. Methods
modified for specific situations are given in the relevant chapters.
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2.1 Culture media
2.1.1 Trypticase soy broth (TSB)
Trypticase soy broth (TSB; BD Bacto Cat. No. 211825) was used for culturing
the test organism S. aureus ATCC 9144 one day before the honey antibacterial
activity test.
TSB was made up 30 g of powder to 1 l of purified water. This was then
dispensed as 10 ml aliquots in universal bottles, autoclaved at 121°C for 15
min and kept at room temperature until used.
2.1.2 Nutrient agar (NA)
Nutrient agar (NA; BD Difco Cat. No. 213000) was used for preparing
S. aureus ATCC 9144 seeded agar plates which were used for testing the
antibacterial activity of honey samples (See Section 2.5).
NA was made up 3.45 g of powder to 150 ml of purified water in a 250
ml flask. This was then stopped with a cotton plug and autoclaved at 121°C
for 15 min and kept at room temperature until used.
2.1.3 Mueller-Hinton broth (MHB)
Mueller-Hinton broth (MHB; Difco Becton Dickinson Cat. No. 275730) is a
medium commonly used for antimicrobial susceptibility testing of organ-
isms (National Committee for Clinical Laboratory Standards, 2000) because
it supports the growth of most non-fastidious organisms. It also has a low
thymine and thymidine content and is totally devoid of sulfonamide an-
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tagonists. Although it is less likely that these contents would influence the
activity of honey, the internationally accepted medium was used for general
cultivation of most non-fastidious organisms and also for the broth dilution
assay in this study.
MHB was made up 21 g of powder to 1 l of purified water. This was
then dispensed as 10 ml aliquots in universal bottles, autoclaved at 121°C for
15 min and stored at room temperature until used. The MHB for cultivating
fastidious Campylobacter spp. and H. pylori (see Section 2.2) was stored in a
dark refrigerator.
2.1.4 Reinforced clostridial medium (RCM)
Reinforced clostridial medium (RCM; MERCK Cat. No. 1.05411.0500) was
used for cultivating anaerobes such as C. difficile, Propionibacterium acnes, B.
animalis subsp. lactis and Lactobacillus spp.
To make RCM, 33 g of powder was dissolved in 1 l of purified water,
dispensed in universal bottles as 10 ml aliquots, autoclaved at 121°C for 15
min and then made air-tight. If not used right after this, the sterilised RCM
was stored in a dark refrigerator and, before use, this was boiled for 10 min
and cooled in chilled water to remove any oxygen dissolved in the broth.
2.1.5 Cooked meat broth
Cooked meat broth was used for transporting or storing anaerobes (Clostrid-
ium spp. and P. acnes).
To make cooked meat broth, 1 g of cooked meat granules (LAB M
Cat. No. LAB24) was added into 13.3 ml purified water, sterilised at 121°C
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for 15 min, then the lid was air-tight and the broth was stored in a dark
refrigerator.
2.1.6 de Man Rogosa and Sharpe medium (MRS)
de Man Rogosa and Sharpe medium (MRS; MERCK Cat. No. 1.05463.0500)
agar and broth were used in the cultivation and enumeration of B. animalis
subsp. lactis and Lactobacillus spp.
MRS agar was made by adding powder upto 1 l purified water at the
rate of 66.2 g/l. MRS broth was made at the rate of 52.2 g/l. These were
then autoclaved at 121°C for 15 min and stored at room temperature.
2.1.7 Brain heart infusion yeast extract medium (BHIYE)
BHIYE broth (Moore and Madden, 2000) is an enriched medium used for
cultivating fastidious organisms (Campylobacter spp. and H. pylori).
To make the medium, 37 g of brain heart infusion broth powder (BHI;
BD Bacto Cat No. 237500) and 6 g of yeast extract (YE; Sharlau Cat. No.
07-079) were made up to 1 l of purified water. This was then dispensed as 10
ml aliquots in universal bottles, autoclaved at 121°C for 15 min and stored
in a dark refrigerator if not used immediately. After storage, BHIYE was
boiled for 10 min then chilled in cold water to remove dissolved oxygen in
the broth before use.
2.1.8 Columbia horse blood Helicobacter pylori agar (CHBHP)
CHBHP (Hasegawa et al., 2002) is an enriched agar consisting of Columbia
blood agar base and supplemented with defibrinated horse blood, van-
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comycin, trimethoprim, amphotericin B and polymyxin B. Hasegawa et al.
(2002) originally developed this medium for cultivating H. pylori but in this
study Columbia horse blood agar without antibiotics was also used for
cultivating Campylobacter spp.
To make CHBHP, 22 g of Columbia blood agar base powder (BD Difco
Cat No. 279240) was made up to 500 ml with purified water, autoclaved at
121°C for 15 min, cooled in a 45°C water bath for 30 min then aseptically
supplemented with 10% (v/v) defibrinated horse blood, vancomycin (10
mg/l), trimethoprim (5 mg/l), amphotericin B (5 mg/l) and polymyxin B
(2 500 U/l) and then poured into Petri dishes. As for the CHBHP agar for
cultivating Campylobacter, the agar surface was dried in an incubator at 37°C
for 30 min. The agar plates were stored in a dark refrigerator until used.
2.1.9 Haemophilus medium base agar (HMB)
Haemophilus medium base agar (HMB; Oxoid Cat. No. CM0898) was used
for making chocolate agar plates for cultivating Haemophilus influenzae in
the gas generating systems comparison test in Chapter 3.
HMB chocolate agar was made by dissolving 21 g of powder up to 1 l of
purified water, autoclaving at 121°C for 15 min and then cooling in a 45°C
water bath for 30 min. The cooled agar was then aseptically supplemented
with 10% (v/v) defibrinated horse blood, heated to 56°C until the medium
became brown or chocolate in colour, then poured into Petri dishes.
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2.1.10 Enriching with defibrinated sheep/horse blood and heat-
inactivated horse serum
Defibrinated sheep blood (GIBCO Invitrogen Cat. No. BL204BSL) was asep-
tically added (5%, v/v) into melted agar for enriching the medium and also
for demonstrating the haemolytic properties of some microorganisms.
Defibrinated horse blood (GIBCO Invitrogen Cat. No. BL104BSL) was
used when preparing chocolate agar plates and blood agar plates with
Columbia agar or HMB agar for cultivating fastidious organisms (Campy-
lobacter spp. and H. pylori). The horse blood was added at a rate of 10%
(v/v).
Heat-inactivated horse serum (GIBCO Invitrogen Cat. No. 16050-130)
was used to enrich BHIYE broth for cultivating the fastidious organisms
Campylobacter spp. and H. pylori. The serum was dispensed as 10 ml aliquots
in sterilised universal bottles and then stored in −20°C. When used the
serum was added into broth at a rate of 5% (v/v).
2.1.11 Campylobacter blood-free selective agar
This blood-free selective agar was used for isolating Campylobacter spp.
This selective agar contains charcoal as a protectant, and sodium pyruvate
and ferrous sulfate as reductants, and amphotericin and cefoperazone as
selective antibiotics.
To make the Campylobacter selective agar, 22.75 g of powder (LAB M
Cat. No. LAB 112) was dispersed in 500 ml of purified water, sterilised by
autoclaving for 15 min at 121°C and cooled in a 50°C water bath for 30 min.
Selective antibiotics were re-hydrated by reconstituting 1 vial of selective
supplement (16 mg cefoperazone and 5 mg amphotericin per vial; Lab M
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Cat. No. X112) with 5 ml of sterile water and aseptically added to the cooled
agar. This gives the final concentration of 32 mg/l cefoperazone and 10
mg/l amphotericin. After mixing well, the supplemented agar was poured
into Petri dishes. After the agar had set, the agar surface was dried in an
incubator at 37°C for 30 min. The agar plates were then stored in a dark
refrigerator until used.
2.1.12 Ferrous sulfate-sodium metabisulfite-sodium pyruvate
(FBP) supplement
FBP supplement at the rate of 0.025% has been reported to improve the
aerotolerance of Campylobacter spp. (George et al., 1978a; Gorman and Adley,
2004). To make the FBP supplement stock solution, 6.25 g of ferrous sulfate,
6.25 g sodium metabisulfite and 6.25 g sodium pyruvate were made up
to 100 ml in purified water and then filter-sterilised with a 0.22 µm filter
membrane. The filtrant was dispensed as 4 ml aliquots in sterilised bijou
bottles and stored in −20°C for no longer than 1 month (Hunt et al., 2001).
When used, one bijou bottle of FBP stock was thawed and added into 1 l of
broth or agar aseptically just before pouring the agar into Petri dishes.
As sodium metabisulfite in the supplement is inhibitory to H. pylori
(Goodwin et al., 1985), 6.25% FP (6.25 g ferrous sulfate and 6.25 g sodium
pyruvate per 100 ml) instead of FBP was used as an enrichment supplement
for cultivating H. pylori in BHIYE broth (Jiang and Doyle, 2000).
2.1.13 Modified Christensen’s urea test broth
The urea broth was used for the rapid urease test (RUT) on H. pylori (Mc-
Nulty et al., 1989). As Helicobacter produces a large amount of urease which
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degenerates urea into carbon dioxide and ammonia which subsequently
generates an alkaline environment surrounding the cell, a urea broth con-
taining phenol red as an acidity indicator is useful for quick identification
of the species in cultures. The urea broth contains urea (20 g/l), phenol red
(0.04 g/l), KH2PO4 (2 g/l) and NaCl (5 g/l) in water.
A single colony from a H. pylori agar plate was transferred into 100 µl
of the modified Christensen’s urea test broth and incubated for 30 min at
room temperature. The culture was recognised as H. pylori if the colony and
the broth turned red.
2.2 Bacterial cultures
The organisms used in this study are listed in Table 2.1.
All reference strains were obtained from ESR, New Zealand. Most of
them were supplied as freeze-dried culture, except that H. pylori ATCC
43504 was supplied as slope culture. Most reference strains were revived
by aseptically adding about 0.5 ml of broth recommended by ESR into the
freeze-dried culture ampoule using a sterile Pasteur pipette, mixing carefully
and transforming the rehydrated suspension to suitable solid or broth
medium. Rehydration broth used were: MHB for most facultative anaerobes;
cooked meat broth for anaerobes, MRS broth for Lactobacillus spp.; BHIYE
for Campylobacter spp. C. difficile and P. acnes were then stored in the cooked
meat broth in a dark refrigerator. Other species were incubated at 37°C in
appropriate conditions recommended by ESR. These were then subcultured
on appropriate agar plates and incubated (facultative anaerobes on sheep
blood agar for 1 day, Lactobacillus spp. on MRS agar for 2 days, Campylobacter
spp. on Columbia horse blood agar for 2 days). The colonies on the agar
plates after incubation were then collected on Protect Bacterial Preservers
Beads (Technical Service Consultants Ltd.) except that Campylobacter spp.
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Table 2.1: The bacterial cultures used in this study.
Organism Source
B. animalis subsp. lactis NZ dairy food industry
Campylobacter spp. clinical isolates Medlab
C. coli ATCC 33559 ESR
C. jejuni ATCC 33560 ESR
C. fetus ATCC 27374 ESR
C. difficile ATCC 9689 ESR
C. difficile ATCC 43593 ESR
C. difficile NCTC 11382 ESR
C. difficile clinical isolates Pathlab
E. aerogenes clinical isolate Waikato Hospital
E. cloacae clinical isolate Waikato Hospital
E. faecium ATCC 19434 ESR
E. faecalis ATCC 19433 ESR
E. coli ATCC 25922 ESR
H. pylori ATCC 43504 ESR
L. plantarum ATCC 8014 ESR
L. rhamnosus ATCC 7469 ESR
P. acnes NCTC 737 ESR
P. aeruginosa clinical isolate Waikato Hospital
S. enteritidis clinical isolate Medlab
S. typhimurium phage type 104 (“DT104”) ESR
S. flexneri clinical isolate Waikato Hospital
S. sonnei clinical isolate Waikato Hospital
S. aureus ATCC 9144 ESR
Y. enterocolitica clinical isolate Waikato Hospital
chapter 2 general materials and methods 57
were collected in defibrinated horse blood. These recovered cultures were
then stored at −70°C.
H. pylori ATCC 43504 was recovered by subculturing on Columbia
horse blood chocolate agar plates and incubating at 37°C microaerobi-
cally for 3 days. The microaerobic condition was constructed with a spirits
burn method described in Chapter 3. The recovered H. pylori was then
re-suspended in 1.5 ml of defibrinated horse blood (Stanley and Moore,
2000) in small vials and stored at −70°C.
S. aureus ATCC 25923 was used for testing the antibacterial activity of
the honey samples.
Most of the clinical isolates of facultative anaerobes used in this study
had been isolated from Waikato Hospital patients before this study com-
menced and were stored in a −70°C freezer at Waikato University on Protect
Bacterial Preservers Beads. The isolates were identified in the Microbiol-
ogy Department at Waikato Hospital using a range of morphological and
biochemical techniques and the Vitek automated bacterial identification in-
strument (McDonnell Douglas Health System Company). Before use in this
study, the isolates were subcultured on sheep blood agar plates, incubated
overnight at 37°C and examined for purity.
Three clinical isolates of C. difficile were obtained from Murray Robinson,
Pathlab Bay of Plenty, New Zealand. These were stored in cooked meat
broth when transporting from Pathlab to the Honey Research Unit and were
then stored in a dark refrigerator in the laboratory.
Clinical isolates of Campylobacter spp. (27), S. enteritidis (1) and Y. en-
terocolitica (1) were provided by Chris Picket, Medlab, Hamilton, NZ and
were stored in fastidious anaerobe transport swabs (Copan Italia S.P.A.)
when transporting them from Medlab to the Honey Research Unit. Clinical
isolates of facultative anaerobes were streaked on sheep blood agar plates
and cultured overnight at 37°C and the recovered cultures were collected
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onto Protect Preservers Beads and stored at −70°C. Campylobacter spp. iso-
lates were streaked on blood-free Campylobacter selective agar plates and
cultured at 37°C microaerobically for 2 days. The recovered cultures were
rubbed off the agar with a sterile cotton swab and transferred into 10 ml
BHIYE-FBP broth, then were incubated overnight microaerobically. The
enriched Campylobacter cultures were collected by centrifuging (12 000
rpm, 15 min) and re-suspended in 1.5 ml of BHIYE-FBP containing 10%
glycerol as a cryopreservative agent, in small vials, and stored at −70°C.
As Medlab differentiates Campylobacter spp. isolates only to genus level,
extra identification work to species level was needed for investigating the
effect of manuka honey on different species of Campylobacter. To approach
this, the multiplex polymerase chain reaction was used in this work (Section
2.4).
The culture media used for the work in the susceptibility test are shown
in Table 2.2. For most facultative anaerobes (E. coli, S. typhimurium DT104,
S. enteritidis, E. aerogenes, E. cloacae, S. flexneri, S. sonnei and Y. enterocolitica)
MHB was used in the susceptibility test as suggested by NCCLS (National
Committee for Clinical Laboratory Standards, 2002). RCM was used for
cultivating and enumerating anaerobes C. difficile because the semi-solid
medium would protect the anaerobes from oxygen. MRS broth was used
for handling B. animalis subsp. lactis and Lactobacillus spp.
The choice of the medium for microaerobes (Campylobacter and H. py-
lori), however, was problematic. Campylobacter spp. and H. pylori are widely
known as fastidious pathogens and require strict control of growth condi-
tions. NCCLS has suggested an outline for investigating the susceptibility
of these species to antibiotics, nonetheless there still does not exist a “gold
standard” protocol for studying these two genera (Silley, 2003). For instance,
the agar dilution method using Mueller-Hinton agar supplemented with 5%
defibrinated sheep blood is recommended in the outline, where the blood
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Table 2.2: Bacterial strains and culture media used in the susceptibility test. MHB:
Mueller-Hinton broth. RCM: Reinforced clostridial medium. BHIYE:
Brain heart infusion yeast extract broth. MRS: deMan, Rogosa and Sharpe
medium. CHBHP: Columbia horse blood H. pylori medium. BFCSA:
Blood free Campylobacter selective agar.
Media Microorganisms
MHB Aerobes / facultative anaerobes (P. aeruginosa, S. aureus, E.
coli, Salmonella, Shigella, Enterobacter, Yersinia), microaerobes
(Campylobacter, H. pylori)
RCM Anaerobes (C. difficile)
MRS Anaerobes (B. animalis subsp. lactis, Lactobacillus)
BHIYE Microaerobes (Campylobacter, H. pylori)
CHBHP Microaerobes (Campylobacter, H. pylori)
BFCSA Campylobacter
is for protecting Campylobacter spp. from the damage by oxygen-derived
components such as free radicals and hydrogen peroxide (Bolton et al., 1984;
Corry et al., 1995). However, it is not suitable for a study with honey because
the antibacterial activity of honey is largely or partially due to hydrogen
peroxide (Allen et al., 1991a; Molan, 1992a) which would be inactivated by
catalase present in the sheep blood. Therefore, whenever possible, using
the blood or any substance with catalytic capacity should be avoided when
evaluating the antibacterial activity in honey. As an alternative, MHB freshly
made right before doing the Campylobacter and H. pylori susceptibility tests
was used in this study.
2.3 Honey samples
Manuka honey was obtained from SummerGlow® Apiaries. This was given
a sample ID number M115 in our laboratory. The total and non-peroxide
antibacterial activities of the honey sample were assayed with an agar-well
diffusion method, as described in Section 2.5.
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To distinguish the antimicrobial effect of honey from any osmotic effects,
an artificial honey, which is a sugar syrup simulating the sugar composition
of honey, 30.5% glucose, 37.5% fructose and 1.5% sucrose dissolved in
purified water (Shannon et al., 1979), was included in this study as a control.
To minimise any change in the antibacterial property of honey samples,
both manuka honey and artificial honey were stored in a dark refrigerator
until used.
2.4 Multiplex PCR
Multiplex PCR was used to identify the Campylobacter clinical isolates from
Medlab (Wang et al., 2002).
Campylobacter DNA was extracted by boiling. A loopful of colony for
each isolates was taken from its culture plates, re-suspended in 100 µl of
purified water in an Eppendorf tube, heated in a boiling water bath for 10
min and chilled on ice for another 10 min, followed by addition of 100 µl of
chloroform and brief centrifuging. The supernatant was to be used as the
DNA template, and this was stored at −20°C until the PCR test was carried
out.
Each PCR mix (20 µl) consisted of 6 µl of DNA templates, 2.4 µl of 20
µM primers mix (Sigma Inc.), 8 µl of HotMasterMix (2.5×) (Eppendorf Inc.
Cat. No. 0032 002.714) and 3.6 µl of MilliQ water. The primer pairs used in
this work are shown in Table 2.3. Primer pairs for C. jejuni, Campylobacter coli
and Campylobacter fetus were chosen because campylobacteriosis is reported
to be usually caused by, but not limited to, these species (Nachamkin and
Blaser, 2000).
DNA amplification was carried out in a PTC-100 thermocycler (MJ
Research Inc.) and the cycling conditions used were 94°C for 2 min followed
by 30 cycles of amplification (95°C denaturation for 30 s, 59°C annealing for
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20 s and 68°C extension for 40 s) then 68°C for 6 min of final extension. The
amplified products were electrophoresed in 1.5% agarose gel (Sigma, Cat.
No. A6013) in sodium boric acid (SB) buffer (Brody and Kern, 2004) and
analysed with the ScionImage system.
According to the multiplex PCR, of the 27 Campylobacter clinical isolates
collected from Medlab, 20 were identified as C. jejuni, the rest as C. coli. No
C. fetus was found in the clinical isolates.
2.5 Honey activity identification
The honey samples used in this work had the strength of their antibacte-
rial activity assayed with the agar diffusion method described by Allen
et al. (1991a) which compares the activity of honey with that of a standard
antiseptic phenol.
2.5.1 Type culture preparation
A cryopreserved bead of S. aureus ATCC 9144 was transferred in 10 ml TSB
and incubated at 37°C for 18 hours. The following day, the optical density
of the recovered culture was adjusted to 0.5 at 450 nm with TSB. This was
used as the inoculum.
2.5.2 Seeded square agar plate preparation
Two large square plates (245 × 245mm dish; Corning Inc.) were placed on a
level surface. One plate was used for testing the total antibacterial activity
of honeys and the other one for the non-peroxide activity.
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Two flasks of autoclaved 150 ml nutrient agar were melted in boiling
water for 30 min then maintained in a 45°C water bath for 30 min. Into each
was transferred 100 µl of S. aureus ATCC 9144 inoculum, and the agar was
swirled well without causing bubbles to be incorporated, then poured into
the square plates evenly. The agar plates were covered with a cloth with the
lids on, left on the bench for one hour and then stored at 4°C for overnight.
2.5.3 Antibacterial activity test
A paper sheet numbered with a quasi-Latin square was placed under the
plate as a template so that each honey sample would be placed randomly
(Figure 2.1), then 64 wells were cut on each agar plate with a cooled flamed
8 mm diameter cork borer.
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Figure 2.1: The illustration of the square agar plate with a numbered quasi-Latin
square template for antimicrobial activity testing.
A solution of honey in water was prepared for testing the antibacterial
activity of the honey samples. To 5 ml sterile purified water in a universal
bottle was added 5 g by weight of honey (equivalent to 3.65 ml of honey) to
obtain a 50% (w/w) (equivalent to 42.2%, v/v) solution of honey. The bottle
was closed and warmed in a 37°C water bath for 10 min with occational
stirring to aid mixing. The 50% (w/w) honey solution was then further
diluted to 25% (w/w) by mixing in sterilised bijou bottles 1 ml of the 50%
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(w/w) honey solution with 1 ml sterile purified water or 1 ml of a solution of
0.2% catalase solution (0.02 g catalase powder dissolved in 10 ml of purified
water. Catalase from bovine liver; 1700 units/mg solid; 2150 units/mg
protein; SIGMA Cat No. C9322). The final concentration of catalase in the
21.1% (v/v) honey solution would be 0.1%, a concentration that would be
enough to remove hydrogen peroxide from the honey solution (Allen et al.,
1991a).
A series of concentrations of phenol standard solution (2%, 3%, 4%, 5%,
6% and 7% w/v) was made by dissolving phenol in sterile purified water.
The standard solutions were stored in a dark refrigerator when not in use.
Honey solutions (100 µl of each) were loaded in quadruplicate into the
wells in accordance with the quasi-Latin square sheet, also 100 µl of each
phenol standard in quadruplicate, then the plates were incubated at 37°C
for 18 hours.
After the overnight incubation, the diameter of any inhibition zones
on each agar plate was measured in mm with a digital callipers (Mitutoyo
CD-6”), twice at right-angles to each other. The mean diameter for each zone
and then the square of the mean diameter was calculated. A standard curve
of % phenol against the squared mean diameter of the zones around the
phenol solutions was plotted. A linear regression equation was obtained and
the equivalant phenol concentration (w/v) of the diluted honey solutions
was calculated accordingly from the squared diameter of the zones from
these. The antibacterial activity of the original honey samples was then
obtained by multiplying by the dilution factor (4.69).
2.6 The track dilution method
For viable cell counting, the track dilution technique (Jett et al., 1997) was
used instead of the regular spread plate technique because the former
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requires much less media and plates and, most importantly, takes much
shorter time to carry out than the latter. The time shortening is essential
particularly when handling microaerobes and anaerobes as this reduces the
risk of the loss of their viability in the air. It generally takes approximately
15–20 min to allow excess moisture absorption on the agar surface with the
spread plate method, whereas the track dilution technique takes only 2–5
min.
The track dilution method used was slightly modified from that reported
by Jett et al. (1997). An incubated broth culture was serially diluted in 10-fold
steps in sterile saline to get 8 dilutions of the culture (10−1, 10−2, 10−3, 10−4,
10−5, 10−6, 10−7 and 10−8), then 10 µl of each dilution was loaded as spots
along one edge of an agar plate in a 100 mm × 100 mm square Petri dish
(Techno-Plas Co.), then this edge of the plate was tipped up by a 45°–90°
angle so that the diluted cultures ran down toward the opposite edge. The
plate was allowed to dry on the benchtop for 30 seconds and then incubated
under appropriate conditions. After incubation the dilution with which the
colony number ranged between 30–300 was chosen and the colony-forming
units were recorded (Figure 2.2).
The cell density of the undiluted broth culture was calculated using the
following equation:
Cell density (CFU/ml) = Colony count
10µl
× 103 ×Dilution factor (2.1)
As an example, in Figure 2.2 the track with 133 CFU is chosen for
calculation, therefore the initial density of the culture would be
Cell density (CFU/ml) = 133× 102 × 103 = 1.33× 107CFU/ml (2.2)
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Figure 2.2: The serial diluted culture spread on a square agar plate. CFU: colony
forming units. TNTC: too numerous to count. In this example the track
with 133 CFU, on which the culture is diluted by 103-fold, is chosen,
and thus the initial density would be 1.33×107 CFU/ml.
3
S P I R I T S B U R N M E T H O D F O R C U LT U R I N G
N O N - A E R O B I C O R G A N I S M S
As some gastrointestinal bacteria used in this project are not aerobes whereas
a large expense would be incurred if gas generating systems with a GasPak
are purchased, it was necessary to seek an alternative solution instead
of using commercial gas generating systems. This chapter describes the
evaluation of a simple and cost-effective gas generating system for culturing
non-aerobes.
The frequently used methods for culturing non-aerobes, including com-
mercial and non-commercial, are described. The utility of the different
gas generating systems are studied practically by comparing the growth
rate and colony size of various microaerobes (Campylobacter, Helicobacter,
Lactobacillus, Bifidobacterium, Haemophilus) and anaerobes (Clostridium, Propi-
onibacterium, Bacteroides) in different gas generating systems. The advantages
and disadvantages for each method are discussed.
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3.1 Introduction
The successful isolation and culture of some bacteria is largely dependent
on conditions such as temperature, oxygen and media requirement. In order
to obtain reliable culturing of non-aerobic organisms, several gas generating
systems have been developed.
With commercial methods gas chambers and gas-pack systems are
usually used. The gas chamber has been the “gold standard” for non-aerobes
as it has the merit of adjusting the gas mixture to meet the requirement of
the growth of the cultures. For middle- to small-scale laboratories that are
unlikely to be able to afford a gas chamber, several types of gas-pack systems
are available on the market. However, the cost of gas-pack system may still be
prohibitive to small laboratories, and also it takes 30 min–2 hours to generate
a microaerobic or anaerobic atmosphere in accordance with manufacturer’s
instruction (http://www.mgc.co.jp/eng/products/abc/anaeropack/kenki.
html [accessed: 12/May/2009]), during which time the bacteria are subjected
to a range of atmospheric conditions.
Several culturing methods associated with non-commercial gas systems
have also been developed. Karmali and Fleming (1979) used the Fortner’s
principle to isolate Campylobacter from stools. In this report Karmali et al.
utilised the ability of facultative anaerobes such as Proteus rettgeri, S. aureus,
E. coli, Klebsiella aerogenes or P. aeruginosa to reduce the oxygen tension in
a closed environment so that the growth of oxygen-sensitive organisms
such as C. jejuni was possible. However, the growth of C. jejuni did not
occur if the other organisms were not concomitantly cultured onto the same
agar plate. Pennie et al. (1984) used steel wool to react with oxygen in the
atmosphere to produce a suitable environment for C. jejuni. The candle
jar (Reddy et al., 2007) is one of the most well known non-commercial
methods for culturing microaerophilic organisms. In this old-fashioned
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device the burning of the candle consumes some oxygen and also produces
CO2 in the atmosphere. Morshed et al. (1995) used a candle jar to grow
H. pylori. The candle jar has also been used for cultivating Actinomyces
actinomycetemcomitans (Slots, 1982), meningococci (Goldschneider et al.,
1969), Neisseria gonorrhoeae (Punsalang and Sawyer, 1973), Bartonella koehlerae
(Droz et al., 1999), H. influenzae (Thornsberry and Kirven, 1974) and Bordetella
holmesii (Weyant et al., 1995). However, the candle jar method has also been
criticised as being unreliable when compared with commercial gas systems.
As the reduction of oxygen in a candle jar may not be sufficient for some
microaerobes, its application is limited (Bolton and Coates, 1983; Luechtefeld
et al., 1982; Wang et al., 1982; Wang and Luechtefeld, 1983).
The spirits burn method, originally described by Ribeiro et al. (1985),
was reported to leave 10.5–14% oxygen in the jar, and this concentration is ac-
ceptable for most of the microaerobes. Popovic-Uroic and Sterk-Kuzmanovic
(1992) compared the spirits burn method with the Fortner’s principle and
found it to be superior. However in these two reports only a very limited
number of species were tested with the spirits burn method (C. jejuni, C.
coli and C. laridis by Ribeiro et al.; C. jejuni and C. coli by Popovic-Uroic and
Sterk-Kuzmanovic) and it is unknown whether or not the method would be
applicable to other microaerophilic organisms.
The performance of the non-commercial methods has never been com-
pared with that of the commercial methods. As the work described in
this thesis frequently used several non-aerobes, it was essential to seek
an economical incubation method rather than using commercial gas-pack
apparatus for cultivating microaerobes because this would otherwise have
exceeded the funds available with the large volume of work to be carried
out. The purpose of this study was therefore to compare the utility of the
spirits burn method for several common non-aerobes. The growth of the
bacterial cultures was compared in all of the systems.
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3.2 Gas generating systems evaluated
3.2.1 AnaeroPack system
The GasPak system (MGC AnaeroPackTM, Mitsubishi Gas Chemical Com-
pany Inc.) consists of a 2.5 l jar and an AnaeroPack sachet. The sachet was
opened and put into the jar along with the inoculated culture media and an
anaerobic indicator strip (BBL GasPak disposable anaerobic indicator. Cat.
No: 70504). The jar was incubated at 37°C.
3.2.2 CO2 incubator
Cultures were incubated in a Sanyo CO2 incubator (Sanyo MCO-17AIC)
connected with a food grade CO2 cylinder, size D 6 800 l. The CO2 injection
was set to 5% and the temperature to 37°C. A small amount of sterilised
water was placed inside in a pan to maintain the humidity in the incubator.
3.2.3 Candle jar
A storage tins (3.5 l) was purchased from a local shop. A 3 cm candle was
fixed in a glass Petri dish and was lit with a lighter. This was placed in the
3.5 litre tin along with the inoculated culture media and covered with the
tin’s lid. The tin was sealed with a strip of adhesive vinyl tape to avoid air
leakage and incubated at 37°C for the appropriate time (Table 3.1).
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3.2.4 Spirits burn method
The same tin (3.5 l) as used for the candle jar was used in this method.
A glass Petri dish was used to contain 500 µl of methylated spirits. The
amount of methylated spirits can be increased proportionally if a larger
tin is required. The Petri dish was placed on top of the uppermost Petri
dish containing the inoculated media in the tin. The methylated spirits was
lit with a lighter right before the lid was placed on the tin. The lid was
sealed with a strip of adhesive vinyl tape to avoid air leakage and then was
incubated at 37°C.
3.3 Comparison of the growth of non-aerobes
3.3.1 Bacterial cultures and media
The cultures used for comparison of growth were: C. jejuni ATCC 33560,
C. coli ATCC 33559, C. fetus ATCC 27674, H. pylori ATCC 43504, L. rham-
nosus ATCC 2469, L. plantarum ATCC 1100, B. animalis subsp. lactis and H.
influenzae. Although not being a microaerobe, H. influenzae was included
in the test because the candle jar and CO2 incubator are usually used to
cultivate this species in clinical disciplines. The incubation conditions used
are summarised in Table 3.1.
3.3.2 Culture preparation
Each culture was recovered by rubbing the surface of a frozen culture with a
sterilised cotton swab then streaking this onto an appropriate agar as listed
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in Table 3.1. Microaerobes were incubated with the spirits burn method and
anaerobes in a gaspack jar. Most organisms were incubated overnight except
that Campylobacter were incubated for 2 days and H. pylori for 3 days.
The recovered colonies were collected with a cotton swab and suspended
in 0.85% (w/v) sterile saline. The optical density at 625 nm was adjusted to
0.08 with saline then was further diluted by 300 fold using suitable broth
media. This gave a final culture density of approximately 105 cfu/ml and
was used as the inoculum for the comparisons of the incubation systems.
3.3.3 Comparison of the performance of the gas generating
systems
The evaluation of the performance of gas generating systems was done
in two ways. The growth in broth media was evaluated by comparing the
ratio of CFU/ml before incubation with that of after incubation in each gas
system. On the other hand, the performance on agar plates was evaluated
by comparing the size of the colonies after incubation.
Table 3.1: Incubation conditions for the comparison of non-aerobic culture systems.
CHB: Columbia horse blood; BHIYE: Brain heart infusion yeast extract;
MRS: de Man Rogosa and Sharpe; HMB: Haemophilus medium base; -A:
agar; -B: broth.
Organisms Media Incubation period (Days)
Campylobacter spp. CHB-A, BHIYE-B 2 days
H. pylori CHB-A, BHIYE-B 3 days
Lactobacillus spp. MRS-A, MRS-B 2 days on agar, 1 day in broth
B. animalis subsp. lactis MRS-A, MRS-B 2 days on agar, 1 day in broth
H. influenzae HMB-A, HMB-B 1 day
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3.3.3.1 Viable count determination
The viable counts for each broth culture before and after incubation in
each gas systems were performed with the track dilution technique on
appropriate agar plates.
As the initial cell density in each medium may not always be the same,
growth rate instead of the final cell density was used for evaluating the cell
growth in each gas system. Viable counts before and after incubation were
recorded and the growth rate in each gas system was calculated with the
following equation:
Growth rate = log10 ( CFU/ml after incubationCFU/ml before incubation) (3.1)
Each plate count was performed in duplicate. The growth rate in all gas
generating systems were compared using one-way ANOVA.
3.3.3.2 Colony size evaluation
All inocula were quadrant streaked with 10 µl loops on the appropriate
agar plate. The largest colony diameter for each culture was measured
in millimetres with digital callipers. Each evaluation was performed in
duplicate. The colony size in all gas generating systems were compared
using one-way ANOVA.
3.3.4 Results
The rate of growth of the cultures and the size of the colonies obtained
in the various gas systems are presented in Figures 3.1 and 3.2. Overall
the results obtained using the spirits burn method were equivalent to or
superior to the commercial GasPak, CO2 incubator or candle jar methods.
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The viable count results (Figure 3.1) showed that most microaerobes
used in this work grew with the spirits burn method as well as or better
than in the CO2 incubator, GasPak or candle jar. Mostly the results with
the spirits burn method were better than with any other method. Although
CO2 is generally required for stimulating the growth of H. influenzae, the
spirits burn method was found to be as beneficial to its growth as the CO2
incubator.
The colony size (Figure 3.2) revealed similar trends as with growth
rates. Generally most cultures formed larger colonies with the spirits burn
method than the other methods. For H. pylori, environments other than the
spirits burn jar failed to give colonies on agar plates.
An interesting thing in the results is that Bifidobacterium and Lactobacilli
grew vigorously in all tested conditions, regardless of the species being
anaerobes. This suggested a probability that non-commercial gas systems
may support the growth of some anaerobes. This hypothesis motivated
the author to further test the gas systems with some anaerobes in the next
section.
3.4 The comparison of the growth of anaerobes
3.4.1 Bacterial cultures and media
The cultures of anaerobes used for the comparison of the growth were: P.
acnes, clostridia (Clostridium butyricum, C. difficile, C. perfringens, Clostridium
sporogenes and Clostridium tetani), Bacteroides (Bacteroides fragilis, Bacteroides
stercoris and Bacteroides ureolyticus). The incubation conditions used are
summarised in Table 3.2. All cultures were incubated overnight except that
with P. acnes it was for 7 days.
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Figure 3.1: The growth rates of micro-organisms when cultured in broth under
different atmospheres. The growth rates were obtained from the for-
mula log10 ( CFU/ml after incubationCFU/ml before incubation) and are represented as the mean from
duplicate determinations.
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Figure 3.2: Colony diameter (mm) when cultured in different atmospheres. The
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Table 3.2: Incubation conditions for the comparison of anaerobic culture systems.
RCM: Reinforced clostridial medium; -A: agar; -B: broth.
Organisms Media Incubation period (Days)
Clostridium spp. RCM-A, RMC-B 1 day
P. acnes RCM-A, RMC-B 7 days
Bacteroides spp. RCM-A, RMC-B 1 day
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The evaluation was carried out by cultivating the bacteria both in broth
and on agar plates as described previously. In a preliminary test it was
shown that the growth of the anaerobes in RCM broth was visually identical
in all gas system. Also, anaerobes were not the main subject in this thesis.
Therefore, it was decided that the evaluation be recorded by identifying
whether or not the anaerobes grow in the tested conditions (i. e. observe
visually the increase in turbidity), rather than examining the CFU/ml as
was done in the previous section.
3.4.2 Results
The result for the growth of anaerobes in gas systems are shown in Table 3.3.
It was found that all tested anaerobes were able to grow in broth whereas
in all but the GasPak there was no growth on the agar plates. P. acnes was
the only species that failed to grow on the agar plate in all gas conditions.
Columbia agar plates supplemented with 5% sheep blood were also tried in
addition to RCM for P. acnes, but the species still did not form any colonies
in any conditions even if the incubation was prolonged up to 2 weeks.
3.5 Discussion
Overall the results obtained using the spirits burn method were equivalent
or superior to those obtained using a commercial GasPak, a CO2 incubator
or a candle jar.
For most Campylobacter spp. and for H. pylori it is recommended that
O2 should be reduced down to 5–7% (Corry et al., 1995; Versalovic and Fox,
2003). To achieve this environment in a small / middle-scale laboratory,
the GasPak method or candle method is usually used. In the viable count
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Table 3.3: Growth of anaerobes in different gas systems. +: growth visible. −: no
visible growth.
Cultures Spirits Candle CO2 Gaspak
Broth Agar Broth Agar Broth Agar Broth Agar
Clostridium butyricum + - + - + - + +
Clostridium difficile + - + - + - + +
Clostridium perfringens + - + - + - + +
Clostridium sporogenes + - + - + - + +
Clostridium tetani + - + - + - + +
Propionibacterium acnes + - + - + - + -
Bacteroides fragilis + - + - + - + +
Bacteroides stercoris + - + - + - + +
Bacteroides ureolyticus + - + - + - + +
test it was found that cultures of these species could be raised satisfactorily
in either the spirits jar, CO2 incubator or candle jar, with the spirits jar
generating the highest growth rate. However, it was observed that H. pylori
failed to form colonies in the colony size test in either the CO2 incubator,
the candle jar or GasPak (Figure 3.2) whereas the growth was observed in
the broth media (Figure 3.1) under these atmospheric conditions.
The failure of the candle jar is not surprising, albeit, in theory, the
amount of oxygen consumed and CO2 generated should be similar, if not
identical, by burning a candle or burning methylated spirits. In fact, H.
pylori during the evaluation sometimes formed colonies whereas at other
times it did not. It was noticed that the burning time of the candle in a jar
varied significantly, which may consequently have led to the difference in
the amount of oxygen consumed in the jar. Indeed, it was also observed that
the flame of the candle lasted for a markedly shorter time if the exposed
wick was too short, because then the flame would easily be extinguished by
the melted wax that was on the top of the candle (Figures 3.3(a) and (b)).
Therefore the consumed oxygen in a candle jar may differ from time to time,
and perhaps this is why a candle jar is sometimes thought to be unreliable
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Figure 3.3: (a) In theory, the candle in an air-tightened jar should reduce oxygen
concentration and generate a microaerophillic environment; (b) in reality,
however, the melted wax flows into the cavity on the top of candle
and the flame is extinguished before the oxygen in the jar is fully
consumed. On the other hand, (c) the flame by burning methylated
spirits is consistent each time because it will continue to burn until there
is no oxygen left in the jar as long as there is sufficient volume of the
alcohol in the glass Petri dish.
(Bolton and Coates, 1983; Luechtefeld et al., 1982; Wang et al., 1982; Wang
and Luechtefeld, 1983), especially when cultivating fastidious microaerobes
like H. pylori on the surface of an agar plate. On the other hand, the flame
of burning methylated spirits was consistent each time because the volume
of spirits is the only factor that may affect the duration of the flame, which
is relatively easy to control (Figure 3.3(c)).
Another possible explanation for the difference between the spirits burn
method and the candle jar is that the large surface area of the flame in the
dish of alcohol made the production of CO2 and the reduction of O2 more
efficient. The candle was also found to be releasing smoke right after the
flame extinguished which was not observed in the spirits burn method, and
this may have a negative effect on some fastidious organisms.
The composition of the atmosphere appears to be less critical for broth
cultures, as can be seen from Figure 3.1, all of the microaerobes being
cultivated successfully in all of the atmospheres. In the viable count test
all cultures were incubated in the broth in various atmospheres and then
inoculated on the agar plates which were then incubated in the spirits burn
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jar, whereas in the colony size test the microaerobes were inoculated directly
on the agar plates which were then incubated in various atmospheres. It
is possible that the broth media provided the cultures with a protection
from inappropriate atmospheres; the broth may reduce the chance of air
contacting the bacterial cells directly whereas on the surface of agar there
is no protection provided to the cells. When cultured directly on an agar
surface, only the spirits burn method allowed colonies to form whereas
when broth culture were used H. pylori multiplied in all microaerobic
conditions by 2–4 log10.
The protection to the broth culture seems to be applicable to anaerobes
too (Table 3.3). Not surprisingly, the atmosphere generated by the spirits
burn method is not suitable for Clostridium and Bacteroides species on the
agar surfaces, as the concentration of the oxygen left in the jar is unaccept-
able for obligate anaerobes (Ribeiro et al., 1985). The growth of anaerobes in
broth culture was reasonably good in all atmosphere conditions including
the spirits burn method and the candle jar. Although detailed viable count
and colony size tests were not carried out with anaerobic species, this might
suggest that the non-commercial gas systems could also be used for incu-
bating anaerobes in broth media as an economical alternate. It would be
of interest to test this with other anaerobes in the same condition in future
work.
CO2 is usually required to stimulate the growth of some cultures such
as H. influenzae. The results revealed that the CO2 incubator provided a good
environment for this species and it is interesting to note that the spirits burn
method and the candle jar were as efficient as the CO2 incubator, although
the candle jar appeared to be relatively unstable.
For species generally used as probiotics (L. plantarum, L. rhamnosus and
B. animalis subsp. lactis) all tested atmospheres were found to support their
growth. It is interesting that although B. animalis subsp. lactis is generally
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considered to be an anaerobe, non-GasPak methods seem to be applicable
for the species even on the agar surfaces.
The spirits burn method also has several potential other advantages
over other gas generating systems. With the spirits burn method, a more
rapid production of a microaerobic condition could be achieved than
with the commercial GasPak system. According to the manufacturer’s
instruction (http://www.mgc.co.jp/eng/products/abc/anaeropack/kenki.
html and http://www.mgc.co.jp/eng/products/abc/anaeropack/bikouki.
html [accessed 16/06/08]), it takes about 30 min–2 hours to generate a
microaerophilic or anaerobic atmosphere. On the other hand, the spirits
burn method takes only a few seconds to reduce the oxygen in the jar. The
fast reaction reduces the potential risk of the organisms being exposed to
oxygen at the initial stage of the incubation.
The spirits burn method generates moderate humidity in the jar at the
very first stage which can be observed from dense condensation of water
on the wall of the tin, bottles and Petri dishes. As several organisms such
as Campylobacter spp. and Helicobacter spp. prefer humid condition for their
growth (Fraser et al., 1992; Versalovic and Fox, 2003), this may also help
the growth of such cultures. Furthermore, the flame warms the container at
the start and therefore may reduce the time required to reach the optimum
temperature for growth of the bacteria.
The spirits burn method has a significant advantage over other sys-
tems when considering simplicity. According to the instruction from the
manufacturer, the GasPak needs to be sealed in a jar within 1 minute after
tearing open the outer foil to achieve maximum performance as the reaction
starts right after opening the sachet. This also means the paper sachet is
not re-usable should air leakage or any mistake be found afterwards. On
the other hand, the reaction would not start with the spirits burn method
or the candle jar until a flame is lit, and also the whole process can be
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repeated if necessary. Unlike candle jars, no melted candle wax, which is
hard to clean out, is produced with the spirits burn method. Although the
CO2 incubator has the same advantage, the concentration of the CO2 may
fluctuate when opening the door and handling plates or bottles. The acidity
of media may also increase due to the formation of carbonic acid under long
term incubation and this may affect the result of antibiotic susceptibility
tests.
Cost saving may be one of the most significant merits of the spirits
burn method over the commercial solutions. With the spirits burn method,
a 3.5 l or 11.5 l incubation size requires only 500 µl or 1.5 ml of alcohol,
respectively. On the other hand, the MGC GasPak system recommends 1
sachet for a 2.5 l jar or 3 sachets for a 7.0 l jar and the cost per test would
be over one thousand times more expensive than that of the spirits burn
method (Table 3.4).
3.6 Safety issues
As this method uses only a small volume of spirits, there should be minimal
concern about the combustion. Also the ‘transparent’ flame has never been a
safety issue as it is limited to the Petri dish and extinguishes within seconds.
However caution should be made when sealing the container with vinyl
tape as the flame heats up the top of the lid and may burn the hand holding
it. Wearing cotton gloves when sealing the tape, or, alternatively, marking
the position of the Petri dish on the lid and keeping hands away from the
area should avoid the hazard.
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3.7 Conclusion
The spirits burn method gives a significant improvement over the candle
jar, and it is also concluded that commercial gas generating systems are
not necessarily always required to cultivate cultures of non-aerobic species.
Although not specifically tested in this study, it might also be useful for
cultivating other microaerobes and even anaerobes in a budget-constricted
laboratory. On the basis of these findings, the technique was used wherever
microaerophilic conditions were required in the studies described in this
thesis.
4
S U S C E P T I B I L I T Y O F E N T E R O B A C T E R I A T O H O N E Y
As the aim of this study was to evaluate if manuka honey is likely to be
useful for gut infections, it was necessary to first find how susceptible the
gastrointestinal bacteria are to the honey.
In this chapter the minimum inhibitory concentration (MIC) and min-
imum bactericidal concentration (MBC) of manuka honey and artificial
honey to common pathogenic gastrointestinal bacteria were tested using
the broth microdilution method. The susceptibility of probiotics was also
measured to find if they would be likely to survive the treatment of enteric
infections with honey.
Part of the work in this chapter has been published (see Appendix):
Lin, S.M. Molan, P.C. and Cursons, R.T. (2009). The in vitro susceptibility of
Campylobacter spp. to the antibacterial effect of manuka honey. 28(4):339–344.
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4.1 Introduction
4.1.1 Honey and gastrointestinal pathogens
As pointed out in Chapter 1, bacterial gastrointestinal disorders are one of
the most common clinical diseases. These are largely caused by, but not
limited to, Enterobacteriacea (E. coli, Shigella, Enterobacter, Yersinia), Salmonella,
Campylobacter and H. pylori. Several “opportunistic” microorganisms such
as C. difficile may be associated with gastroenteritis although they normally
do not cause disease (see Chapter 1).
Honey has been reported to show a significant antibacterial activity
against a wide range of bacteria (reviewed in Chapter 1), but those reports
of efficacy of honey are not always comparable with each other for several
reasons. On the one hand, the detail on the honey being tested is not clearly
given. For instance, Badawy et al. (2004) compared the antibacterial activity
of four Egyptian clover honey samples, each of which had been stored for a
different period of time (7 months, 12 years, 16 years and 21 years) against E.
coli O157:H7 and S. typhimurium and reported that the activity declined with
time. However, Badawy et al. (2004) did not state whether honey samples
had been stored at room temperature or in a dark refrigerator but it is known
that antibacterial activity of honey is sensitive to light and to heat (Molan,
1992b). In some reports (for example, Adebolu (2005) and Obi et al. (1994))
even the floral source of the tested honey was not given but the activity of
honey can vary greatly among different floral types (Allen et al., 1991b). It
has also been known that the potency of honeys sharing the same floral
source could differ in activity by up to 100-fold Molan (1992b). Therefore, it
is necessary to have the antibacterial activity of honey standardised.
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On the other hand, many published reports failed to give details on the
bacteria being tested such as the inoculum density. As the more bacterial
cells there are in the testing environment, the more likely for the bacteria
to overcome the toxicity of antibacterial agents, it is important to state the
number of the cells being involved in the assessment of an antibacterial
agent.
The objectives of this study were to investigate the antibacterial activity
of a standardised manuka honey against a number of standardised number
(inoculum density) of type strains and clinical isolates of gastrointestinal
pathogens from patients with diarrhoea. Additionally, to understand the
potential impact of the antibacterial activity of manuka honey on normal
flora, the sensitivity of some probiotic species to manuka honey was also
examined in this chapter. The data obtained in the study in this chapter
were also used as the basis for the work in the following chapters.
4.2 Materials and methods
4.2.1 Honey samples used in this study
Manuka honey samples (internally labelled as M113 in the Honey Research
Unit laboratory collection) from Bee & Herbal NZ Ltd. and from Summer-
Glow Apiaries Ltd. (labelled M115 in the laboratory collection) were used
for testing the susceptibility of gastrointestinal bacteria to manuka honey.
These honeys were labelled “UMF 16+” on their packages, and were there-
fore supposed to have a minimum antimicrobial activity equivalent to 16%
phenol. However, it was not realised until the susceptibility tests with some
species (C. difficile and Campylobacter spp.) had been done that these honeys
had antimicrobial activity equivalent to that of 29.4% and 16.5% phenol,
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respectively, when checked with the method reported by Allen et al. (1991a)
as described in Section 2.5. The M113 batch had an exceptionlly high non-
peroxide activity, nearly twice as high as it was labelled. Consequently, the
MIC and MBC results obtainined using the honey sample M113 with nearly
twice the antibacterial potency would be expected to be approximately half
of those using manuka honey M115 (Peter Molan personal communication).
Therefore, in this chapter most microorganisms were tested with manuka
honey sample M115, the honey sample with a medium-level activity, except
that Campylobacter spp. and C. difficile were tested with M113. An artificial
honey was included in this test to simulate the sugar composition of honey
(see Section 2.3). The honey samples were stored in a dark refrigerator until
used.
4.2.2 Bacterial strains and culture media used in this study
E. coli, S. typhimurium DT104, S. enteritidis, E. aerogenes, E. cloacae, S. flexneri,
S. sonnei, Y. enterocolitica, Campylobacter spp., H. pylori, Lactobacillus spp. and
B. animalis subsp. lactis were used in the susceptibility test in this chapter.
See Table 2.2 for the culture media used for the work in this chapter.
4.2.3 Cell density control
For most non-fastidious organisms, each culture was recovered from cryop-
reservative beads by transferring one bead into 10 ml MHB then incubating
at 37°C overnight. The optical density of the recovered culture was adjusted
to 0.08 at 625 nm by addition of MHB and then was further diluted 300-
fold (10 µl culture in 3 ml MHB). This was used as the inoculum for the
susceptibility testing.
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The anaerobes B. animalis subsp. lactis, Lactobacillus spp. and C. difficile
were handled similarly except that these were cultured with MRS (B. animalis
subsp. lactis and Lactobacillus spp.) and RCM (C. difficile) in GasPak canisters
instead of with MHB in the ambient atmosphere.
For the fastidious species Campylobacter and H. pylori each isolate was
recovered by rubbing the surface of the frozen stock culture with sterilised
cotton swabs then streaking it onto blood-free Campylobacter selective agar
and CHBHP agar, respectively, followed by incubating microaerobically at
37°C for 48 h and 72 h, respectively. The recovered colonies were collected
with cotton swabs and suspended in fresh MHB. The optical density at 625
nm was adjusted to 0.08 with fresh MHB then was further diluted 300-fold.
The broth cultures prepared with the method described above had a
final culture density of approximately 3×105 cells/ml which was confirmed
with the track dilution method as described in Chapter 2. These were used
as the inocula through the sensitivity testing repeated in this chapter.
4.2.4 Honey preparation
Double-strength solutions of manuka honey and artificial honey were pre-
pared with pure water, then an equal amount of double-strength MHB,
MRS or RCM broth (prepared by adding twice the recommended amount
of broth powder in pure water) was added to make single-strength manuka
honey and artificial honey solutions. These single strength honey solutions
were considered as the “original” honey solutions. For example, to make an
original honey solution of 40% (v/v), 4 ml of honey (measured as 5.48 g, as
honey has an average density of 1.37 g/ml) was added to 1 ml of pure water
in a universal bottle and then placed in a 37°C water bath for 5 min to aid
dissolving. After mixing with a wooden stick, the 5 ml of double strength
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honey (80%) was added with 5 ml of double strength broth to achieve the
desired final concentration (40%).
The original honey solutions made with MHB and MRS broths were
filter-sterilised with 0.2 µm filters (Sartorius Co.) before serial dilution. The
original honey solution made with RCM broth, however, was not able to
be filter sterilised because RCM broth contains a small amount of agar as a
protectant, which makes it impossible to pass through the filter membrane.
Because the MIC and MBC of artificial honey would presumably be
higher than that of manuka honey, the concentration of original artificial
honey used was twice as high as that of original manuka honey in the
test. A higher concentration of original honey solution was used if the MIC
appeared to be higher than the detectable range of the MIC test. Up to 50%
original honey solution (16.6% after inoculating broth culture as stated in the
following sections) was made. It is unlikely that the ingested honey would
be at as high level as 20% in the gut because the high osmolarity would
inhibit emptying of the stomach (Peter Molan personal communication). If
an even higher concentration of honey was found to be required to inhibit
the growth of the tested microorganisms, the MIC was recorded as “>
16.6%”.
4.2.5 Honey serial dilution
For facultative anaerobes and microaerobes, a broth microdilution method
on microplates was used. Of the 12 wells in each column in a microplate, to
the first was added 40 µl honey solution, and to the remaining 11 wells were
added 40 µl MHB. For serial dilution, 160 µl honey solution was added into
the second well in the column and then 160 µl was sequentially transferred
to the following wells till the tenth well. The last two wells served a growth
control (culture and broth added but no honey) and sterility check (plain
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broth). After that 80 µl of inoculum was added into each well except the last
well in which 80 µl plain broth was added instead. The final concentrations
of honey solution after inoculating bacteria in successive columns are shown
in Table 4.1.
Table 4.1: The original concentrations of honey solutions used in each column, and
the final concentration in each microplate well after serial dilution and
inoculating cultures.
Original concentration: 50% 40% 30% 20% 10%
Well 1 16.60% 13.20% 9.90% 6.60% 3.33%
Well 2 13.30% 10.64% 7.98% 5.32% 2.66%
Well 3 10.65% 8.52% 6.39% 4.26% 2.13%
Well 4 8.50% 6.82% 5.12% 3.41% 1.70%
Well 5 6.80% 5.40% 4.05% 2.70% 1.36%
Well 6 5.45% 4.36% 3.27% 2.18% 1.09%
Well 7 4.35% 3.48% 2.61% 1.74% 0.87%
Well 8 3.49% 2.78% 2.09% 1.39% 0.70%
Well 9 2.79% 2.24% 1.68% 1.12% 0.56%
Well 10 2.23% 1.79% 1.34% 0.89% 0.45%
For anaerobes (B. animalis subsp. lactis, Lactobacillus spp. and C. difficile)
a 10 times larger volume of broth in glass tubes was used instead of mi-
croplates. This macrodilution was for protecting the anaerobic cells from
contact with the air during the process.
4.2.6 MIC and MBC determination
The growth of non-fastidious organisms in the microplates was monitored
at 37°C for 18 hours using a microplate reader (BMG FLUOStar OPTIMA)
and the results were observed as the monitored growth curves. The mi-
croplate with the fastidious organisms Campylobacter spp. and H. pylori
was incubated microaerobically at 37°C for 48 hours using the spirits burn
method. The tubes with anaerobes were incubated anaerobically at 37°C for
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18 hours using a gas pack system (MGC AnaeroPakTM). The results of both
microaerobes and anaerobes were observed visually at the end of incubation.
The lowest concentration of honey needed to completely inhibit the growth
of an microorganism in the 18 h period of incubation was defined as the
minimum inhibitory concentration (MIC) of honey for the microorganism.
After the MIC determination, from each well or tube 10 µl was subcul-
tured on appropriate agar plates without honey present to see if the various
concentration of honey had been bacteriostatic or bactericidal for the tested
organisms. The lowest concentration of honey the bacteria had been exposed
to that completely inhibited the growth of the subcultured microorganism
was considered to be the minimum bactericidal concentration (MBC). If
the MIC was greater than 16.6%, which was the highest final concentration
available in the MIC test, then subculturing was omitted as this suggested
that the microorganism is relatively resistant to the honey and also that it
would be of no practical importance to further investigate the MBC with a
yet higher level honey. The broth cultures in the growth control wells were
also subcultured on agar plate as positive controls. The susceptibility test
for each species was replicated 5 times.
4.3 Statistical analysis
The difference between manuka honey M115 and the artificial honey for
each species in results was analysed by the Wilcoxon test in the statistical
package R (http://www.r-project.org) (R Development Core Team, 2008).
Two-sided P < 0.05 was considered statistically significant. Analysis was
omitted for any species for which the MIC or the MBC was higher than
16.6%.
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4.4 Results
4.4.1 Facultative anaerobes
All the facultative anaerobes had a lower MIC value with manuka honey
M115 than with artificial honey (Table 4.2). Generally, manuka honey at a
concentration less than 8% could inhibit the growth of the tested gastroin-
testinal bacteria. Although Enterobacter spp. had higher MICs than other
tested microorganisms, the concentrations of manuka honey required to
inhibit their growth were still lower than those of sugar syrup (approx.
11% cf >16%). The MBCs of manuka honey were generally higher than the
MICs of the same honey by one or two dilution steps. The MIC and MBC
of manuka honey M115 against the P. aeruginosa isolate were found to be
relatively higher than those against other species of bacteria (approximately
16.6%).
4.4.2 Microaerobes
The results showing the sensitivity of Campylobacter spp. are shown in Table
4.3. The susceptibility test revealed that the growth of all 29 species of
Campylobacter were strongly inhibited by manuka honey M113. The MIC of
manuka honey for Campylobacter ranged from 0.8% to 1.1% whereas that of
artificial honey was 3–4 times higher than that of manuka honey (3.1–4.3%),
revealing that the MIC of manuka honey for each strain was significantly
lower than that of artificial honey (P < 0.05).
The MIC of manuka honey M115 for H. pylori was significantly lower
than that for artificial honey (5.64 ± 1.57 cf. 16.6 ± 0; P < 0.05). Given that the
potency of manuka honey M113 used for Campylobacter spp. was 1.78-time
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Table 4.2: The minimum inhibitory and bactericidal concentrations (% v/v) of
manuka honey M115 and artificial honey for non-fastidious gastroin-
testinal pathogens. The values are represented as means of replicates ±
standard deviation. The determinations of the MIC and MBC values for
each isolate were carried out after 18 h incubation, and were replicated 5
times. NT: not tested.
Species MIC MBC
Manuka Artificial Manuka Artificial
E. coli 6.87±0.97 > 16.6 7.48±0.83 NT
S. aureus 3.74±0.39 > 16.6 6.53±0.54 NT
P. aeruginosa 15.94±1.32 > 16.6 16.6±0 NT
Y. enterocolitica 4.79±0.54 > 16.6 5.45±0 NT
S. typhimurium DT104 7.48±0.83 > 16.6 10.65±0 NT
S. enteritidis 6.8±0 > 16.6 8.5±0 NT
E. aerogenes 11.89±2.15 > 16.6 16.6±0 NT
E. cloacae 10.65±0 > 16.6 16.6±0 NT
S. flexneri 7.58±1.14 > 16.6 8.5±0 NT
S. sonnei 6.61±0.47 > 16.6 8.5±0 NT
(29.4/16.5) that of manuka honey M115 which had been used for H. pylori,
we may presume that the MIC of manuka honey M115 for Campylobacter spp.
would be about 1.42–1.96 %. It may consequently be presumed that the MIC
of manuka honey with the same potency would be lower for Campylobacter
spp. than for H. pylori.
The subculturing after determining the MIC showed that growth oc-
curred when subculturing from concentrations of honey below the MIC
whereas there was no growth from concentrations at and above the MIC.
This revealed that the MIC of either manuka honey or artificial honey was
also minimum bactericidal concentration (MBC) for H. pylori and for all of
the Campylobacter spp. in this study.
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Table 4.3: The minimum inhibitory concentration (% v/v) of manuka honey and
artificial honey for microaerobes. Campylobacter and H. pylori were tested
with manuka honey M113 (equivalent to 29.4% phenol) and M115 (equiv-
alent to 16.5% phenol), respectively. The values are represented as means
of the replicates ± standard deviation. The determination of the MIC
values for each isolate was carried out after 48 h incubation, and was
replicated five times. The values of MBC were the same as those of MIC
and were therefore not shown in this table.
Strains Manuka honey Artificial honey
C. jejuni 1 0.84 ± 0.08 3.13 ± 0.39
C. jejuni 2 1 ± 0.12 3.58 ± 0.38
C. jejuni 3 1 ± 0.12 3.44 ± 0.55
C. jejuni 4 0.8 ± 0.09 3.13 ± 0.39
C. jejuni 5 0.88 ± 0.14 3.58 ± 0.38
C. jejuni 6 1.05 ± 0.1 3.27 ± 0.32
C. jejuni 7 0.92 ± 0.17 3.75 ± 0.47
C. jejuni 8 0.96 ± 0.12 3.75 ± 0.47
C. jejuni 9 1 ± 0.12 3.92 ± 0.47
C. jejuni 10 0.8 ± 0.09 3.58 ± 0.38
C. jejuni 11 0.91 ± 0.1 3.58 ± 0.38
C. jejuni 12 1.05 ± 0.1 3.92 ± 0.47
C. jejuni 13 0.96 ± 0.12 3.92 ± 0.47
C. jejuni 14 0.88 ± 0.14 3.61 ± 0.66
C. jejuni 15 0.96 ± 0.12 3.75 ± 0.47
C. jejuni 16 1.05 ± 0.1 3.75 ± 0.47
C. jejuni 17 0.8 ± 0.09 3.92 ± 0.47
C. jejuni 18 1 ± 0.12 3.92 ± 0.47
C. jejuni 19 0.96 ± 0.12 3.58 ± 0.38
C. jejuni 20 0.92 ± 0.17 3.61 ± 0.66
C. jejuni ATCC 33560 1 ± 0.12 3.58 ± 0.38
C. coli 1 1.05 ± 0.1 4.09 ± 0.38
C. coli 2 1 ± 0.12 4.3 ± 0.68
C. coli 3 1.14 ± 0.12 4.09 ± 0.38
C. coli 4 1.1 ± 0.17 3.92 ± 0.47
C. coli 5 1.2 ± 0.15 3.92 ± 0.47
C. coli 6 1.14 ± 0.12 4.09 ± 0.38
C. coli 7 1.1 ± 0.17 3.92 ± 0.47
C. coli ATCC 33559 1.05 ± 0.1 4.09 ± 0.38
C. fetus ATCC 27374 0.96 ± 0.12 3.44 ± 0.55
H. pylori ATCC 43504 5.64 ± 1.57 16.6 ± 0
Mean of C. jejuni (n=21) 0.94 ± 0.08 3.63 ± 0.24
Mean of C. coli (n=8) 1.1 ± 0.06 4.05 ± 0.13
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4.4.3 Anaerobes
The results showing the sensitivity of the anaerobes are listed in Table 4.4.
The MIC of M113 manuka honey for C. difficile ranged between 2–3.6%, and
the MBC between 4–5.4%. The C. difficile tested were much more resistant
to artificial honey than natural honey, as can be seen from the high MIC (>
16.6%).
Table 4.4: The minimum inhibitory and bactericidal concentrations (% v/v) of
manuka honey M113 and artificial honey for C. difficile. The values are
represented as means of the replicates ± standard deviation. The deter-
minations of the MIC and MBC values for each isolate were carried out
after 18 h incubation, and were replicated five times. NT: not tested.
Strains MIC MBC
Manuka Artificial Manuka Artificial
C. difficile isolate 1 2.24 ± 1.28 > 16.6 5.15 ± 0.97 NT
C. difficile isolate 2 3.13 ± 0.78 > 16.6 5.41 ± 0.99 NT
C. difficile isolate 3 2.63 ± 0.81 > 16.6 4.23 ± 0.5 NT
C. difficile NCTC 11382 3.67 ± 0.43 > 16.6 4.91 ± 1.07 NT
C. difficile ATCC 9689 3.15 ± 0.87 > 16.6 4.72 ± 0.68 NT
C. difficile ATCC 43593 1.90 ± 0.69 > 16.6 4.66 ± 0.62 NT
4.4.4 Probiotics
The results for the sensitivity of the anaerobes to manuka honey M115 are
shown in Table 4.5. The results revealed that these species are relatively
tolerant to both manuka honey M115 and artificial honey. This is especially
obvious in B. animalis subsp. lactis and Lactobacillus spp., for which there is
no statistically significantly difference in the MIC values between the two
types of honey for each species (P > 0.05).
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The MBC of both manuka honey M115 and artificial honey for all tested
probiotics are very high. For all species a concentration of higher than 13.3%
of manuka honey was required to kill the probiotics. Because higher than
16.6% of manuka honey M115 seems to be required to kill B. animalis subsp.
lactis and Lactobacillus spp., it was not possible to compare the MBC values
of the manuka honey with those of artificial honey.
Table 4.5: The minimum inhibitory and bactericidal concentrations (% v/v) of
manuka honey M115 and artificial honey for the normal flora in the
gastrointestinal tract. The values are represented as means of replicate ±
standard deviation. The determination of the MIC values for each isolate
was carried out after 18 h incubation, and was replicated five times. NT:
not tested.
Species MIC MBC
Manuka Artificial Manuka Artificial
E. faecalis ATCC 19433 9.89 ± 1.9 > 16.6 16.6 ± 0 NT
E. faecium ATCC 19434 9.36 ± 1.05 > 16.6 13.3 ± 0 NT
B. animalis subsp. lactis 11.88 ± 4.9 14.7 ± 3.31 > 16.6% > 16.6%
L. plantarum ATCC 8014 14.15 ± 3.62 16.6 ± 0 > 16.6% > 16.6%
L. rhamnosus ATCC 7469 14.29 ± 2.67 16.6 ± 0 > 16.6% > 16.6%
4.5 Discussion
Because some of the species in this work were done with double-potency
manuka honey (M113; with non-peroxide antimicrobial activity equivalent
to that of 29.4% phenol) whereas other species were done with manuka
honey M115 which is equivalent to 16.5% phenol, the MIC and MBC values
obtained in this chapter cannot be compared directly. Despite this, it is
possible to convert the mean MIC and MBC values for species tested with
manuka honey M113 by multiplying them by 1.78 (i. e. 29.4/16.5) so as to
compare them with the MIC/MBC of manuka honey M115.
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Overall the average concentration of manuka honey required to inhibit
the growth of most organisms tested in this study was very low, which
agrees with most other studies that tested or reviewed the efficacy of manuka
honey against organisms with manuka honey (Al Somal et al., 1994; Cooper
and Molan, 1999; Cooper et al., 2002a,b; French et al., 2005; Molan, 2006).
The exceptionally high concentrations required to control P. aeruginosa are
probably because of the biofilm, as has been widely known to be linked to
its resistance against antimicrobial agents (Drenkard, 2003; Mah et al., 2003;
Ryder et al., 2007).
Most publications only considered the MIC of the honey for microor-
ganisms and rarely did they estimate the antibacterial property further. In
this study the MIC and the MBC of the total activity of honey for some
common gastrointestinal microorganisms were tested. The effectiveness of
the non-peroxide antibacterial activity alone will be discussed in Chapter 5.
4.5.1 Facultative anaerobes
Most facultative anaerobes tested were inhibited by the manuka honey with
antimicrobial potency near the median level (equivalent to approx. 16%
phenol) even when the honey was diluted 10-fold or more. On the other
hand, the artificial honey which imitates the sugar content of a normal
honey failed to inhibit the growth of all tested microorganisms even at the
highest concentration used in the test (16.6%). This suggests that it is not the
osmolarity but other antibacterial factors in the honey that are responsible
for the inhibition of the growth of the bacteria.
In this susceptibility test, S. typhimurium DT104, a multi-antibiotic re-
sistant strain of Salmonella, was included because the prevalence has been
increasing for the last few years, and it is revealed that this strain can be
inhibited by manuka honey at a concentration less than 10%. Although
chapter 4 susceptibility of enterobacteria to honey 99
antibiotic-resistant microorganisms are being increasingly reported and the
number of resistant bacteria tested with honey is still limited so far, the
efficacy of manuka honey against these seems promising. Prior studies have
shown that honey is effective on MRSA and VRE (Cooper et al., 1999, 2002b;
Natarajan et al., 2001).
Interestingly, bacteria with antibiotic-resistance properties were reported
as soon as antibiotics were commonly used among the medical professions
(Bennett and Parkes, 1944; Bondi and Dietz, 1945; Gallardo, 1945), whereas
resistance to honey has not been reported regardless of it having been used
as a medicine for millennia. The fact that bacteria have failed to develop
resistance to honey is perhaps partially because the antibacterial efficacy
of honey has not been widely known by medical professionals, and also
partially because many of the reported antibacterial activities of honey
being used had not been well standardised using a reference antiseptic.
The result has been that a wide range of MIC values have been reported in
the literature (in some cases these have ranged from less than 20% up to
100% for the same bacterial species; see Table 1.2), and consequently it is
impossible to detect whether or not resistance to honey has developed.
Microorganisms are unlikely to acquire antibacterial resistance if they
are treated with compounds targeting multiple loci (DeVito et al., 2002). As
reviewed in Chapter 1, honey is a complex substance and the antibacterial
activity is multi-factorial (Molan, 2009). Rose Cooper at University of Wales
Institute has conducted a long-term study to select wound pathogens re-
sistant to manuka honey by continuously exposing bacteria to a sub-lethal
concentration of honey, but honey-resistant bacteria have not yet developed
successfully (Cooper et al., 2009). A similar study conducted at Sydney
University also failed to develop honey-resistant strains of S. aureus and
P. aeruginosa whereas these bacteria had increased their resistancy to other
antibacterial agents under similar condition in the study (Blair et al., 2009).
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Although the number of antibacterial-resistant strains that have been tested
with honey is relatively limited and whether or not bacteria would even-
tually develop resistance to honey was not evaluated in this study, the
sensitivity of S. typhimurium DT104 to manuka honey in this study may par-
tially, if not fully, suggest the usefulness of honey on treating multi-resistant
strains of bacteria increasingly seen in medical disciplines.
4.5.2 Microaerobes
Although the data obtained from this study cannot fully represent the profile
of the genus Campylobacter, it is still obvious that the species tested are very
susceptible to manuka honey regardless of their strains. The susceptibility
test using manuka honey M113 gave a mean MIC value of 0.98% (standard
deviation 0.15%) for the 30 C. strains (this includes 21 C. jejuni, 8 C. coli and
1 C. fetus).
The exceptionally low MIC for the artificial honey suggests that this
microorganism may be highly susceptible to osmolarity. Doyle and Roman
(1982) reported that C. jejuni could grow in brucella broth containing 1.5%
of NaCl but failed in 2.0% NaCl or greater, and although large amount of
C. jejuni (105–106 CFU/ml) may increase the tolerance in 6.5% salt at 4°C,
the viable cells significantly decreased in 4.5% salt at room temperature. In
that report Doyle showed that nalidixic acid-resistant thermophilic Campy-
lobacter (NARTC) was generally tolerant to salt concentration, yet it still was
unable to grow in the presence of 2.5% NaCl. Doyle and Roman (1982) also
noted that a few strains would adapt to up to 6.5% NaCl after frequent
subculturing and claimed that osmolarity might not be ideal for inhibiting
the growth of Campylobacter spp. Interestingly, Reezal et al. (1998) noted
that the osmotic effect on Campylobacter was seen regardless of whether
the osmolyte in the medium was glucose or salts. Accordingly, the high
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susceptibility of Campylobacter spp. to honey solutions observed in this study
may be due in part to the osmotic effect of the sugar content as well as
to other antimicrobial factors. However, given that the difference in the
MIC of manuka honey and artificial honey were large (0.98 ± 0.15 cf. 3.74 ±
0.5), the other antibacterial factors must also be largely contributing to the
effectiveness of manuka honey.
The high susceptibility of Campylobacter spp. to osmolarity, however,
may not be of practical consequence from an antimicrobial viewpoint. The
concentration of sugar in the gut would decline rapidly down below the
MIC through absorption across the mucosa and consequently may not
inhibit the growth of Campylobacter spp. in the gut. Sugar is usually used for
oral rehydration therapy or as immediate treatment for hypoglycaemia due
to its rapid absorption through intestinal villi (Cuccurullo, 2004). Therefore
dietary sugar is unlikely to contribute to the inhibition of campylobacteriosis.
On the other hand, although formerly named Campylobacter pyloridis,
the susceptibility of H. pylori to honey appears to be quite different from
Campylobacter spp. Although the manuka honey used with H. pylori had
about half the antibacterial potency of that used with Campylobacter spp.,
the mean MIC value would be expected to decline by 1.78-times (i. e. 3.17 ±
0.88) if the same honey as with the Campylobacter spp. work had been used.
This calculated mean MIC value for H. pylori is still much higher than that
for Campylobacter spp. As discussed above, Campylobacter seems to be highly
sensitive to the osmotic effect, these being low MIC values even in artificial
honey, whereas much higher concentration of artificial honey was required
to inhibit H. pylori. Al Somal et al. (1994) tested the sensitivity of H. pylori
to manuka honey (with non-peroxide activity equivalent to 13.2 % phenol)
using an agar-well diffusion method with blood agar, and found that H.
pylori can be inhibited with 5% manuka honey over 72 hours incubation.
Ali et al. (1991) also reported that the growth of H. pylori may be prevented
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with honeys from New Zealand and Saudi Arabia as well as carbohydrate
solutions (glucose, fructose, and a mixture of these sugars in ratio of 1:1.23).
In Ali et al.’s work, all carbohydrate solutions at a concentration of 15%
or below were sufficient to inhibit all 28 clinical isolates of H. pylori. This
suggests that besides the antibacterial component of honey, osmotic effect
may be an important parameter for inhibiting or killing the species (albeit
the effect may not be as significant as to Campylobacter).
There has been a clinical report which concern that manuka honey may
not be useful for eradicating H. pylori. McGovern et al. (1999) treated 6
patients who had positive CLO tests (a rapid urease test to detect H. pylori)
and 14C urea breath tests with one tablespoon of manuka honey (with non-
peroxide activity equivalent to 11.7% phenol), 4 times a day for 2 weeks, and
another group of 6 patients was given honey and omeprazole twice a day
for the same period. At the end of the two week trial both groups revealed
positive 14C urea breath test and the authors commented that the honey was
ineffective at eradicating H. pylori. In this short report the authors did not
state if the patients intook the honey before or after each meal. Although it
seems that the McGovern et al. (1999) were following the suggestion in a
magazine that “for ulcer relief ... eat a tablespoon of the honey spread on
bread an hour before each meal”, there has not been any scientific evidence
suggesting that this would be a suitable dose for treating H. pylori, and also
other factors may also have affected the result of the trial. In accordance
with the susceptibility test in this study or with the prior study reported by
Al Somal et al. (1994), 5% honey would be enough to prevent the growth of
H. pylori.
Whilst the dose applied by McGovern et al. (1999) is somewhat con-
troversial, the failure in the reported honey therapy could be explained by
the biofilms. Carron et al. (2006) demonstrated biofilms in human gastric
mucosa formed by H. pylori using a scanning electron microscope (SEM),
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and suggested that this may be the cause why some H. pylori eradication
therapies failed. Indeed, biofilms can protect bacteria from undesirable
environmental factors like atmospheres and drugs, and it has been reported
that a higher concentration of manuka honey than the MIC is required
to eradicate the biofilms on the wound (Cooper and Jenkins, 2008). This
is in agreement with the high MIC/MBC values for P. aeruginosa in Table
4.2 (both the MIC and MBC were approximately at 16.6%). Although in
topical wound control, this can be overcome by consistently covering the
wound with honey impregnated wound dressings or honey gels, this would
not be feasible when honey is intaken orally. It must be emphasized that
most susceptibility tests, including this project, were conducted under the
condition of exposing the microbe to the honey for 72 hours, while any
watery food like honey is unlikely to stay in the stomach for more than an
hour. Therefore, further investigation on the relationship between manuka
honey and the biofilms of H. pylori is required to evaluate the possibility
of using the honey to eradicate H. pylori in the stomach, and at this stage
people should not expect manuka honey to relief peptic ulcers or to eradi-
cate H. pylori from the stomach from the reports based solely on the in vitro
sensitivity tests.
It must also be noted that the result of the susceptibility of H. pylori to
honey in this study definitely is not representative to all H. pylori due to the
small sample size. It was attempted to collect several clinical isolates of H.
pylori from Waikato hospital, NZ and then ESR, NZ but unfortunately this
was not possible because it would take considerable effort to isolate and
culture the species. Also, because of the difficulty on culturing H. pylori and
Campylobacter, microaerobes were omitted from the studies in the following
chapters.
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4.5.3 Clostridium difficile
Although the sensitivity of C. difficile to manuka honey was determined
with honey with high activity (M113), the MIC and MBC of honey with
median activity (M115) for the anaerobes can be estimated to be about twice
the MIC or MBC of that shown in Table 4.4. This would give MIC values
between 4% and 7.5%, and MBC between 8% and 11%.
The sensitivity of C. difficile to antimicrobials including honey can be
somewhat controversial because drugs can be effective against the bacterial
cells but not the endospores. Although the C. difficile tested did not reveal
resistance to manuka honey, the efficacy of honey against its endospore is
unknown. In fact, even a high concentration of manuka honey is unlikely to
be effective against bacterial endospores. Honey is stored aseptically in bee
hives because of the enzymatic production of hydrogen peroxide during
the ripening. When beekeepers collect honey from honey combs, the honey
is exposed to the ambient environment and the outside of the honeycomb
which may increase the chance it being contaminated by microbes (Cooper
et al., 2009). Microbial contamination is of no concern in an undiluted honey
because of the low aw in which most microbes cannot survive. However,
spores introduced into honey are not killed because spores can survive in
high osmolarity, and although hydrogen peroxide is sporicidal at 0.88 M
(Baldry, 1983), it is not produced until honey is diluted because the water
activity is too low for glucose oxidase in honey to work. Even if honey is
diluted so that the production of hydrogen peroxide is activated, the typical
concentration (1 mM) is still far too low to kill spores (Molan, 1992a). Indeed,
bacterial spores, particularly the Bacillus genus and Clostridium botulinum,
are regularly found in honey (Snowdon and Cliver, 1996), and this is why
honey is usually not recommended to be fed to infants. Although bacterial
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spores in honey are unlikely to germinate, this indirectly indicates that
honey may not be useful for eradicating the bacterial endospores in the gut.
Nonetheless, because it is viable bacterial cells but not spores that
cause C. difficile-associated diarrhoea, the resistance of endospores to honey
may not be of practical concern. In modern medicine, metronidazole or
vancomycin has been used to treat severe C. difficile-associated diarrhoea
but none of the drugs target the clostridial spores. Metronidazole is selec-
tively taken up by anaerobe cells, reduced by indigenous enzymes, and
the end product disrupts the DNA helical structure (Corey et al., 2007;
Franklin and Snow, 2005). Vancomycin, on the other hand, acts by inhibiting
proper biosynthesis of cell wall peptidoglycan in a Gram-positive anaerobe
(Franklin and Snow, 2005). Clostridial bacteria or their spores could have
existed in the gut of a host, but only when the clostridial cells germinate and
outnumber other competitors in the gut can the species cause disease. It is
possible that the antibacterial activity of manuka honey can be of some help
to patients suffering from C. difficile-associated diarrhoea by suppressing
the bacterial cells. Perhaps the capability of honey to stimulate the growth
of probiotics may also indirectly help suppress the clostridia, although this
hypothesis needs to be further investigated.
4.5.4 Probiotics
Unlike most facultative anaerobes, microaerobes and C. difficile for which
the MIC of the manuka honey with median-activity ranged between 4.5–8%,
2.5–6% and 4–7% respectively, all tested probiotics gave a relatively high
MIC value (equivalent to or above 10%). Together with the even higher
MBC values (>16%), this indicates that it is unlikely that manuka honey
would kill the probiotics in the gut. Although the number of tested species
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is limited, this suggests that probiotics might be relatively more tolerant to
the honey than gastrointestinal pathogens.
The tolerance of anaerobic probiotics to manuka honey is unexpected.
Honey, particularly manuka honey, is frequently reported to inhibit pathogens
due to several mechanisms, among which hydrogen peroxide may be the
major factor that decreases the growth of non-aerobes. Microaerobes and
anaerobes do not tolerate the damage caused by reactive oxygen species
because they produce no, or small amount of, catalase and superoxide
dismutase. B. animalis subsp. lactis and Lactobacilli are considered to be
anaerobes (Sneath and Holt, 1986) and, in theory, they should have revealed
equivalent to or higher sensitivity than facultative anaerobes to honey. Al-
though some probiotics have been known to produce hydrogen peroxide
as a defence mechanism to compete against other microbiota in the gas-
trointestinal tract (Servin, 2004), which may indirectly indicate the relative
tolerance of the probiotics of the peroxide activity of the honey, several
other possible reasons can also be featured. Firstly, probiotics, especially
Bifidobacterium spp., require glucose as their energy source (Sneath and Holt,
1986) and honey is rich in glucose. This may have compromised the dam-
age the honey caused to the bacterial cells. However, MRS medium used
for cultivating probiotics in this project contains 2% glucose that should
be sufficient for the organisms (http://service.merck.de/microbiology/
tedisdata/prods/4973-1_10660_0500.html), therefore lack of glucose in
the medium for supporting their growth is unlikely. Secondly, some com-
ponents such as galactooligosaccharide and fructooligosaccharide in honey
may have functioned as prebiotics so that the growth of the probiotics was
stimulated even in the existence of the animicrobial activity of the honey,
although further investigation is required to prove the hypothesis. Thirdly,
the tested probiotic species may have some mechanisms that overcome, or
at least tolerate, the antibacterial factors of manuka honey. As described
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above, glucose (and hence osmolarity) is not inhibitive to the species. Bifi-
dobacterium and Lactobacillus spp. are also known to be acidotolerant, which
was used to design the selective MRS media for these species (it has a pH
of 5.7; de Man et al., 1960), and this could have made the acidity of honey
to be less inhibitive in probiotics. The effect of methylglyoxal in honey to
probiotics as well as on other gastrointestinal bacteria is, unfortunately, not
well known yet.
The sensitivity results for probiotics in this chapter is in agreement
with recent research by Rosendale et al. (2008). Rosendale et al. studied
the effect of several traditional medicines including manuka honey on
probiotics (L. rhamnosus, Lactobacillus reuteri and B. animalis subsp. lactis) as
well as enteropathogens (E. coli, S. typhimurium and S. aureus) by means of
observing their growth turbitimetrically rather than determining the MIC.
In that report Rosendale et al. (2008) denoted the activity of the manuka
honey as “UMF20+” and did not state what percentage of phenol the
non-peroxide activity was equivalent to. According to the unique manuka
factor rating system, a manuka honey labelled UMF20+ means that honey
has a non-peroxide antibacterial activity equivalent to equal to or greater
than 20% phenol, which the activity is significantly higher than that of the
manuka honey used in this thesis. Despite the high antibacterial activity
being used, the group found that all probiotic growth increased while that
of enteropathogens decreased. Interestingly, the same authors also noticed
that some other traditional medicines (bee pollen, rosehip, blackcurrant oil
and propolis) had either synergistic or antagonistic interactions on the effect
of the honey on probiotics depending on the combination of the traditional
medicines used. Although there has been very limited research on the effect
of manuka honey on probiotics in the literature, this small project in this
thesis as well as the work by Rosendale et al. (2008) suggest the possibility
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of probiotics being more tolerant to manuka honey than enteropathogens
are.
4.6 Conclusion
In short, most gastrointestinal bacteria are susceptible to the antimicrobial
activity of manuka honey but not to artificial honey. The isolated C. jejuni
and C. coli were found to be exceptionally sensitive to manuka honey. This
may be partly due to their high sensitivity to osmotic action. Most tested
organisms can be inhibited by manuka honey even if it is diluted 10–20
fold, and can also be killed with slightly higher concentration of the honey.
Probiotics which we do not want to kill are found to be more tolerant to
manuka honey than gastrointestinal pathogens are.
5
T H E E F F E C T O F AT M O S P H E R E
As part of the antibacterial activity of a honey is due to hydrogen peroxide,
and because the oxygen is required to get glucose oxidase in a diluted honey
solution to transform the glucose content to hydrogen peroxide and gluconic
acid (Equation 1.1), it is possible that in the anaerobic gastrointestinal
environment this reaction would be suppressed, which consequently could
lead to a lower total antibacterial activity in manuka honey.
This chapter describes the study of the effect of gastrointestinal atmo-
sphere on the overall and non-peroxide antimicrobial activities of manuka
honey. The MIC and MBC of a normal manuka honey as well as the one
treated with the enzyme catalase are compared in aerobiosis and anaerobio-
sis.
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5.1 Introduction
As reviewed in Chapter 1, hydrogen peroxide is one of the major antibacte-
rial factors in honey, and it is produced, slowly, only when honey is diluted
(Equation 1.1). When humans ingest honey, ingested water and body secre-
tions dilute the honey and consequently, in theory, hydrogen peroxide is
produced in the gastrointestinal tract.
As shown in Equation 1.1, however, oxygen is also required to produce
hydrogen peroxide and this may not be available in the gastrointestinal
environment because that is generally anaerobic. It is in fact hard to predict
whether there would be any effect on the antimicrobial activity of honey that
is result from a less oxygenic environment such as in the gastrointestinal
tract. Since oxygen is unavailable or limited in the tract, the actual antibacte-
rial activity in honey could be at least impaired due to hydrogen peroxide
being unable to be produced.
Environmental atmosphere, on the other hand, can also affect bacterial
metabolism and consequently the growth of microorganisms which makes
prediction more difficult. Facultative anaerobes can survive in both aero-
bic and anaerobic conditions by switching their metabolism (Yamamoto
and Droffner, 1985), and because aerobic respiratory metabolism is more
efficient than anaerobic fermentative metabolism, the growth of facultative
anaerobes under anaerobic conditions is normally slower than that under
aerobic conditions. As the mechanism of action of non-peroxide antibacterial
substances in manuka honey remains to be understood, several possible
scenarios were foreseen. Faster growth of a microorganism in an aerobic
environment may lead it to overcome some levels of the negative effect
caused by antibacterial substances in honey; in other words the cells may
be more susceptible in anaerobiosis. The aerobic environment could also
accelerate the metabolism of bacterial cells, which may therefore speed up
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the bacterial cells’ uptake (hence make it more sensitive) or efflux and/or
metabolism (to detoxify) of extracellular antibacterial components. Yet, it is
also possible that the shift in the overall effect is not significant due to the
overall uptake and efflux being balanced in the cells.
In a preliminary test, an agar well diffusion trial using some facultative
anaerobes was conducted to study the effect of anaerobic incubation on
the activity of honey. It was intended to compare the inhibition zones seen
on nutrient agar plates in aerobic, microaerobic and anaerobic conditions.
However, in this preliminary test, inhibition zones were seen only in aerobic
and microaerobic conditions. In contrast, a relatively opaque zone instead
of an inhibition zone was seen in the anaerobic condition (Figure 5.1). As
the observed opaque zone around the well was denser than the background,
it was thought that the dense zone was an indicative sign of the stimulative
effect of honey on the growth of the seeded bacteria. The reason why the
antibacterial activity in honey did not take effect in the anaerobic condition
in this preliminary test is not clear. Although there would have been no
ongoing production of hydrogen peroxide in GasPak canister, non-peroxide
antibacterial substances should have taken over the antimicrobial action. In
the anaerobic incubation the growth of the tested facultative anaerobe was
significantly slower than those in aerobic or microaerobic conditions, which
could be observed from the size of the colonies impregnated in the agars.
Perhaps the antibacterial substances in the honey had diffused out of the
well so that the concentration had been diluted down below the MIC before
the substances could inhibit the slow-growing bacteria. Also at the same
time, sugar or other components in honey could have helped the bacterial
cells to overcome the undesirable environmental stresses (peroxide/non-
peroxide activity from honey and low oxygen level in this preliminary
test).
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Aerobic condition Anaerobic condition
Figure 5.1: The comparison of the result of agar diffusion assay in the aerobic and
anaerobic (GasPak) conditions. In the photographs nutrient agar plates
seeded with S. typhimurium DT104 (approx. 105 cfu/ml in the agar)
were incubated at 37°C overnight. In each well 100 µl of 25% manuka
honey M115 solution was loaded.
Because this informal preliminary test had suggested that the agar
well diffusion technique may be not be suitable for evaluating the effect
of environmental atmosphere on the antibacterial activity in honey, in the
work in this chapter the MIC/MBC values were obtained using the broth
microdilution method instead.
5.2 Materials and method
Facultative anaerobic gastrointestinal bacteria chosen from Table 2.1 were
used for testing the effect of atmosphere on the antibacterial activity of
the honey because these microorganisms were able to grow in a wide
range of atmospheres. The ones used were: E. coli, Salmonella, Enterobacter,
Enterococcus, Yersinia and Shigella. All organisms were cultured in MHB.
Culture, handling and inoculum preparation were conducted as described
previously in Section 4.2.
Manuka honey sample M115, which has an antimicrobial activity equiv-
alent to 16.5% phenol, was used. An artificial honey (AH) which is a sugar
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syrup was used as a control to find if osmolarity was the factor that was
inhibiting the growth of the tested bacteria.
To investigate the effect of hydrogen peroxide activity in manuka honey
on the facultative anaerobes, manuka honey solution containing 0.1% (w/v)
catalase was also included in the test. A solution of 0.2% w/v catalase
soluion was made by adding 0.02 g of catalase in 10 ml of distilled water
and then this was filtered through a 0.22 µm filtre membrane. The same
amount of the 0.2% w/v catalase stock solution and double-strenth honey
were mixed so that there was 0.1% catalase in the final honey solution. The
amount of catalase used was enough to eliminate any hydrogen peroxide
activity in the honey (Allen et al., 1991a). This solution of manuka honey
with catalase was treated in the same way as that without catalase, and had
the same final concentrations as those without catalase in the microplate
after serial dilution and inoculation (Section 4.2.5). As the MIC/MBC of
manuka honey and artificial honey in aerobic conditions had been measured
in Chapter 4, the MIC/MBC values from Chapter 4 were integrated in the
results in this chapter (Table 5.1 and 5.2).
To compare the effect of different atmospheres on the MIC/MBC of
the honey, the susceptibility test was undertaken in aerobic and anaerobic
atmospheres simultaneously. The anaerobic condition was generated with a
gaspack system (MGC AnaeroPakTM). All cultures were incubated at 37°C
overnight.
The MIC of the honeys under anaerobic conditions was observed visu-
ally because it was impossible to do this using the microplate reader. Other
than this, the processes of the MIC/MBC evaluation were the same as those
described in Section 4.2.6. The MIC/MBC of manuka honey for the species
were compared between the two atmospheres using two-way ANOVA in R
statistical package (R Development Core Team, 2008).
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5.3 Results and discussion
In this chapter, the effect of atmospheric condition (anaerobic environment)
on the antibacterial activity of manuka honey was studied to evaluate the
likely efficacy of the honey on the pathogens in the gastrointestinal tract.
The values formed for the MIC and MBC of honey in aerobic and anaerobic
conditions are shown in Tables 5.1 and 5.2. For comparison, data from
Chapter 4 are also integrated in these tables. As far as the author is aware,
this is the first study that looks at the alteration of the effectiveness of
manuka honey in an oxygen-limited environment. Many clinically impor-
tant gastrointestinal pathogens have been extensively studied in aerobic
conditions (Cooper et al., 2009; Molan, 2009), but no consideration on the
efficacy against the facultative anaerobes in a low oxygen concentration
has been given. In fact, during the study we noticed that in all of the treat-
ments, bacterial growth under anaerobic conditions was much slower than
under aerobic conditions as can be observed visually from the size of the
pellet of bacteria settled at the bottom of the microplate wells, suggesting
the possibility that the anaerobic atmosphere could indeed alter the cells’
morphology and therefore the actual sensitivity to an antimicrobial.
Table 5.1 allows the MIC of honeys in aerobic and anaerobic conditions
to be compared. ANOVA reveals that overall both atmosphere and honey
type significantly effect the MIC (P < 0.05) for each. The MIC values for
manuka honey in anaerobic condition appeared to be equivalent to or
lower than those in aerobic condition, and the degree of difference varied
depending on the species (varied from less than 1% to more than 4%).
This suggests that bacteria are slightly more susceptible to the total activity
of manuka honey under anaerobic condtions, with E. faecalis being an
exception which had a numerically but not statistically higher MIC in
anaerobic condition.
chapter 5 the effect of atmosphere 115
Table 5.1: The results of the effect of atmosphere on the MIC (% v/v) of manuka
honey, manuka honey plus catalase, and artificial honey. The values are
represented as means of replicate ± standard deviation. The results for
aerobic work are copied from Table 4.2 and 4.5. The determination of the
values for each isolate was repeated 5 times. DNG: The culture did not
grow. *: signifincantly different for each species for aerobic vs. anaerobic
conditions for each treatment (P<0.05).
Species Atmospheres MIC
Manuka Manuka+catalase Artificial
E. coli Aerobic 6.87±0.97 7.48±0.83 > 16.6
Anaerobic 6.8±0 6.8±0 > 16.6
P. aeruginosa Aerobic 15.94±1.32* 16.6±0* > 16.6
Anaerobic DNG DNG DNG
Y. enterocolitica Aerobic 4.79±0.54* 7.48±0.83 16.6
Anaerobic 3.49±0 6.8±0 16.6
S. typhimurium DT104 Aerobic 7.48±0.83 7.48±0.83 > 16.6
Anaerobic 6.53±0.54 6.8±0 > 16.6
S. enteritidis Aerobic 6.8±0 6.8±0 > 16.6
Anaerobic 6.8±0 6.8±0 > 16.6
E. faecalis Aerobic 9.89±1.9 8.93±0.86 > 16.6
Anaerobic 10.65±0 10.22±0.86 > 16.6
E. faecium Aerobic 9.36±1.05 8.5±0 > 16.6
Anaerobic 8.16±0.68 6.8±0 > 16.6
E. aerogenes Aerobic 11.89±2.15* 16.66±0 > 16.6
Anaerobic 7.48±0.83 16.66±0 > 16.6
E. cloacae Aerobic 10.65±0* 15.99±1.34* > 16.6
Anaerobic 5.72±0.54 13.3±0 > 16.6
S. flexneri Aerobic 7.58±1.14* 9.36±1.05* > 16.6
Anaerobic 2.93±0.28 6.8±0 > 16.6
S. sonnei Aerobic 6.61±0.47* 8.93±0.86* > 16.6
Anaerobic 2.34±0.23 6.8±0 > 16.6
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Table 5.2: The results of the effect of atmosphere on the MBC (% v/v) of manuka
honey, manuka honey plus catalase, and artificial honey. The values are
represented as means of replicate ± standard deviation. The results for
aerobic work are copied from Table 4.2 and 4.5. The determination of the
values for each isolate was repeated 5 times. NT: Not tested. *: signifin-
cantly different for each species for aerobic vs. anaerobic conditions for
each treatment (P<0.05).
Species Atmospheres MBC
Manuka Manuka+catalase Artificial
E. coli Aerobic 7.48±0.83 8.5±0 NT
Anaerobic 8.5±0* 14.62±1.62* NT
P. aeruginosa Aerobic 16.6±0 > 16.6 NT
Anaerobic > 16.6 > 16.6 > 16.6
Y. enterocolitica Aerobic 5.45±0 8.5±0 > 16.6
Anaerobic 6.8±0* 10.22±0.86* > 16.6
S. typhimurium DT104 Aerobic 10.65±0 16.6±0 NT
Anaerobic 10.65±0 16.6±0 NT
S. enteritidis Aerobic 8.5±0 16.6±0 NT
Anaerobic 13.3±0* 16.6±0 NT
E. faecalis Aerobic 16.6±0 13.3±0 NT
Anaerobic 15.94±1.32 15.94±1.32* NT
E. faecium Aerobic 13.3±0* 13.96±1.32* NT
Anaerobic 9.79±1.05 10.65±0 NT
E. aerogenes Aerobic 16.6±0 16.6±0 NT
Anaerobic > 16.6 > 16.6 NT
E. cloacae Aerobic 16.6±0* 16.6±0 NT
Anaerobic 8.5±0 > 16.6 NT
S. flexneri Aerobic 8.5±0* 16.6±0 NT
Anaerobic 5.45±0 16.6±0 NT
S. sonnei Aerobic 8.5±0* 10.65±0 NT
Anaerobic 3.66±0.34 9.36±1.05 NT
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To investigate the effectiveness of the non-peroxide activity in manuka
honey, the enzyme catalase was added into the manuka honey to remove
any activity due to hydrogen peroxide. The MIC results show that bac-
teria have a slightly higher sensitivity to the non-peroxide activity under
anaerobic conditions, a similar trend that has been previously shown in the
total antibacterial activity under anaerobic conditions. The non-peroxide
antibacterial activity in manuka honey has now been identified as being
due to methylglyoxal (Adams et al., 2008; Mavric et al., 2008), and the MIC
may represent the effectiveness of methylglyoxal. However, it is noteworthy
that methylglyoxal may combine with the N-terminal segment of proteins
(Inoue and Kimura, 1995) that generally exist in a medium and that may
result in extra amounts of methylglyoxal being required to interact with
bacteria. Therefore, it may be questionable to regard this as the “MIC for
methylglyoxal”.
No inhibition on the tested microbes was observed in artificial honey in
both atmospheric environments (all MIC values were ≥16.6%). This indicates
that the osmolarity of honey would not practically inhibit bacteria both in
intestinal or external conditions. Although there would be some difference
in the actual MIC values if the range of honey concentrations tested had been
wider, that still would not be of very much practical importance because
the concentration of sugar in the gut is unlikely to reach a high level.
Some interesting aspects can be seen when the sensitivity of each
bacterial species to the bacteriostatic activity of manuka honey with and
without hydrogen peroxide removed are compared. For some species (E.
coli, P. aeruginosa and Salmonella) the honey with catalase added revealed
equivalent or marginally higher MIC than a normal manuka honey (P>0.05),
whereas for some other species (Yersinia, Enterobacter and Shigella) a much
higher concentration of the manuka honey with catalase was required
to inhibit their growth (P<0.05). Unexpectedly, E. faecalis and E. faecium
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were found to be slightly more sensitive to manuka honey with catalase
than without catalase, although this is numerically but not statistically
different (P>0.05). Perhaps this numerical increase in the sensitivity result
of Enterococcus spp. is simply because of the limited number of the species
being examined. Alternatively, it may be that the catalase used is toxic
to the bacteria. More species samples would be needed to ascertain this
phenomenon.
On the other hand, the bactericidal profile of manuka honey appeared
to be largely different from what has been described above for the MIC
values, as the atmosphere factor appears to account less for the effect on
the MBC (P > 0.1). More species (E. coli, P. aeruginosa, Yersinia, S. enteritidis
and E. aerogenes) gave higher MBC values with normal manuka honey in
anaerobic than in aerobic condition (P<0.05), whereas equivalent or lower
MBC values were seen in S. typhimurium DT104 and E. faecalis (P> 0.05),
and significantly lower in E. faecium, E. cloacae and Shigella (P<0.05). This
was same for the MBC values of manuka honey with catalase except E.
faecalis (significantly higher MBC value in anaerobic condition; P<0.05) and
E. cloacae (numerically higher MBC value in anaerobic condition; P>0.05).
The MBC values for manuka honey with catalase had yet higher values
than for those without catalase for all atmospheric conditions. Again, E.
faecalis in air was the only exception (significantly lower in aerobic condition;
P<0.05). Some of the tested microorganisms were marginally more resistant
to the bactericidal effect of the non-peroxide activity in the honey (E. coli
in air and E. faecium in both atmospheres; P>0.05), but for most species
(E. coli and E. cloacae in anaerobic, Yersinia, Salmonella and Shigella) a much
higher concentration of honey was required to kill the cells when hydrogen
peroxide had been removed (P<0.05).
Although P. aeruginosa is usually considered an aerobe, and in the MIC
test this species indeed did not show any growth in anaerobic condition,
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after subculturing on an agar plate in the air P. aeruginosa was found to be
still surviving as shown in the MBC data (Table 5.2).
Some species of bacteria showed equivalent sensitivity to manuka honey
with or without hydrogen peroxide present, whereas others showed up
to 4 times higher MIC values if catalase was added in the honey. This
suggests that the non-peroxide antibacterial factors contribute most of the
antibacterial activity of manuka honey because otherwise the activity should
have been eliminated by enzyme catalase and should have given high MIC
values similar to those with artificial honey. Although Enterobacter spp.
appeared to be relatively tolerant to the non-peroxide activity, they still
were more sensitive than to artificial honey, which suggest that the activity
can still be useful to inhibit these species. The MBC test, on the other hand,
suggests that the non-peroxide activity of manuka honey has a relatively
“mild” effect on bacterial cells. It can be seen in Tables 5.1 and 5.2 that the
MBC of the total activity of manuka honey was higher than the MIC and,
with some species, catalase appears to destroy the activity much further.
If the MBC of manuka honey with and without catalase is compared, it is
clear that to some species the concentration of the non-peroxide activity
required to kill the cells is more than twice of that of the total activity.
The increase in the MIC and MBC values indicates that hydrogen peroxide
actually plays a role in manuka honey to inhibit bacteria, and this effect
seems to be more significant with some species of bacteria. Manuka honey is
usually mistakenly called “non-peroxide honey” in literature for the public,
whereas Tables 5.1 and 5.2 indicates that manuka honey in fact can have
both peroxide and non-peroxide activities, although some species appear to
be less sensitive to the hydrogen peroxide in the honey.
Although the difference in the MIC/MBC between different atmospheric
environments could have been because of enzyme glucose oxidase in honey
was unable to convert glucose into hydrogen peroxide in the absence of
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oxygen, the anaerobic environment might have also caused environmental
stress to the facultative anaerobes which may lead to some morphological
adaptations in the cells.
To inhabit in virtually every area in the world, prokaryotes have had to
develop appropriate mechanisms to survive or thrive under a wide variety
of conditions. Not only do they need to be able to inhabit some specific
environments (e. g. hyperthermophiles, halophilic/acid-tolerant bacteria),
but they also need to be able to adjust to sometimes prolonged extreme
conditions. The air can actually be considered an extreme condition because
without an appropriate amount of protective enzymes (catalase and super-
oxide dismutase) cells would be damaged by oxidative stress caused by ROS
(Iuchi and Weiner, 1996). Many bacterial stress responses have been found to
be genetically regulated. When bacteria transit from an aerobic environment
to one that is anaerobic (for instance, when gastrointestinal pathogens enter
the gastrointestinal tract), there would be a change in genetic expression
which is regulated by the f umarate and nitrate reduction (FNR) regulatory
protein (Barton, 2005). FNR is in a dimer form and binds stably to DNA
in an anaerobic environment and, in an aerobic condition (with 1–10 µM
oxygen) the structure turns into monomers and decreases in the ability to
bind DNA. With the FNR regulation system, organisms in an anaerobic
environment can reduce the production of enzymes involved in aerobic
metabolism and increase that required for anaerobic respiration.
Atmospheric factors have been reported to significantly affect certain
antibiotics. Rosenblatt and Schoenknecht (1972) reported that gentamicin,
streptomycin, kanamycin and erythromycin were less active in an anaer-
obic condition whereas tetracycline and chloramphenicol revealed higher
activities against E. coli. Goldstein and Sutter (1983) noted that active ery-
thromycin deteriorated by more than 50% after 18 hours incubation in
CO2.
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Environment atmospheric stress may also result in the modification of
the morphology of bacterial cells which consequently alters the sensitivity
to antimicrobials. P. aeruginosa, either in planktonic or in biofilm forms,
appeared to be more resistant to antibiotics if oxygen was limited (Field
et al., 2005), whereas anaerobically grown E. coli K-12 was reported to fail in
biofilm formation (Colón-González et al., 2004). Likewise, it is possible that
the FNR or other gene regulations regarding environmental stress response
may affect the sensitivity of bacterial cells to antibiotics or antibacterials
such as hydrogen peroxide or methylglyoxal in honey. This, together with
the response to other stresses such as pH and enzymes (that are discussed
in Chapter 7), will be discussed in Chapter 8.
6
T H E P H A R M A C O D Y N A M I C S O F M A N U K A H O N E Y
In this chapter the pharmacodynamics of the antibacterial activity of manuka
honey is described. The hypotheses are: that the pharmacodynamics of
manuka honey are like those of conventional antimicrobial agents; that the
number of viable organisms continuously exposed to a constant concen-
tration of manuka honey declines as exposure time passes; and that after
bacterial cells have been exposed to manuka honey for a short period the
antimicrobial effect of manuka honey persists for a while even after the
removal of the honey.
In the first part, the time-to-kill test that evaluates the time required
to eliminate bacterial cultures persistently exposed in a constant level of
manuka honey was investigated. The second part of this study investigated
the postantibiotic effect of manuka honey in which bacterial cells were
exposed to the honey temporarily and the survival of the treated cells after
that was monitored.
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6.1 Introduction
Antimicrobial agents are capable of inhibiting or killing organisms if their
concentrations are above the MIC or MBC, and this has widely been used
for evaluating the efficacy of drugs. The principle of the MIC test is to
expose the targeted micro-organisms to an antibacterial agent of interest
at a series of concentrations of antibacterial agents for a pre-defined time
(usually overnight) and monitor the growth of the organisms. The minimum
concentration which inhibits the growth of the organisms is then recorded as
the MIC. Similarly, the minimum concentration of the antimicrobial agents
that is required to kill the tested organisms is termed the MBC. This is
usually approached by subculturing the broth media from the MIC test to a
fresh solid medium on which microbes may still be alive.
In the MIC test the concentrations of antibacterial agent remain at a
high or constant level through the assay. However, this is clearly not feasible
in vivo for several reasons.
On some occasion in vivo it is desirable for an antimicrobial agent to
take effect on the bacterial cells in a short time because the actual exposure
time of the cells to the active ingredient may actually be much shorter than
is the case when the MIC test is conducted in vitro. A significant example is
the usage of antibiotics in ophthalmology. As eyedrops are usually washed
off within minutes after being applied on the infected eyes, the bacteriostatic
and bactericidal information obtained from the MIC/MBC tests alone are
not useful for evaluating the efficacy of antimicrobial agents in treating
such cases. Several efficacy assays of the antibiotics used for H. pylori
eradication have been criticised to be inadequate because they fail to control
the viability of the organisms within 3 hours (Irie et al., 1997). Similarly,
MIC/MBC values usually do not account for the significantly fluctuating
drug concentration within a body as time passes due to various factors in
chapter 6 the pharmacodynamics of manuka honey 124
the host. The active amount of antimicrobial agents may decline, as can
be seen on the degradation of penicillins, cephalosporins, cephamycins,
ertapenems and carbapenems by ESBL (extended spectrum β-lactamase)
secreted by Gram-negative bacteria such as E. coli, Klebsiella pneumoniae,
Proteus mirabilis, P. aeruginosa and some Enterobacteriaceae (Bradford, 2001;
Jones, 2001; Paterson and Bonomo, 2005). The active ingredient may also
be substantially diluted by large amount of body fluid or exudate, and
therefore the total concentration eventually goes below the MBC or even
MIC. Alternatively the active ingredient may be excreted out of the body
through the urinary system (Kasper et al., 2005) before it has time to be of
effect on bacteria. Therefore the efficacy of antibacterial agents in treating
infections may not be as good as that indicated from in vitro susceptibility
tests.
The situation described above is not limited to chemical antibiotics but
is applicable to honey too. The efficacy of honey is generally considered
to be lower than that of antibiotics, which also means the concentration
required to suppress the growth of bacteria is higher than that of antibiotics
(approx. 100 mg/ml cf. µg/ml). In wound treatment the active component in
honey would diffuse into the wound from the dressing, and eventually the
active concentration would decline to that below the MIC to the pathogens
on the wound. Likewise, honey intaken orally would be greatly affected
by dilution by large amounts of body fluid e. g. saliva, gastric juice and
intestinal fluid and water from food and drink. A short transit time due to
rapid peristalsis in the gastrointestinal tract may also result in a short period
of contact with bacterial cells. Although it is unknown how much of the
antibacterial activity of honey exactly would be able to reach the stomach
or the lower intestine so as to inhibit gastrointestinal pathogens, it is very
clear that the achievable concentration would be much lower than the initial
concentration taken in. To evaluate the antibacterial efficacy of honey on
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bacteria in such conditions, several pharmaceutical parameters other than
the conventional sensitivity test are required.
In pharmacology several parameters, namely pharmacokinetics and
pharmacodynamics (PK/PD), are used to evaluate dynamically the efficacy
of a drug (Dalhoff, 1997). Pharmacokinetics in antibiotic research monitors
the fluctuation of the concentration of the antibiotic after delivery into a
living host (Dalhoff, 1997). As the drug concentration during the treatment
can be affected greatly by biological metabolism e. g. preantibiotic, the phar-
macokinetics evaluation is usually approached by quantitatively analysing
the parent drug and its metabolites using chromatographic systems and
producing serum concentration versus time curves (Dalhoff, 1997). Pharma-
cokinetics, however, is not always possible because this parameter involves
monitoring the level of the known substances, and evaluating the pharma-
cokinetics of a complex substance of unknown composition such as manuka
honey is not feasible.
Pharmacodynamics, on the other hand, is used in antibiotic research for
predicting the eradication of bacteria by an antibacterial agent. It describes
the exact effect of an antimicrobial substance on bacterial cells and thus is
increasingly used for evaluating the mode of action of antibacterial agents
(Jacobs, 2003) and for predicting bacterial eradication. Several suggested
pharmacodynamics parameters include, but are not limited to, the area
under the plasma concentration-time curve (AUC), the drug’s peak concen-
tration (Cmax), and the time the drug concentration exceeds the MIC (T >
MIC) (Nicolau, 2003). The effectiveness of a number of antibiotics has been
well predicted by these models (Nicolau, 2003).
The postantibiotic effect (PAE) is one of the pharmacodynamics pa-
rameters. It describes the persistent suppression of bacterial growth after a
short exposure of bacteria to antibacterial agents (Craig and Gudmundsson,
1996). This was first systematically observed by Parker and Marsh (1946)
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who noticed that after staphylococci had been exposed to penicillin, the
organisms did not resume multiplying immediately after the removal of the
drug but instead remained constant in number for a while, before beginning
to multiply again at their normal rate. The duration of the lag seems to de-
pend on individual bacterial species or even strains, the concentration of the
drug and the time for which bacteria have been exposed to the drug. Eagle
and Musselman (1949) tested several cocci including α- and β-haemolytic
streptococci, staphylococci, pneumococci and enterococci with penicillin,
and noticed that the persistent effect of the drug reached a maximum level
at the concentration that was most rapidly bactericidal for the organism.
In this study the authors also found that beyond the maximum effect, the
persistence of effect did not increase further even with a 10 000-fold increase
in the level of the drug. Similarly, the persistence reached its maximum
within one to two hours of exposure time, and even 24 hours of exposure
did not significantly prolong the period of persistence. Interestingly, for
some strains the duration of persistence increased directly as the proceeding
exposure time to penicillin increased (Eagle, 1949). Eagle noticed that once
a bacterium had been treated with a large enough amount of antibiotic
even for a short time, the cells were ‘bombarded’ so that the microorganism
required extra time to recover from the damage, and meanwhile the cells
would not replicate until they had completely recovered from the damage,
regardless of the absence of antibiotics. In other words, antimicrobial agents
may not need to be present continuously during treatment of infections.
Indeed, this is one of the main principles when estimating the interval
required between dosages of a drug (Odenholt, 2001). A thorough review
of the persistent effect of antimicrobial agents has been published by Craig
and Gudmundsson (1996).
The principle of assaying the postantibiotic effect is to compare the
time required for bacteria treated within an antibacterial agent and for un-
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treated control bacteria to reach the same growth speed as each other. This
is generally done by exposing bacteria to a medium containing an antimi-
crobial agent for a short term (normally 1–2 hours), followed by removing
the antibacterial agent by means of centrifugation, dilution, inactivation or
membrane filtration (Craig and Gudmundsson, 1996). The bacterial cells are
then incubated in a fresh medium without the antibacterial agent and the
growth curve is observed. It must be noted that because the PK/PD param-
eters may vary greatly among bacterial species, and also that because they
may not be directly relevant to the MIC/MBC (Irie et al., 1997), it is unlikely
that PK/PD parameters can be predicted with the usual susceptibility tests.
Although honey has been proven to have substantial antimicrobial ac-
tivity even against the organisms that modern antibiotics fail to eradicate
(Molan, 2009), this has mostly been demonstrated with conventional suscep-
tibility tests or with observations during clinical trials. And despite the large
number of published report showing the significant antimicrobial activity
and efficacy of the honey, it is not known at all whether or not the honey
would reveal any of the PK/PD parameters against microbes. This may be
partially because honey is a complex mixture of carbohydrates, and it is
unlikely to approach a pharmacokinetics study without knowing the exact
antimicrobial substance. Also, there has been comparatively little interest in
the PK/PD properties even of modern antibiotics until recently. Therefore it
is important to study the pharmacodynamics of the antimicrobial activity
of honey, so as to evaluate the utility of manuka honey for internal use.
This information would also be of help for the medical professionals to
understand the usefulness of honey if the pharmaceutical properties of
honey could be studied in further details.
Therefore in this study it was intended to first investigate how long it
would take manuka honey to eliminate micro-organisms, and to investigate
if honey would have the postantibiotic effect that other common drugs do,
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so that a ‘honey-exposed’ microorganism would still be inhibited even if the
honey gets diluted to a low level afterwards.
6.2 Materials
From the work in Chapter 5, it was clear that the concentration of arti-
ficial honey required to inhibit organisms was much higher than that of
manuka honey. Therefore only manuka honey (M115) was used in this
pharmacodynamics assay.
6.2.1 Bacterial strains
Salmonella, Shigella, Enterobacter, P. aeruginosa, Enterococcus, E. coli, Y. enteroco-
litica, B. animalis subsp. lactis and Lactobacillus were used in the pharmaco-
dynamics tests. H. pylori, Campylobacter and C. difficile were not tested in this
study due to the difficulty of culturing them. B. animalis subsp. lactis and
Lactobacillus were omitted in the time-to-kill test because according to the
MBC test in Chapter 4, it is clear that a high level of manuka honey (16%)
cannot kill these species even after 18 hours of persistent incubation.
Culture handling and inoculum preparation were as described previ-
ously in Chapter 5 except that the optically adjusted broth culture was
diluted 30 times instead of 300 times so that the final concentration would
be approximately 3×106 cfu/ml which was 10 times as concentrated as that
had been used in the work in other chapters. This was used as the inoculum.
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6.2.2 Culture media
Mueller-Hinton broth (MHB) was used for cultivating most organisms
as described earlier. Man-Rogosa-Sharpe medium (MRS) was used for
cultivating B. animalis subsp. lactis and Lactobacillus spp. as described earlier.
These broths were also used for washing honey off from bacterial cells.
Double-strength broths were used for preparing honey solutions. Solid
media in square agar plates (100×100×20 mm) and in regular Petri dishes
were used for the viable cell counting.
6.2.3 Diluent broth for serial dilution
Broth (MHB for most organisms; MRS for Bifidobacterium and Lactobacillus)
was aseptically dispensed in sterile bijou bottles to make 0.9 ml in each. The
lids were tightened so that the broth would not evaporate during storage.
These dispensed broth in bijou bottles were for serially diluting bacterial
solutions during the viable cell counting.
6.3 Time-to-kill analysis
Briefly, honey solutions were made by firstly preparing 109 time that of the
desired concentration, followed by adding 0.1× volume of bacterial inoculum
(approximately 3×106 cfu/ml) in the honey solutions. This way the desired
honey concentrations to be tested were obtained, and at the same time the
final cell density in the honey solutions was also controlled at approximately
3×105 cfu/ml so as to be in agreement with the cell density had been used
in other chapters. Viable cell counting was conducted at hourly intervals for
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6 h (or longer if no significant decline in the viable cell number was seen in
the preliminary test for any species).
6.3.1 Methods
With pure manuka honey and sterile water, 11.1%, 22.2%, 33.3% and 44.4%
(w/v) honey solutions were prepared. These honey solutions were further
diluted with the same volume of double-strengh broth medium so that the
final concentrations of the honey solutions would be 5.5%, 11.1%, 16.5% and
22.2%. After filtration through sterile 0.22 µm membranes, 9 ml of filtrant
for each concentration was collected in a sterile universal bottle.
To each of the 9 ml honey filtrants, 1 ml of the inoculum was added so
that the final honey concentrations in each bottle were 5%, 10%, 15% and
20%. From each of these honey solutions 0.1 ml was removed for viable
cell counting using the track dilution method (Section 2.6). The remainder
of each inoculated honey solution was incubated at 37°C and viable cell
counting was conducted at hourly intervals. The agar plates for viable cell
counting were incubated at 37°C overnight. The colonies obtained were
counted afterwards and a plot of log10CFU/ml vs time (h) was drawn
accordingly.
6.3.2 Results
This section reveals the results of the time-to-kill assay which estimates the
time required for manuka honey to kill E. coli, Salmonella spp., P. aeruginosa,
Y. enterocolitica, Shigella spp., Enterobacter spp. and Enterococcus spp. when
the bacterial cells are constantly exposed to honey solutions.
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For most of the enteropathogens tested in this study, honey solutions
with concentrations higher than the MBC or even MIC were capable of
killing the majority (90%) of the organisms within a few hours (Figures
6.1–6.9). E. coli, Yersinia, Pseudomonas and S. typhimurium DT104 lost their
viability within 2–4 hours in honey solutions whereas it took 4–6 h to kill S.
enteritidis, Shigella, Enterobacter.
Some species, on the other hand, were found to be resistant to the
bactericidal activity of manuka honey. Enterococcus spp., unlike the other
gastrointestinal bacteria, appeared to be tolerant to the honey for more
than 12 hours (Figures 6.10 and 6.11). E. faecium seems to be slightly more
susceptible to the honey than E. faecalis but still the rate of decline in the cell
density was much lower than with the other other gastrointestinal bacteria.
6.3.3 Discussion
In Chapter 4 the susceptibility to manuka honey (MIC) with several gastroin-
testinal organisms was evaluated using the microdilution method which
measures the growth curve of an organism in honey solutions at a series
of constant concentration through 18 hours. The method is widely used
in many laboratories due to its convenience and simplicity, but this also
draws some concerns from practical viewpoint. The growth curve only
reflects the multiplication of bacterial cells in the media whereas it does not
indicate if the cells are being killed or merely temporarily inhibited by the
antibacterial agent. To evaluate whether or not the bacterial cells are killed
when exposed to the honey for long time, in Chapter 4 the MBC test was
also conducted. In that test, most enteropathogens were found to have MBC
values at around 6–7% manuka honey whereas for some species the MBC
value was rather higher (Pseudomonas, Enterobacter and Enterococcus spp. at
approx. 13%; B. animalis subsp. lactis and Lactobacillus at over 16%), suggest-
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Figure 6.1: The decline in the viable cell number of E. coli on incubation in solutions
of manuka honey.
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Figure 6.2: The decline in the viable cell number of S. typhimurium DT104 on
incubation in solutions of manuka honey.
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Figure 6.3: The decline in the viable cell number of S. enteritidis on incubation in
solutions of manuka honey.
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Figure 6.4: The decline in the viable cell number of P. aeruginosa on incubation in
solutions of manuka honey.
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Figure 6.5: The decline in the viable cell number of Y. enterocolitica on incubation
in solutions of manuka honey.
0 1 2 3 4 5 6 7 8
0
1
2
3
4
5
6
10%
15%
20%
Time (h)
Lo
g1
0 
C
FU
/m
l
Figure 6.6: The decline in the viable cell number of E. aerogenes on incubation in
solutions of manuka honey.
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Figure 6.7: The decline in the viable cell number of E. cloacae on incubation in
solutions of manuka honey.
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Figure 6.8: The decline in the viable cell number of S. flexneri on incubation in
solutions of manuka honey.
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Figure 6.9: The decline in the viable cell number of S. sonnei on incubation in
solutions of manuka honey.
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Figure 6.10: The decline in the viable cell number of E. faecalis on incubation in
solutions of manuka honey.
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Figure 6.11: The decline in the viable cell number of E. faecium on incubation in
solutions of manuka honey.
ing that some species may be relatively more tolerent to the antibacterial
activity of manuka honey than are the other organisms.
This time-to-kill study, however, seems to have uncovered some hidden
information which had not been found in the MIC and MBC studies. In
theory, the time required for honey to kill bacteria should be longer if the
bacteria reveal higher MBC of the honey because that would mean the
bacteria are more tolerant to it. It might take some time for the honey to
diffuse into the bacterial cells and have its bioactivity have full effect on the
metabolisms in the cells. Comparing with the MBCs in aerobic condition
shown in Figure 5.1, however, it can be seen that species with high MBC
are not necessarily able to survive in the honey for long time. Among those
species that gave high MBC result (approx. 16%), P. aeruginosa completely
lost its viability within as short time as Salmonella typhimurium as long as the
honey concentration is higher than the MBC. This suggests that P. aeruginosa,
and perhaps other species that are not included in this research project, may
be actually not as hardy as the impression the high MIC/MBC gives. As
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long as the honey concentration is high enough, it is possible to eradicate
this species as easily as most of other tested facultative anaerobes like E. coli.
In other words, the time-to-kill profile may not always be in agreement with
the MBC for bacteria.
In contrast to other species, hardly any decline in viable cells could be
seen with Enterococcus spp. after 11 hours incubation regardless of being
constantly incubated even in a high concentration (20%) of honey solution.
The number of surviving Enterococcus cells might eventually decline down to
zero if the incubation is elongated. This would account for the finding that
the MBC for this species was ranged from 13.3% to 16% honey (Table 4.5), the
incubation time in that experiment being 18 h. The relatively high tolerence
of this species in this study is in agreement with Lamont et al. (2006) that
Enterococcus is a rather resistant pathogenic genus in comparison with other
microbes. According to the results obtained in Chapter 4 and here, the
honey would need to be kept in contact with the bacterial cells to eradicate
this species. This is possible if the honey is used to eradicate enterococcal
infection on topical wounds because it is very easy to treat the bacteria by
constant cover of the infected site with honey wound dressings or honey
gels; however this would not be feasible in the gastrointestinal tract because
honey can be easily flushed, diluted or absorbed in the tract. On the other
hand, since enterococci play a role in maintaining the microenvironmental
ecology in the gut (Murray and Baron, 2003), perhaps this also suggests
that some probiotics like gastrointestinal enterococci would generally not
be affected by intake of manuka honey.
It must be noted that although manuka honey is now increasingly
recognised as an exceptionally effective antibacterial agent, the overall
time-to-kill results show that one should not expect manuka honey to
eradicate or inhibit microbes within a matter of seconds or minutes. As
shown in the time-to-kill test, manuka honey takes at least one hour to have
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a microbicidal effect on bacterial cells when at a concentration of 20% and
a longer time if its concentration is lower. Practically, this also means that
the MIC/MBC for gastrointestinal pathogens is not meaningful because the
actual concentration of the honey is unlikely to be maintained above the
MIC level for that length of time. In the next section, therefore, what would
happen to bacterial growth if honey contacts the cells only for a short time
is explored.
6.4 The post-antibiotic effect of manuka honey on
organisms
Because of the complexity of the postantibiotic test, a brief outline of the
whole process is firstly given here, and the exact details are described
chronologically in the next subsection.
Firstly, a honey solution was made by preparing 109 time that of the
desired concentration and transferred in a 15 ml centrifuge tube. MHB
with the same volume as the honey solution was also prepared in another
centrifuge tube as a control. For each species, a tube with honey and
another tube for control were handled simultaneously (i. e. two tubes for one
species). A broth culture with approximately 3×106 cfu/ml was prepared.
The broth culture with 0.1× volume of that of the honey solution was then
added so that the desired honey concentrations to be tested were obtained,
and at the same time the final cell density would be approximately 3×105
cfu/ml, the cell density that had been used in other chapters. All tubes were
incubated for 1 h to induce the postantibiotic effect, with viable cell counting
being conducted right after the incubation. The bacteria were washed by
centrifuging the tubes and replacing the supernatant with pre-warmed
MHB. After this, all tubes were incubated with viable cell counting being
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conducted at hourly intervals until a significant increase in the turbidity
was seen visually in the honey-treated tube.
To check the sterility, an additional centrifuge tube with MHB was also
included. This MHB tube was handled in the same way as the testing group
described above through the whole process, except that the bacterial broth
culture was replaced with MHB.
Most the viable cell counting was conducted using the track dilution
method as described in Section 2.6. Before the postantibiotic test being
conducted, 0.9 ml of MHB in bijou bottles was prepared as described in
Section 6.2.3 as the diluent for serial dilution. The dilution range of the
series was 10−1×, 10−2×, 10−3×, 10−4×, 10−5×, 10−6×, 10−7× and 10−8×. Also,
the conventional streak plate technique was used to count the cell number
in case the cell density was predicted to be less than the detectable range of
the track dilution method (i. e. < 103 CFU/ml). This was done by spreading
0.1 ml and 1 ml of broth culture on two MHA plates. The detectable range
of the cell number in the works in the postantibiotic effect test, therefore,
would be from 10 CFU/ml to 1012 CFU/ml.
To control the growth speed of bacteria, all media and solutions used in
this study were pre-warmed at 37°C before used.
6.4.1 Methods
The following describes the method used for the postantibiotic assay for
each species in 20% manuka honey M115.
6.4.1.1 Day 1 - Preparation
One day before the experiment 3.09 g honey was weighed out and stored in
a dark refrigerator.
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Also, stock culture from the −70°C freezer was recovered by incubating
on MHA at 37°C overnight. A single colony of the recovered culture was
taken to ensure that this was a pure culture and this was inoculated into 10
ml MHB and was further incubated at 37°C overnight.
6.4.1.2 Day 2 - PAE induction
To ensure the culture was in the log phase, 1 ml of the overnight culture
was transferred to another 10 ml fresh MHB, and incubated for another 2
h at 37°C. While waiting for this incubation to finish, 10 ml 22.2% (v/v)
honey solution (3.09 g honey, 5 ml double strength MHB and 2.78 ml water)
was prepared. This honey solution was filtered through a 0.22 µm sterile
membrane and from the filtrant 9 ml was transferred to a sterilised 15 ml
centrifuge tube (Greiner Co.). Another sterilised 15 ml centrifuge tube filled
with 9 ml sterile MHB was also prepared as a control. Both tubes, along
with a bottle of MHB, were kept at 37°C until use.
While pre-warming the solutions stated above, the inoculum was pre-
pared as described in Section 6.2.1 so that the bacterial cell density would
be approximately 3×106 CFU/ml.
To the contents of each pre-warmed centrifuge tube, 1 ml of inoculum
solution was added, mixed well, then 100 µl of the broth culture was
removed from each tube and serially diluted with pre-dispensed 0.9 ml
MHB. All tubes were then incubated in a shaking incubator for 1 h (37°C, 150
rpm). While waiting for the incubation, each serially diluted broth culture
(10 µl) was loaded onto square agar plates for viable cell counting and the
plates were incubated at 37°C overnight. This time point was recorded as
“t0” and the result of CFU counting as “C0” to check if the starting cell
density in the tubes with honey and for control are approximately the same.
1 h after “t0”, 100 µl was taken from each tube and serial diluted in 0.9
ml MHB as before, then all tubes were centrifuged at 1 600 ×g for 10 min at
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room temperature. Meanwhile, the serial diluted inocula were loaded onto
square agar plates as before and incubated at 37°C overnight. This time
point was recorded as “t1” and the CFU result as “C1”.
After centrifuging, the 9 ml supernatant in each tube was carefully
replaced with the same volume of warm MHB without disturbing the
pellets so as not to suck the bacteria in the pellets into the pipette along
with the supernatant. The bacteria in the pellets were then washed by
vortexing the tubes for 2 seconds, then centrifuging for 10 min at 1 600×g and replacing with fresh warm MHB. The washing was then repeated
twice. Then 100 µl was taken from each of the tubes for viable cell counting
as before. The time point and CFU results were recorded as “t2” and “C2”
respectively. The tubes were then incubated in a shaking incubator (37°C,
150 rpm) for 1 hour. Note that theoretically the washing should have taken
30 min (three washings, 10 min for each time), but in practice the washing
process took approximately 1 h.
After “t2”, serial dilution for viable cell counting and further incubation
were repeated every 1 hour, and the time stage and CFU results were
recorded as “t3”, “t4”, “t5” and “C3”, “C4”, “C5” and so on until a significant
increase in the turbidity was observed visually in the honey-treated tube.
6.4.1.3 Day 3 - PAE evaluation
After the overnight incubation of the agar plates, the viable colony forming
units on each agar plate were counted and the cell density (CFU/ml) for
each time point was calculated. A “log10 (CFU/ml) vs time” chart was
drawn accordingly as shown in Fig 6.12.
The PAE was obtained from the following formula: PAE = T2 - T1 where
T2 is the time the honey-treated bacteria required to increase by 1 log10 in
viable count after washing, and T1 is the time the control group required
under the same conditions.
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Figure 6.12: An illustrative graph of the calculation of the postantibiotic effect (PAE).
In this figure the PAE is 1.4 hours. Source: adapted from Craig (1996).
6.4.2 Results and discussion
This section describes the result of postantibiotic effect (PAE) on enterobac-
teria caused by 20% (v/v) manuka honey. The “log10 (CFU/ml) vs time”
charts for the various species of bacteria are shown in Figures 6.13–6.26. It
must be emphasised that the postantibiotic effect test is to examine whether
the exposure to honey has affected the metabolism of the bacterial cells that
remain alive, so that their subsequent growth is slowed. In other words, the
study is to investigate for how long the rate of growth after 1 h exposure
to and 1 h washing process of honey (i. e. gradient of the log plots after t2)
remains less than the control before they becoming parallel.
Traditionally, the postantibiotic effect assay is done by monitoring the
recovery of antibiotic-treated bacteria in terms of CFU/ml. In carrying
out this work here, several serious drawbacks with this assay came to
light. It takes a long time to prepare, execute and finish the test, which
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Figure 6.13: The postantibiotic effect of manuka honey on E. coli.
results in taking up as long as almost one week to run one single test.
The lengthy process during the test could largely increase the chance of
contamination and mistake, both of which are critical because otherwise it
is almost impossible to obtain a good quality colony counting results at the
end (as can be seen from the Figures). It was also found to be impossible to
handle more than 2 species i. e. 5 tubes (two tubes for each species, plus one
tube for sterility control) in a run because it would take too much time to
handle the samples, and the time needs to be strictly controlled (particularly
when washing honey off by centrifuging, and also when serially diluting
and inoculating bacteria on agar plates hourly). The requirement in time
control also had made it impossible to conduct any replication in each
single test because this would greatly increase the number of apparatus
and media, and therefore the handling time. The lack of replication could
have led to the difference in the bacterial cell number at the starting point
between the tube with honey treated and the tube for control in some
species (Figures 6.15, 6.20, 6.21 and 6.23). Repetitive fluctuation in broth
temperature may effect the growth of “recovering” bacteria. Not knowing
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Figure 6.14: The postantibiotic effect of manuka honey on S. typhimurium DT104.
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Figure 6.15: The postantibiotic effect of manuka honey on S. enteritidis.
chapter 6 the pharmacodynamics of manuka honey 146
0 1 2 3 4 5 6 7 8 9
0
1
2
3
4
5
6
7
8
9
10
Control
Honey
Time (h)
Lo
g1
0 
C
FU
/m
l
Figure 6.16: The postantibiotic effect of manuka honey on P. aeruginosa.
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Figure 6.17: The postantibiotic effect of manuka honey on Y. enterocolitica.
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Figure 6.18: The postantibiotic effect of manuka honey on E. aerogenes.
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Figure 6.19: The postantibiotic effect of manuka honey on E. cloacae.
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Figure 6.20: The postantibiotic effect of manuka honey on S. flexneri.
0 1 2 3 4 5 6 7 8 9
0
2
4
6
8
10
12
Control
Honey
Time (h)
Lo
g1
0 
C
FU
/m
l
Figure 6.21: The postantibiotic effect of manuka honey on S. sonnei.
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Figure 6.22: The postantibiotic effect of manuka honey on E. faecalis.
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Figure 6.23: The postantibiotic effect of manuka honey on E. faecium.
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Figure 6.24: The postantibiotic effect of manuka honey on B. animalis subsp. lactis.
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Figure 6.25: The postantibiotic effect of manuka honey on L. plantarum.
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Figure 6.26: The postantibiotic effect of manuka honey on L. rhamnosus.
the range of CFU during the incubation in fresh broth after washing means
a wide range of serial dilution was needed (hence large amount of agar
plates, diluent and handling time is required). Also, not knowing how long
it would take bacteria to re-grow after honey is removed means a single test
could take as long as or more than 12 hours. With all the issues described
above, the estimation of the postantibiotic effect values therefore cannot be
precise. Nevertheless, these data do allow the author to see that there are
big differences between species in the postantibiotic effect of manuka honey.
Similar to the findings with the time-to-kill test, the results from the
postantibiotic tests showed that the MIC/MBC may not fully describe the
susceptibility of bacteria to manuka honey. The susceptibility test result
showed that for most species the MIC was 5–10% honey and the MBC
was 8.5–16% honey, whereas postantibiotic effects of manuka honey on
these species seems to be not always proportional to the MIC or the MBC.
Generally most organisms such as Salmonella spp. and E. coli have the MIC
of 7–8% and the postantibiotic effect of around 2–2.5 h. For Enterobacter
spp., for which the MIC and MBC values are relatively higher, a moderate
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postantibiotic effect of around 2–2.5 h was also obtained. For Y. enterocolitica
the MIC and MBC were very low. With this species there was a longer
postantibiotic effect than with most other organisms (nearly 4.5 h). With P.
aeruginosa it was expected that there would be a minor postantibiotic effect
because of the high MIC for this species, whereas the results revealed that
the postantibiotic effect was surprisingly long (more than 3.5 h). On the
other hand, hardly any postantibiotic effect was observed with E. faecalis
and E. faecium (less than 0.5 h). A similar result was seen with the probiotics
B. animalis subsp. lactis, L. plantarum and L. rhamnosus.
The length of the prevention of bacterial regrowth by manuka honey
may be due more to its bactericidal effect on bacterial cells than to the MIC.
For comparison, the results of the MIC test as well as those of pharmaco-
dynamics are placed side by side (Figure 6.27). From Figure 6.27 it is also
clear that the species with higher time-to-kill results require a very short
time for recovery. It is possible that the honey concentration used in the
time-to-kill and the PAE tests (20%) being just above the MIC for B. animalis
subsp. lactis, Lactobacillus and Enterococcus may have been responsible for
the long time-to-kill result and short PAE. A shorter time-to-kill and longer
PAE would be expected if higher concentration of honey were used to treat
the species. However, this hypothesis is not supported by the observations
with P. aeruginosa because the results with P. aeruginosa should have had a
similar trend as there was with these species. Also, for those species with
short time-to-kill results, the honey concentration at just above MIC did not
elongate the result in the time-to-kill studies as much as more than 10 hours.
An alternative possibility is that perhaps manuka honey has different modes
of bactericidal action on different species. Several antibiotics, for instance
daptomycin, are known to have rapid bactericidal effects at or just above the
MIC (Fuchs et al., 2002; Rybak et al., 2000), and the situation observed in P.
aeruginosa is somewhat similar to this, although a surprising phenomenon
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seen in daptomycin, the delay in the growth of microbes at concentration
just below the MIC or even as low as 0.2 times the MIC for more than 12
hours (Pankuch et al., 2003) is not observed in our study. It is possible that
the bactericidal mechanisms in manuka honey may be especially effective
with some species (P. aeruginosa and Y. enterocolitica in this study), and be
moderately effective to most other species (E. coli, Salmonella, Enterobacter
and Shigella) and be of relatively low effectiveness to the probiotics used in
this study.
The postantibiotic effect and time-to-kill are increasingly important
pharmacodynamic parameters in clinical areas because these provide infor-
mation on optimising the therapeutic regime in response to the increasing
prevalence of bacterial species resistant to antibiotics. Especially the for-
mer may help reduce the dose or increase the interval between doses by
investigating how an antimicrobial agent affects bacterial cells after being
removed.
6.4.3 A spectrophotometric method for the post-antibiotic as-
say - a trial
Given that several issues had severely restricted the efficiency of the pharma-
codynamics assay that is based on the standard viable counting technique,
a spectrophotometrical method using a microtitter plate reader was consid-
ered to improve the efficiency. This spectrophotometrical method shares in
the postantibiotic effect induction and honey removal with the conventional
cell-counting based method, but differs from the traditional counterpart in
two aspects. Firstly, the monitoring of the bacterial recovery after the cells
being washed was done by a microplate reader with a built-in incubator
(BMG FLUOstar OPTIMA) so that the number of simultaneously handleable
sample is increased whilst the overall working load is largely decreased.
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Secondly, the postantibiotic effect is determined by examining the difference
in the time the honey-exposed and control bacteria required to reach parallel
log phase in the monitoring growth curve (Figure 6.28).
This spectrophotometric method was tried to compare the postantibiotic
effect of 20% of manuka honey M115 with that obtained using the standard
method. It was also intended to try to compare the postantibiotic effect
induced by different concentrations of honey with different types of antibac-
terial activity. A series of binaraly diluted (20%, 10% and 5%) manuka honey
M115, honeydew (a honey with peroxide activity as its only antibacterial
activity) and artificial honey were included in this trial. Each of the honey
samples was further subdivided into that with and without 0.1% catalase
added. Because the spectrophotometric method was not well standardised
at this stage, only E. coli was included in the test (Figures 6.29, 6.30 and
6.31).
Comparing Figure 6.31 with the postantibiotic effect of 20% manuka
honey on E. coli with the traditional method (Figure 6.13), however, it is
seen that the spectrophotometric method gave a significantly longer postan-
tibiotic effect (3–4 h) than the ones obtained from the viable couting method
(1–2 h). The cause of the difference is yet to be found. In theory, the two
methods should have given similar results because the treatment on the
Figure 6.28: Theoretical graph of postantibiotic effect (PAE) determination using
spectrophotometry.
chapter 6 the pharmacodynamics of manuka honey 156
0 1 2 3 4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1
1.2
Broth
Broth+C
0%
0%+C
5%M
5%M+C
Time (h)
O
.D
.
0 1 2 3 4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1
1.2
Broth
Broth+C
0%
0%+C
5%H
5%H+C
Time (h)
O
.D
.
0 1 2 3 4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1
1.2
Broth
Broth+C
0%
0%+C
5%A
5%A+C
Time (h)
O
.D
.
0 1 2 3 4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1
1.2
Broth
0%
5%M
5%H
5%A
Time (h)
O
.D
.
0 1 2 3 4 5 6 7 8 9
0
0.2
0.4
0.6
0.8
1
1.2
Broth+C
0%+C
5%M+C
5%H+C
5%A+C
Time (h)
O
.D
.
(A)
(B)
(C)
(D)
(E)
Figure 6.29: Growth curves monitored by a microtiterplate reader of E. coli culture
after 1 hour exposure of 5% honey. Comparisons of the growth curves
are made within subfigures (A): manuka honey M115, (B): honeydew
honey, (C): artificial honey, (D): honeys without 0.1% catalase added,
and (E): honeys with 0.1% catalase added. Abbreviations used in the
keys: M, manuka honey M115; H, honeydew honey; A, artificial honey;
C, catalase solution (0.1%).
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Figure 6.30: Growth curves monitored by a microtitterplate reader of E. coli culture
after 1 hour exposure of 10% honey. Comparisons of the growth curves
are made within subfigures (A): manuka honey M115, (B): honeydew
honey, (C): artificial honey, (D): honeys without 0.1% catalase added,
and (E): honeys with 0.1% catalase added. Abbreviations used in the
keys: M, manuka honey M115; H, honeydew honey; A, artificial honey;
C, catalase solution (0.1%).
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Figure 6.31: Growth curves monitored by a microtitterplate reader of E. coli culture
after 1 hour exposure of 20% honey. Comparisons of the growth curves
are made within subfigures (A): manuka honey M115, (B): honeydew
honey, (C): artificial honey, (D): honeys without 0.1% catalase added,
and (E): honeys with 0.1% catalase added. Abbreviations used in the
keys: M, manuka honey M115; H, honeydew honey; A, artificial honey;
C, catalase solution (0.1%).
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bacterial cells (the exposure of cells to the honey, washing off etc.) were
all the same, unless the way how the re-growth of bacteria was monitored
would make any difference to the postantibiotic effect result. In fact, several
alternatives based on bioluminescence, bacterial morphology, infrared spec-
troscopy, radiometry, fluorometry and others including spectrophotometry
have been suggested (Nicolau, 2001). However, Rescott et al. (1988) also no-
ticed a significant variation between the spectrophotometric method and the
standard viable counting method when testing the effect of tobramycin on
E. coli while the variations between the two methods when using ampicillin
and ciprofloxacin were not statistically significant. Stubbings et al. (2004)
compared the two methods using 22 antibiotics with 3 strains of E. coli and
a strain of S. aureus, and concluded that bacteriolytic antibiotics gave poor
correlation in the results obtained with the classical and spectrophotometric
methods. It is also pointed out that other biological factors (cell phase,
inoculum density, changes in bacterial morphology), and the machinery
factor (growth detection threshold and incubating temperature) could cause
deviation in the postantibiotic effect results (Domínguez et al., 2001). Indeed,
a decline in the viable counting right after washing honey off was noticed
in the traditional method whereas this is not reflected in the growth curves
obtained spectrophotometrically in which all curves shared a common base
line. Also it must not be forgotten that the optical density is related to the
cell mass but not to the cell number, and whether or not honey made any
alternation to the cell mass is not clear. Therefore, it might be unwise at this
stage to compare the postantibiotic effect obtained from the two methods
until the monitoring techniques are to be standardised.
Comparing the re-growth latency among the honeys with different con-
centration, on the other hand, revealed that the postantibiotic effect induced
by honey in E. coli seems to be dependent on the concentration as well
as the type of honey. At 5%, only manuka honey but not other types of
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honey induced a postantibiotic effect. That postantibiotic effect can still be
observed even if the pre-existing hydrogen peroxide was removed, despite
it appearing from Figures 6.29, 6.30 and 6.31 that hydrogen peroxide also
contributes to the postantibiotic effect in the total antibacterial activity in
manuka honey. As the honey concentration rises to that above the MIC, it
appears that all honey types including the sugar syrup are capable of induc-
ing a postantibiotic effect in the species, although this is more significant
in manuka honey and honeydew honey. However, although the postantibi-
otic effect induced by honeydew honey increases as its concentration rises,
that latent phenomenom for it at concentrations of both 10% and 20% is
reduced to the level of that equivalent to artificial honey once catalase is
added in. This is understandable because hydrogen peroxide is the major
antibacterial factor in honeydew honey, and osmolarity would be the only
factor to cause a postantibiotic effect once the hydrogen peroxide activity is
removed. Manuka honey, on the other hand, still can induce a postantibiotic
effect after its hydrogen peroxide activity has been removed. Interestingly,
neither the effect of hydrogen peroxide nor that of non-peroxide antibacte-
rial components on the postantibiotic effect in manuka honey seems to be
directly correlated with the honey concentration because the exact increase
in postantibiotic effect from 5% to 10% and then to 20% is in fact decreasing
if we substract the postantibiotic effect by 20% artificial honey from other
honey. This might suggest that each antibacterial factor in the honey (i. e.
osmolarity, hydrogen peroxide and non-peroxide) may work differently
depending on the honey concentration. Unfortunately the sample size is too
limited in this trial to analyse the role which each antibacterial factor plays
in the pharmacodynamic effect of manuka honey.
The mechanisms by which honey or antibacterial agents induce a postan-
tibiotic effect in bacteria are poorly known, largely because alterations in
morphology or metabolism are not uniform in microorganisms. Observation
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using electron microscopy showed that some classes of antibiotics increased
the number of crosswalls or the thickness of the cell wall in staphylococci, or
induce intracellular electrodense aggregation in P. aeruginosa (Gottfredsson
et al., 1993) and the release of intracellular components (Sakagami et al.,
1999). Barmada et al. (1993) observed with E. coli that during the postantibi-
otic state the functional protein synthesis but not DNA and RNA synthesis
was halted for 4 hours after tobramycin had been removed. Stubbings et al.
(2006), on the other hand, reported that the gentamicin-induced postan-
tibiotic effect on E. coli coincided with the recovery of protein synthesis
whereas the one induced by rifampicin coincided also with DNA synthesis.
The effects of a single antimicrobial agent on cell morphology can also vary
dramatically with bacterial species. It was reported that para-aminobenzoic
acid (PABA) could induce E. cloacae to produce filaments, and could elon-
gate and thicken the peripheral cells of P. aeruginosa, while with S. aureus
PABA increased overall cell wall thickness and thickened transverse cell
walls (Richards et al., 1993). A single alteration in morphology such as DNA
synthesis could also vary in opposite ways, so that in E. coli and S. aureus
the synthesis was suppressed whereas this was relatively enhanced in Gram-
negative bacilli (Gottfredsson et al., 1995). The differences in morphological
alteration after exposure to various antimicrobial agents may suggest that
there exist multiple mechanisms behind the postantibiotic effect. This might
also apply to honey because of its complexity which is largely the result of
various external factors, and that complexity could have had multiple effects
on bacterial cells. However, more detailed research on the mechanism by
which honey inhibits/kills bacteria is required to find if this is so.
7
T H E E F F E C T O F G A S T R O I N T E S T I N A L A C I D I T Y A N D
E N Z Y M E S O N T H E A N T I B A C T E R I A L A C T I V I T Y O F
M A N U K A H O N E Y
In this chapter the effect of acidity and digestive enzymes on the antibacterial
activity of manuka honey are described.
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7.1 Introduction
Any ingested food would get into the colon through the stomach. At the
same time, a large number of microorganisms can also be ingested: in addi-
tion to topical wounds, oral ingestion is thought to be the major “entrance”
through which microorganisms can invade in a host. It is estimated that
over 1010 bacteria each day may enter the host through the mouth (Wilson,
2008), and therefore a defence system against these microbes is essential to
maintain the host’s health.
In healthy individuals, before the food reaches the colon it is digested
by the digestive system while passing through the tract. As it passes, the
gastrointestinal tract secretes fluid with a range of functionality that helps
degrade food ingredients into small molecules. The enzymes digest pro-
teins, carbohydrates and lipids in the food. The gastric protease, pepsin,
hydrolyses the amino-terminal side of the aromatic amino acids phenylala-
nine, tryptophan and tyrosine (Keil, 1992). The acidity, on the other hand,
provides an optimum environment for the enzymes to react and also assists
food degradation. Gastric digestion is then followed by intestinal digestion
carried out by various enzymes such as trypsin, chymotrypsin, amylase
and lipase, which work in association with bile salts. The pH in the chyme
is spontaneously neutralised to approximately 7–8 by pancreatic fluid, so
acidity no longer plays a role in digesting food in the intestine (Wilson,
2008).
The gastrointestinal environment also plays an essential role as a defence
line in the body, of which the gastric acidity may contribute the major part
of the antiseptic action. The acidity in the stomach (pH 2) prevents bacterial
colonisation on gastro-epithelial cells and also eliminates the majority, if
not all, of the invasive organisms (Wilson, 2008). It is estimated that the
number of viable cells can decline from incoming 1010 bacteria to less than
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103 CFU/ml (Wilson, 2008), although this number can also rise up to 105–106
depending on individuals and the time in a day, especially the time after
a meal (Wilson, 2008). The significant rise in pH in the small intestine,
however, decreases the potential to inhibit the growth of bacteria so that
the viable cells could increase up to approximately 1013–1014 in the large
intestine (Wilson, 2008). In a simulated digestion study it was reported
that E. coli O157:H7 and S. flexneri are inactivated significantly in simulated
gastric fluid, with the inactivation rate decreased as the dose of antacid
increased (Tamplin, 2005).
Gastric enzymes may also affect the bacterial cells. However, the short
transit time in the stomach may make the antiseptic effect of pepsin less
significant than that of acidity. Although the small intestine is believed to be
the main part of the digestion in a host because of the long stay in the tract,
the antimicrobial effect of intestinal enzymes is also not obvious as can be
seen from a study done by Gorbach et al. (1967). They reported that the
estimated colonisation in the gastrointestinal tract in 18 healthy individuals
increased from less than 50 CFU/ml in the stomach to 50–100 CFU/ml
in the duodenum, to 100–1 000 CFU/ml between the upper jejunum and
the upper ileum, and this then abruptly increased to more than 500 000
CFU/ml in the distal ileum. This can be because the digestive enzymes
together with bile acids are absorbed by the tract (Martini, 2001), but it can
also be because the indigenous microbiota have adapted to the intestinal
environment (Wilson, 2008).
The enzymic activity and the acidity of digestive fluid not only affects
bacterial cells but may also affect the property of antimicrobial agents. In
fact, several antibiotics have been reported to lose their stability or efficacy
in the gastrointestinal environment, which is largely due to the acidity. An
example is that amoxycillin and metronidazole appear to be stable at a
normal gastric pH (1.0–2.0) whereas clarithromycin can be degraded at this
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pH in about 4 hours (Erah et al., 1997), and some proton pump inhibitors
are therefore administered to ensure the acid-susceptible drugs are not
inactivated by the acid during H. pylori eradication therapy (Axon, 1991).
In honey, hydrogen peroxide is one of the major antibacterial factors
and its production (Equation 1.1) can be affected by many factors including
heat, light and acidity (Crane, 1979). It is reported that the enzyme glucose
oxidase that catalyses the reaction in which hydrogen peroxide is formed
works well at pH 7 whereas the activity, hence the accumulation of hydrogen
peroxide, is negligible at pH 3 (Crane, 1979). Thus the gastric environment
is obviously too acidic for the enzyme to produce hydrogen peroxide. Also,
pepsin as well as other digestive enzymes and salts in the tract may destroy
the enzyme and affect the non-peroxide antibacterial activity of manuka
honey. Therefore it was necessary to investigate how well the activity of
the honey would work when subjected to acidity and the enzymic factors.
In this chapter, the influence of acidity and then that of gastrointestinal
enzymes on the antibacterial activity of manuka honey is investigated.
7.2 The effect of acidity on the antibacterial activity
of manuka honey
7.2.1 Materials and method
7.2.1.1 Bacterial cultures and media
The bacterial cultures used in this study were: E. coli, Shigella spp., P. aerugi-
nosa, Salmonella spp., Enterobacter spp., Enterococcus spp. and Y. enterocolitica.
Mueller-Hinton broth (MHB) was used to cultivate the cultures. The cultural
inocula were prepared as described in Chapter 4.
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Before the study was carried out, it was considered to use buffered me-
dia to minimise the possible pH fluctuation due to the bacterial metabolism
during the incubation. However, different buffer solutions have different op-
timum buffering capacity, and to cover the wide range of pH that would be
used in this study (pH 2–8) it would be required to use media made up with
different buffer solution for different pH range, and the different buffering
acids and salts could also further influence the bacterial metabolisms and
the activity of manuka honey. This would add more undesirable complexity
in addition to the effect of acidity being studied. It is also reported that
the pH of both inoculated and non-inoculated media do not fluctuate sig-
nificantly during incubation unless it is anaerobically incubated for more
than 24 hours (Jansen and Bremmelgaard, 1986). Therefore it was decided
to make broth and honey solutions with various pH values by adjusting the
pH with 1 M HCl or 1 M NaOH to minimise the possible variables involved.
It was also realised in a preliminary test that the range of the final
concentration of honey in microplate wells, which is achievable by serially
diluting a single initial concentration of honey with the dilution method
used in Chapter 4, was too narrow to cover the possible MIC in this study
(Table 4.1). For example, the detectable range of MIC is 2.23–16.6% if 50%
honey solution is used, and it was found that all bacteria could grow in 16.6%
alkaline honey whereas they could not survive in 2.23% acidified honey.
Because a range of pH values (pH 2–8) was to be examined simultaneously,
it was required to expand the range of the final concentration in microplate
wells. Therefore a binary dilution method starting with honey of a high
concentration (40%) was used in this study. The range of concentrations of
honey prepared in this study was 0.156%, 0.312%, 0.625%, 1.25%, 2.5%, 5%,
10%, 20%, and 40%.
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The manuka honey used was the medium activity M115. Artificial honey
was also used to distinguish the antibacterial efficacy of honey at each pH
from antibacterial activity caused by osmolarity.
For each pH tested, MHB and honey solutions of the same pH were
prepared. Aliquots of single strength MHB with different pH values were
prepared by adjusting the pH with HCl or NaOH. Aliquots of honey with
different pH values were prepared by firstly making a double strength
honey solution and adding an equivalent volume of double strength MHB,
and then adjusting the pH with HCl or NaOH. All solutions were sterilised
by filtering through a 0.22 µm membrane.
To measure the MIC at each pH, the microdilution method was con-
ducted, in triplicate, as described previously (Chapter 4). After the MIC
test, the MBC for each condition was also examined as described previously
(Chapter 4).
7.2.2 Results and discussion
Figures 7.1–7.11 show the results of the susceptibility measurements with the
various species at various pH values. Despite the wide interval between each
concentration level, it is still obvious that generally there was a declining
MIC and MBC as the environmental acidity increased. Most microorganisms
failed to survive at a pH below 3 or 4 in the controls (no honey present). The
presence of honey made no difference to survival at these pH values. The
decline in MIC and MBC can be seen both in manuka honey and artificial
honey, although the MIC and MBC values of artificial honey are significantly
higher than those of manuka honey. Like what has been shown in previous
chapters, this result shows that the osmolarity again is not practical.
It is possible that the antimicrobial activity provided by the unknown
non-peroxide antimicrobial component itself is to some degree destroyed
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Figure 7.1: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against E. coli. The results shown are mean values (n=3)± SD.
or inactivated by the acidity. The inhibitive effect of the acidity on the
bacterial cells could have at the same time compensated for the loss of
activity. However, if this was the case then the MIC and MBC of manuka
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Figure 7.2: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against S. typhimurium DT104. The results shown are
mean values (n=3) ± SD.
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Figure 7.3: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against S. enteritidis. The results shown are mean values
(n=3) ± SD.
2 3 4 5 6 7 8
0
5
10
15
20
25
30
35
40
Manuka-MIC Manuka-MBC Artificial-MIC Artificial-MBC
pH
Co
nc
en
tra
tio
n 
of
 h
on
ey
 (%
)
Figure 7.4: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against P. aeruginosa. The results shown are mean values
(n=3) ± SD.
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Figure 7.5: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against Y. enterocolitica. The results shown are mean
values (n=3) ± SD.
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Figure 7.6: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against S. flexneri. The results shown are mean values
(n=3) ± SD.
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Figure 7.7: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against S. sonnei. The results shown are mean values
(n=3) ± SD.
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Figure 7.8: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against E. aerogenes. The results shown are mean values
(n=3) ± SD.
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Figure 7.9: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against E. cloacae. The results shown are mean values
(n=3) ± SD.
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Figure 7.10: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against E. faecalis. The results shown are mean values
(n=3) ± SD.
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Figure 7.11: The effect of pH on the MIC and MBC of manuka honey M115 and
artificial honey against E. faecium. The results shown are mean values
(n=3) ± SD.
honey at low pH should have been as high as that with artificial honey, but
it was not. This indicates that, before the pH decreases to the level at which
bacteria can not survive at all, the antimicrobial activity of manuka honey
remains stable in acidic condition.
In contrast to the acidic conditions, the alkalic environment (pH above
7) seems to be slightly destructive to the antimicrobial activity in manuka
honey, as seen in the remarkedly higher MIC and MBC values at pH 8 with
manuka honey for all species of bacteria. The alteration in the antimicrobial
activity in acidic and alkalic condition may possibly be partly caused by the
decrease in activity of glucose oxidase that is responsible for the generation
of hydrogen peroxide, as the activity of the glucose oxidase of honey is
maximised at around pH 6.1 and declines as the pH moves toward the
acidic and alkaline sides (Schepartz and Subers, 1964). In the study of
Schepartz and Subers, the activity of glucose oxidase declined from 100% at
pH 6 to approximately 40–50% at pH 8–9 or 20–30% at pH 2–3. Whilst acid
may compensate the loss in the activity of the enzyme, pH 7–8 is in fact
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preferable to many microorganisms and therefore the loss in the activity
of glucose oxidase in such moderate alkaline environment could have also
reflected on the MIC and MBC results. This suggests that the acidity itself
can influence the antibacterial efficacy of honey. On the other hand, it is
possible that the alkaline environment also has a negative effect on the non-
peroxide components in manuka honey. Snow and Manley-Harris (2004)
found using an agar diffusion assays that exposure to a range of alkaline
pH caused the non-peroxide activity of manuka honey to be lost in less
than 30 min (within 10 min, the honey lost 50%, 100% and 100% activity
at pH 9, 10, and 11 respectively). The finding in the work in this chapter
is in agreement with the work by Adams et al. (2008) in which treatment
of manuka honey with NaOH and then titration back to the original pH
resulted in irreversible loss of the non-peroxide antibacterial component in
their HPLC assay. The lability of dicarbonyls, hence of methylglyoxal, in an
alkaline environment has also been reported by Bowden and Fabian (2001).
The increase in the MIC and MBC at pH 8, however, shows only a partial
loss of activity because the efficacy is still greater than that of the artificial
honey in the identical condition, suggesting that at pH 8 manuka honey still
can inhibit microorganisms by means of peroxide or non-peroxide action in
addition to osmolarity.
Acidity, especially that in the stomach, in comparison with other defence
mechanisms in the gastrointestinal tract (e. g. enzymes, mucus, immunoglob-
ulin), is the primary barrier in a host to defend against incoming bacteria
(Giannella et al., 1972, 1973), and the failure in the growth of bacteria in
the extreme pH as shown in this study may make humans feel that the
importance of the antibacterial property of manuka honey is less obvious.
One should not forget, however, that bacteria may break through the acid
barrier because they may have adapted to the extreme pH before being
ingested in the body. Many species of bacteria including gastrointestinally
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important pathogens such as E. coli, Shigella, V. cholerae, S. typhimurium and
H. pylori (Merrell and Camilli, 2002) have been reported to be able to tolerate
extreme pH using many mechanisms, including altering membrane lipid
composition (Yuk and Marshall, 2004) or proteins (Leyer and Johnson, 1993),
or through numerous pH-influenced gene regulations (Hall et al., 1995).
Such acid or alkaline adaptation can be induced by exposing the cells in
mildly acidic or alkaline conditions for one to two cell-doubling generations.
As such mild environmental stress can easily be found in food or food
processing, bacteria causing food-borne gastroenteritis in fact may have
been able to tolerate acid/alkaline stress, and consequently the acidity in
the stomach or intestinal tract may be less effective against these adapted
bacteria. In this respect, the antibacterial activity of manuka honey may be
of additional help to the gastrointestinal defence system.
Whereas bacteria adapted to acidic conditions would be tolerant to a yet
more extreme environment, at the same time they can also be more sensitive
to other types of environmental stress. E. faecalis that is pre-incubated at pH
10.8 can subsequently tolerate pH 11.9 but not pH 3.2 (Flahaut et al., 1997).
In the same study, the same species exposed to pH 4.8 was found to survive
at pH 3.2 but not at pH 11.9 (Flahaut et al., 1997). A similar phenomenon can
also be observed with E. coli (Rowbury et al., 1993; Rowbury and Hussain,
1996). As acidic/alkaline (and, in fact, many other environments) stress
responses involves various mechanisms, one adaptation could lead the cells
to be adversely more sensitive to other stress. Similarly, cells of the same
species with and without adaptation to acidic/alkaline environment may
differ in the sensitivity to manuka honey. As in this study the bacterial
cultures were prepared in neutral Mueller-Hinton broth (pH 7.4) before the
sensitivity test was carried out, it would not be surprising if the efficacy of
manuka honey in acidic/alkaline environment in vivo happen to vary from
this in vitro study, and of course it would also be of interest to investigate
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the sensitivity of the acid/alkaline adapted strains to manuka honey in the
future.
7.3 The effect of gastrointestinal enzymes on the
activity of manuka honey
Following study of the effect of pH on the total antimicrobial activity of
manuka honey, the effect of gastrointestinal enzymes on the honey was
investigated. It has been reported that glucose oxidase from Aspergillus niger
and Penicillium notatum is stable against pepsin (Stecher et al., 1968) and an
acidic environment, however the activity was lost completely at pH 1 (Keilin
and Hartree, 1948). However, it is not known whether or not the glucose
oxidase of honey has the same stability as that of fungal glucose oxidase. If
there were any difference in the result of the sensitivity test to be carried out
in this section, that could be either because the bacterial cells are digested or
damaged by the proteinases, or because the enzymes responsible for total
and non-peroxide antibacterial activities in manuka honey are affected by
the proteinases through an unknown mechanism.
To simulate the gastric and intestinal environments, simulated gastric
fluid (SGF) (Rockville, 1990a) and simulated intestinal fluid (SIF) (Rockville,
1990b) were used in this section.
Whereas bile salt is not an enzyme, nor is it included in the simulated
intestinal fluid formula in the United States Pharmacopeia (Rockville, 1990b),
bile was also used in the study to evaluate whether or not bile would affect
the overall antibacterial activity of the honey. This decision was based on
two reasons. One was that bile is secreted into the intestine. The other was
it has been reported that bile appears to have antibacterial activity against
some microorganisms (Begley et al., 2005; Hanninen, 1991) and therefore
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bile, together with the other proteinases, could assist the antibacterial action
of the honey.
7.3.1 Materials and method
The bacterial species used and the preparation of inoculum were the same
as in Section 7.2.
Only manuka honey (M115) was tested because it had been clear in the
previous section that a very high concentration of artificial honey would
be required to treat gastrointestinal bacteria even if an acidic environment
was to be conducted in this test. The sensitivity test was conducted and
analysed with the microdilution method, with repeats to give a total of
5 times, as described in Chapter 4, with an exception that 0.1 volume
of gastrointestinal enzyme solution was added in serially diluted honey
solution before standardised inoculum was added.
To make simulated gastric fluid (SGF), 3.2 g pepsin (pepsin A from
porcine gastric mucosa; SIGMA Cat. No. P7000-25G), 2.0 g NaCl and 7.0 ml
concentrated HCl were dissolved in purified water, then more water was
added to make up 1 litre (Rockville, 1990b). This had a pH of 1.2 and was
stored at 4°C until used (within 7 days).
Because it was found that pancreatin only partially dissolved in water,
the amount of pancreatin in the simulated intestinal fluid (SIF) used in the
work in this chapter was reduced to one tenth of that suggested in the US
Pharmacopoea (Rockville, 1990b). To make simulated intestinal fluid SIF,
6.8 g KH2PO4 was dissolved in 250 ml purified water and then to this 190
ml 0.2N NaOH, 400 ml water and 1.0 g pancreatin (from porcine pancreas;
AppliChem Cat. No. A0585,0100) were added. After this it was adjusted to
pH 7.5±0.1 with 0.2N NaOH and then purified water was added to make it
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up to 1 litre (Rockville, 1990b). This was stored at 4°C until used (within 7
days).
Bile solution (3%) was made by dissolving 0.3 g bile powder (Sigma Cat.
No. B-8381; bile from bovine, minimum 50% bile acid) in 10 ml purified
water. Simulated intestinal fluid with bile was made by mixing 0.3 g of
bile powder in 10 ml of SIF. A denatured intestinal fluid (heated in boiling
water for 10 min then chilled in ice) with bile was also included in the
test to investigate whether it was an enzymatic or chemical effect should
pancreatin be found to have any influence on the MIC.
Seven different environments as listed in Table 7.1 were studied simul-
taneously. The honey solution was serially diluted first with MHB in sterile
bijoux bottles and inoculated with bacterial culture as described previously
in Chapter 4 (Section 4.2.5 on Page 90) except that the volumes were ten
times greater than those described in Chapter 4. From each bijou 90 µl
of serially diluted honey solution was transferred into microplate wells,
then 10 µl of the other components were added, immediately before the
microplate was monitored at 37°C overnight using a microplate reader to
determine the MIC. To make the decrease in the final concentration of honey
the same in all testing environments, 0.1 volume of sterilised water was also
added in environments 1 and 2 as controls. The MBC was determined as
described in Chapter 4.
The effect of the seven environments on the efficacy of manuka honey
was analysed by the Kruskal-Wallis rank sum test and the pairwise t-test
(with P-value adjusted with the Holm method) in the statistical package R
(http://www.r-project.org) (R Development Core Team, 2008).
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7.3.2 Results and discussions
In the test associated with simulated gastric fluid (SGF) which includes
pepsin and extremely high acidity, all organisms failed to survive even in
the positive control without honey and pepsin. This is in fact predictable
as SGF had a pH of 1.2 whereas most microorganisms are known to lose
their viability at pH below 4 or 5 as shown in Section 7.2. To understand
the effect of the gastric enzyme on the efficacy of the honey, it would
be of benefit to use microorganisms such as H. pylori that are capable of
tolerating an acidic condition. Unfortunately it was not possible to test H.
pylori in this study due to the difficulty of culturing that species. Also to
be noted is that H. pylori survives the acidic conditions in the stomach by
secreting the enzyme urease to hydrolyse urea in the gastric mucosa and
create a less acidic micro-environment which may be at a pH at which
manuka honey is known to work. Because of the urease activity of this
species, it would be somewhat misleading to denote this testing model as
to determine the effect of acidic conditions on the antibacterial activity in
manuka honey. Alternatively, possible solutions to investigate the effect of
pepsin would be to reduce the time for which bacteria are exposed to the
simulated gastric fluid. However, it would be difficult to predict how long
the antibacterial component, especially non-peroxide component, would
be staying in the stomach, because any fluid like honey solution would
promptly pass through the gut whereas it is not known whether or not the
non-peroxide components would persist in the gastric mucosa or epithelial
tissue. Another challenge that can be foreseen is that, if an organism is to be
treated with gastric fluid followed by being transferred to a solid medium,
the sudden fluctuation in the environmental pH would corrupt the cells
(Reddy et al., 2007) which would consequently influence the results.
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Perhaps the best way to assess the effect of pepsin would be to in-
vestigate from the viewpoint of the mechanism of antimicrobial action of
manuka honey. Hydrogen peroxide is unlikely to be relevant to pepsin be-
cause although glucose oxidase would not be destroyed by pepsin (Stecher
et al., 1968), the pH required for pepsin to react is too low for glucose
oxidase to generate peroxide action. On the other hand, the mechanism of
the non-peroxide activity in the honey is not thoroughly understood at this
stage.
Figures 7.12–7.22 show the MIC and MBC values of manuka honey
in the various digestive environments with each species of bacteria. The
MBC values are generally slightly higher than the MIC for all groups (i. e.
1–2 dilution steps different from the MIC). Kruskal-Wallis analysis showed
that the enzymatic environments statistically affect both MIC and MBC
values (P < 0.05). The adjusted pair-wise analyses showed that the results of
environments 3 and 5 are statistically higher than that of environment 1 (P
< 0.05). Overall, however, 10–15% manuka honey under intestinal digestive
conditions was still capable of inhibiting the growth of most gastrointestinal
bacteria. Comparing the MIC of manuka honey with and without pancreatin
or bile being added (environments 1 and 2 cf. environments 3–5), it is seen
that the addition of the intestinal components can negatively affect the
efficacy of manuka honey.
Interestingly, although there was variation in the degree of fluctuation,
most tested species revealed a similar trend in that the addition of either
pancreatin or bile raised the MIC readings (environments 3 and 4). The
increase in MIC is more significant when pancreatin and bile were added
simultaneously (environment 5) (P < 0.05). More interestingly, for most
tested species, the degree of increase in the MIC when both pancreatin
and bile were present (i. e. the difference between the MIC of environments
5 and 2) is almost identical to the sum of the degree of the increase due
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to the individual components (i. e. the sum of “the difference between
environments 3 and 2” and “that between 4 and 2”), suggesting that the
influences of pancreatin and bile are probably additive.
Heated pancreatin (environments 6 and 7) did not dicrease the activity
of manuka honey as great an effect as unheated pancreatin (P > 0.05),
suggesting that denatured pancreatin can less likely affect the efficacy
of the honey negatively. This also indicates that pancreatin can influence
the antimicrobial activity of manuka honey enzymatically. Perhaps this is
approached by destroying proteins that are responsible for the antibacterial
activity of the honey. This hypothesis, however, will need to be proved in
future by investigating the stability of proteins in honey against enzymes.
Whilst the antimicrobial activity of manuka honey still works in the
simulated intestinal environment, it is still somewhat surprising to note that
intestinal enzymes slightly reduced the activity of the honey, and especially
that bile seem to have an additive effect on the reduction. The reduction in
the activity may partially be due to the environmental pH which is slightly
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Figure 7.12: Comparison of the MIC and MBC of manuka honey M115 against E.
coli in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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Figure 7.13: Comparison of the MIC and MBC of manuka honey M115 against P.
aeruginosa in various digestive environments. The results shown are
mean values (n=3) ± SD. The seven environments are described in
Table 7.1.
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Figure 7.14: Comparison of the MIC and MBC of manuka honey M115 against Y.
enterocolitica in various digestive environments. The results shown are
mean values (n=3) ± SD. The seven environments are described in
Table 7.1.
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Figure 7.15: Comparison of the MIC and MBC of manuka honey M115 against
S. typhimurium DT104 in various digestive environments. The results
shown are mean values (n=3) ± SD. The seven environments are de-
scribed in Table 7.1.
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Figure 7.16: Comparison of the MIC and MBC of manuka honey M115 against S.
enteritidis in various digestive environments. The results shown are
mean values (n=3) ± SD. The seven environments are described in
Table 7.1.
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Figure 7.17: Comparison of the MIC and MBC of manuka honey M115 against E.
faecalis in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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Figure 7.18: Comparison of the MIC and MBC of manuka honey M115 against E.
faecium in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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Figure 7.19: Comparison of the MIC and MBC of manuka honey M115 against
E. aerogenes in various digestive environments. The results shown are
mean values (n=3) ± SD. The seven environments are described in
Table 7.1.
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Figure 7.20: Comparison of the MIC and MBC of manuka honey M115 against E.
cloacae in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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Figure 7.21: Comparison of the MIC and MBC of manuka honey M115 against S.
flexneri in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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Figure 7.22: Comparison of the MIC and MBC of manuka honey M115 against S.
sonnei in various digestive environments. The results shown are mean
values (n=3) ± SD. The seven environments are described in Table 7.1.
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more alkaline than the regular testing environment, but since pancreatin is
a mixture of catalytic enzymes including protease (trypsin) produced by
the exocrine cells of the pancreas, the proteolytic enzyme could also have
some membrane damaging effects on the bacterial cells, which in theory
should have resulted in a decrease in the MIC values. The role of pancreatin
in pathogenesis is not well known and the research is limited. Paramithiotis
et al. (2006) assessed the survival of Staphylococcus spp. in the gastrointestinal
tract and found the isolates to be resistant to pancreatin. On the other hand
Chaignon et al. (2007) tested the susceptibility of staphylococcal biofilms
to gastrointestinal enzymatic treatment and found that the eradication
depends on the constituents and the clinical isolates. As the biofilm form
of growth protects organisms from the hosts’ immune systems and also
from antimicrobial therapy, the disintegration of the biofilm matrix from
the hosts’ epithelial cell surface into the environment may help antibiotics
to eliminate the bacteria. It is thought that it is this detaching function,
rather than causing damage to the bacterial cells, is the way pancreatin and
probably pepsin too, helps the host to defeat the bacterial infection.
Unlike the limited reports on pancreatin, a number of studies regarding
the interaction between bile and bacteria have been done and antimicrobial
activity of bile has been reported.
The major function of bile in vivo is to act as a biological detergent which
emulsifies fats in the intestine. This suggests that bile has the potential
for antimicrobial activity by disrupting cell membranes which may be
more effective to Gram-negative than to Gram-positive bacteria due to the
difference in the structure of their cell membranes. Other antimicrobial
actions of bile that have been suggested are: disturbing macromolecule
stability, inducing secondary structure formation in RNA, inducing DNA
damage, altering the conformation of proteins resulting in misfolding or
denaturation, causing oxidative stress by generating oxygen free radicals
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and chelating calcium and iron (Bernstein et al., 1999; Kandell and Bernstein,
1991; Payne et al., 1998; Rajagopalan and Lindenbaum, 1982, 1984; Sanyal
et al., 1991; Schmidt and Zink, 2000).
The type of the bile used may affect the inhibitory effect of bile to
bacterial cells. Grill et al. (2000) reported that bovine bile that contains trihy-
droxyconjugated bile salts, was less inhibitory to bacterial cells than porcine
bile, which contains dihydroxyconjugated bile salts. However, Begley et al.
(2005) suggested that although bovine bile is commonly chosen to assess
the tolerance of bacteria to bile, porcine bile would be more appropriate to
use as it has more similar salt/cholesterol, phospholipid/cholesterol and
glycine/taurine ratios to human bile. It is unknown if the constituents of bile
would interact with the major antimicrobial ingredient of manuka honey.
It is expected that the overall antimicrobial activity of manuka honey with
porcine or human bile would be higher than that obtained in this study
as human bile is more likely to provide inhibition of the bacterial strains.
However, this hypothesis needs to be explored with human bile in future.
Despite of the number of report showing the deleterious effect of bile
on cells, many microorganisms have been found to be resistant to bile. It
is believed that Gram-positive bacteria are generally more sensitive to bile
than Gram-negative bacteria, and therefore bile salt is usually used as a
selective agent in media such as MacConkey medium, Salmonella-Shigella
medium and esculin bile agar. The MIC and MBC values of bile reported
for Gram-negative bacteria are generally substantially higher than those for
Gram-positive bacteria (Drion et al., 1988; van Velkinburgh and Gunn, 1999),
but some Gram-positive bacteria seem to be resistant to bile too. Brook
(1989), Carpenter (1998), Flores et al. (2003) and Saito et al. (2003) reported
that Enterococcus spp. may be isolated from bile or biliary drain devices.
Since bacteria may survive on biliary drain devices where the concentration
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of bile is very high, the fact that the species of bacteria in the study in this
thesis are not killed by the addition of 0.3% bile would not be unexpected.
A possible explanation for the observation that the organisms were
more resistant to the honey when bile (and perhaps pancreatin too) were
present was the induction of adaptation. This is a phenomenon commonly
seen among bacteria that a short-term pre-exposure of bacterial cells to
sublethal levels of stress may induce the cells to adapt to the subsequent
normal level of the stress, and as many stresses may have similar effects
on the cells, an adaptation may also mean they adapt to other stresses at
the same time. This is also termed “cross-adaptation” (Flahaut et al., 1997;
Jenkins et al., 1988; Jones et al., 1993; Leyer and Johnson, 1993; O’Driscoll
et al., 1996; Tompkins et al., 1994; Yuk and Marshall, 2004). Begley et al.
(2005) noted that low levels of bile may rapidly intercalate with membrane
lipids after solubilising them, which results in an increase in the resistance
to further stresses. It is possible that this cross-protection caused manuka
honey to be less effective in the simulated intestinal environment.
It must be emphasised that the bacterial growth, the effect of gastroin-
testinal enzymes and the antimicrobial action of manuka honey cannot be
fully modelled from in vitro studies, because of the complex nature of the
gastrointestinal environment that cannot be fully simulated in a laboratory.
Microorganisms can alter their morphologies and genetic expressions in
response to environmental stress, and the regulation can differ greatly even
from strain to strain. It has also been shown in an E. coli macroarrays assay
that manuka honey can upregulate genes that involve in stress responses,
and downregulate those involved in protein synthesis (Blair et al., 2009).
What has made the puzzle even more complex is that, unlike most antibi-
otics for which the chemical composition and the mechanisms of action
are understood, there are still numerous of aspects in manuka honey that
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remain to be cleared. These difficulties also apply to other gastrointestinal
environment factors described in previous chapters.
7.4 Conclusion
Despite acidity and intestinal enzymes being able to negatively affect the
antibacterial activity of manuka honey, the total antimicrobial action of
the honey under these conditions is still significantly higher than that
of sugar syrup. Environmental stress such as gastrointestinal acidity and
enzymes, perhaps as well as the atmospheres as discussed in Chapter 5,
may actually not only affect manuka honey but also cause alteration in
bacterial morphology. To thoroughly understand the characteristics and
the mechanism of non-peroxide activity in manuka honey it is therefore
necessary to further investigate the relationship between the honey, the
microorganisms and their stress responses.
8
G E N E R A L D I S C U S S I O N
This chapter summarises and discusses the results, findings and weaknesses
of the work in this thesis, and also provides several suggestions for further
studies that could be approached in future.
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This research project arose out of a simple question: would the sub-
stantial antibacterial activity of manuka honey be effective against en-
teropathogens, and would it be as effective (or useful) in gastrointestinal
environment as suggested in in vitro sensitivity testing? This project then
came to an issue that, rather than it being the effect of gastrointestinal
environment on the antibacterial activity of the honey, perhaps it was also
(and perhaps more) about the effect of the gastrointestinal environmental
stress (anaerobiosis, Chapter 5; exposure time, Chapter 6; acidity and gas-
trointestinal enzymes, Chapter 7) on bacterial sensitivity of microbes to the
honey.
8.1 The antibacterial efficacy of standardised manuka
honey
In this thesis manuka honey with standardised antibacterial activity has been
used to evaluate its potential to treat gastrointestinal bacterial infections.
Honey has been utilised historically to treat infections worldwide, but
unfortunately many of the reports estimating the antibacterial activity in
honey are not comparable because those reports did not standardise the
honey of interest using a reference antiseptic. Furthermore, in those reports
some details that in fact may influence the result of the sensitivity test are
absent.
Manuka honey is now widely known by the public to have exceptional
antibacterial activity, but it is widely believed that all manuka honey has the
same activity. An extensive survey done by Allen et al. (1991a) has shown
clearly that not all manuka honey is the same, and also that some manuka
honey samples in fact do not have any detectable antibacterial activity if the
enzyme catalase is added to remove hydrogen peroxide. Allen et al. (1991b)
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found that the antibacterial activity of 50 manuka honey samples tested for
both total activity and non-peroxide activity varied greatly in potency, from
not detectable to equivalent to that of over 30% phenol solution. Indeed, at
the beginning of this PhD project, a manuka honey with a very high level of
activity (M113) was used because it was not realised that the activity was
much higher than that stated on the label. After it was realised, a honey
with a near-median level of activity was used (M115).
Some species of bacteria are inhibited by quite low levels of osmolarity,
so inhibition by honey that is observed may be due to the sugar content
rather than to hydrogen peroxide or non-peroxide factors. This is why it is
important to include an artificial honey as a reference, so that the antibacte-
rial efficacy of factors other than the osmolarity can be distinguished.
Another variable that is commonly missed out in studies that are in the
literature is the cell density of the bacteria being tested in the susceptibility
assay. It is generally observed that the higher the cell number, the more
resistant the cells are to antimicrobial agents. Depending on the species of
bacteria or the antibacterial agents being tested, the MIC could rise 4 to
16-fold with as little as 0.5 log10 increase in inoculum density (Aldridge
and Schiro, 1994). Wiegand and Burak (2004) reported that the MIC of
eight tested antibiotics against P. shigelloides dramatically increased from≤0.03 mg/l with 105 CFU/ml up to 16 mg/l with 106 CFU/ml. It has also
been observed that the influence of inoculum size substantially increased
if the inoculum exceeded 9×107 CFU/ml (Edwards et al., 1991), if the an-
tibacterial agents were tested under anaerobic conditions (Aldridge and
Schiro, 1994; Edwards et al., 1991), or if the antibacterial agents were not
rapidly bactericidal (Eng et al., 1985). The influence of inoculum density on
sensitivity studies is understandable because an increase in the inoculum
would reduce the effective concentration or the per-cell concentration of
antibacterial agents (Udekwu et al., 2009). Therefore, without the informa-
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tion on the cell density being given, it would be difficult to determine if
the reported sensitivity of the microbes to the antibacterial agents being
tested is actually over-estimated or under-estimated. In this thesis both the
antibacterial potency and the cell density are standardised, and this makes
the findings from this thesis of greater value than those from other similar
work where this was not done.
Although the materials used in the work in this thesis have been con-
trolled, it must not be forgotten that one should not expect the results
obtained in this in vitro project to be reflecting the actual efficacy of manuka
honey when it is used to treat bacterial gastroenteritis in vivo, because the
gastrointestinal tract is an extremely complex micro-ecosystem, and it is
impossible in a laboratory to mimic all factors that are involved in the tract.
In this PhD project, the sensitivity of a number of gastrointestinal mi-
crobes to manuka honey was first determined in the “simplest” condition
(i. e. an in vitro environment that is commonly used in an antimicrobial agent
sensitivity test; Chapter 4), followed by considering the anaerobic condi-
tions that could result in there being no hydrogen peroxide produced in
manuka honey (Chapter 5). The possible recovery in the growth of bacterial
cells simulating if honey is removed from the bacteria by absorption from
the intestine or by flow past immobilised bacteria in the gut was studied
(Chapter 6), then lastly the possible influence of the gastrointestinal pH as
well as enzymes on the potency of manuka honey was studied (Chapter
7). Note that in these chapters, each factor was considered separately. For
instance, in Chapter 7 where the effects of acidity and enzymes on the MIC
and MBC values was studied, the possible influence caused by the anaerobic
conditions is not taken into count. Similarly, in the pharmacodynamic assays
(Chapter 6) neither the presence / absence of oxygen nor the gastrointestinal
acidity/enzymes were considered. In vivo, these factors certainly would be
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involved simultaneously, but that would make the investigation much more
complex.
Despite the fact that the work in this thesis is over-simplified from
the viewpoint of the real gastrointestinal environment, the results of this
thesis do demonstrate that the antibacterial properties of manuka honey
may aid in the treatment of bacterial infection in the gut. Additionally, the
unexpected tolerance of probiotics to the antibacterial activity of manuka
honey may also help improve the gastroenteritis symptoms (as reviewed in
Chapter 1), as honey could be used therapeutically without disturbing their
growth. This may be helped by the prebiotic action of honey on probiotics
as described in Chapters 1, 4 and 6. However, the major concern to evaluate
whether or not honey is likely to help clear infection in the gastrointestinal
environment would be whether a sufficient concentration of honey could be
achieved in the tract, because the concentration of manuka honey would be
diluted in the gut by secretions and by water in food or drink. ORS (oral
rehydration solution) has been widely used to treat gastroenteritis, and
perhaps one may replace the carbohydrate component in ORS with manuka
honey so that the rehydration solution may provide an antibacterial function
in addition to merely rehydrating the patient. To achieve this, the amount of
the honey in the rehydration solution would need to be re-evaluated because
the concentration of the carbohydrate in ORS is 75 mmol/l (World Health
Organisation, 2006), or 0.87% v/v glucose. Considering that honey contains
approximately 40% glucose, the concentration of glucose in ORS would be
equivalent to that of 2.175% honey solution. This concentration of honey
is clearly too low to have a practical antibacterial effect on bacteria in the
gut, and therefore the recipe of the honey rehydration solution needs to be
modified rather than just replacing the glucose in ORS with the equivalent
strength of manuka honey. In the clinical trial done by Haffejee and Moosa
(1985), an oral rehydration soltuion that contained 5% (v/v) of pure honey
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(floral source not given) was used and achieved suscessful results and faster
clearance of bacterial infection. Another possible solution that may be of
some help to ensure the achievable antibacterial concentration of manuka
honey in the gut, and also the time the concentration of honey remains
above the MIC/MBC, would be to ingest the honey when the tract is empty
so that the active component in the honey would not be largely diluted
in vivo. It is also possible that there would be an increase in concentration of
antibacterial activity when water is abosrbed in the gut. However it is not
known whether or not the antibacterial factors in manuka honey would also
be absorbed in the gut, and further research is required to elucidate this.
The effect of acidic conditions and that of pepsin on the antibacterial
activity of manuka honey was unfortunately not determined successfully
because the acidity inhibited the bacteria. In theory, the antibacterial activity
of the honey due to hydrogen peroxide would be destroyed in harsh acid
conditions, as described in Chapter 7. On the other hand, it is not known if
the non-peroxide antibacterial component in manuka honey (now identified
as a high concentration of methylglyoxal; see later) is likely to be destroyed
in the gastric environment. Methylglyoxal has been reported to react with
arginine and lysine residues (Nemet et al., 2006) and is more reactive (i. e.
less stable) in alkaline than in acidic conditions (Nemet et al., 2006). However,
methylglyoxal accounts for only half of the non-peroxide activity because
an unidentified synergist is now known to be involved in the action of non-
peroxide antibacterial activity of the honey (Molan, 2008a). Therefore the
stability of this activity in the presence of pepsin and acid still needs to be
experimentally proved. If the gastric factor is of much concern, perhaps this
issue can again be minimised by ingesting manuka honey when the stomach
is empty because in the absence of chyme containing large quantities of
undigested proteins there would be less stimulation of secretion of gastrin,
and therefore acids and enzymes (Martini, 2001).
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Although measurements of MIC and MBC are commonly used to eval-
uate the efficacy of antibacterial agents, these parameters would not be
meaningful in the case of evaluating the treatment of enteropathogens using
honey. It is presumable that the fluidity of honey and the possibility of
the absorption of the antibacterial components in the honey would result
in a very short contact time of honey with bacteria in the gastrointestinal
tract. The time-to-kill and the postantibiotic assays have shown that the
MIC/MBC parameters are not sufficient to evaluate the efficacy of honey
in vivo because the conditions for the MIC/MBC test do not resemble that
in the tract in terms of the contact time. Also, although the results from
the postantibiotic effect assay conducted in this thesis have shown that the
antibacterial effect of manuka honey persists for a few hours after one hour
of partial inhibition, it is not known whether or not this effect would still
exist at lower honey concentration than that has been used in this thesis
(20%) and/or with shorter contact time of the honey with bacteria.
Note also that honey has also been reported to detach bacterial cells
from the host cells (Alnaqdy et al., 2005; Breton and Pineau, 1999). Attach-
ment to the gastrointestinal mucosa usually is the first step of infection by
enteropathogens, and therefore even if the antibacterial activity of honey
is not strong enough to inhibit bacteria, it may still be useful to treat the
pathogens if the honey is effective in detaching bacteria. Like the postan-
tibiotic effect assays, it would be of interest to test the effect of different
concentrations of the honey as well as that of different contact times on the
detaching effect in the future. Future work should also examine a range of
honeys to find the best type for detaching bacteria. Breton and Pineau (1999)
investigated Robinia pseudoacacia honey, lime-tree (Tilia spp.) honey, lavender
honey, chestnut honey, honeydew from conifers, citrus honey, alpine flowers
honey and “Gatinais” honey. Of these, R. pseudoacacia honey was found the
best. This suggests that the ability to detach varies between honeys.
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Furthermore, honey has been shown to have anti-inflammatory and
antioxidant activities (reviewed in Chapter 1). Since inflammation and
reactive oxygen species (ROS) play a role in gastroenteritis, the possible
usefulness of the anti-inflammatory and anti-oxidative activities of manuka
honey at different conditions may also warrant further studies.
8.2 Environmental stress and the efficacy of
antibacterial agents
Although in this thesis it was initially aimed to evaluate the usefulness
of manuka honey for treating bacterial gastroenteritis, by comparing the
MIC/MBC values obtained with conventional susceptibility testing with
those obtained when including some gastrointestinal factors (anaerobiosis,
exposure time, gastrointestinal acidity and enzymes), most of the environ-
mental factors studied may actually have also affected the bacterial cells
rather than have affected just the antibacterial activity of manuka honey
itself. For example, in Chapter 5 the effect of oxygen limitation on the ac-
tivity of the honey was investigated, because oxygen is required for the
production of hydrogen peroxide, but the results could also have been due
to oxygen limitation also affecting the sensitivity of bacteria to the non-
peroxide activity in manuka honey. In Chapter 7 the studies evaluating the
effect of acidity and enzymes (and bile salts) on the activity of manuka
honey could also have been showing the direct effect of these conditions on
the bacterial cells rather than on the honey.
Bacterial cells have developed numerous mechanisms to be able to sur-
vive a wide range of environments, and therefore it is important to take
the alteration in the environment to be used or the bacterial metabolism
pathway in to account when evaluating the efficacy of an antibacterial agent.
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E. coli, for example, regulates the production of the enzymes catalase and
superoxide dismutase by Fnr, ArcAB, OxyR and SoxRS regulatory systems
in response to dioxygen concentration so as to protect itself from reactive
oxygen species when it is in the air. Also, this species increases anaerobic
fermentative reactions to provide itself with energy in anaerobic conditions
such as in the intestinal tract (Sawers, 1999; Iuchi and Weiner, 1996). As
any environmental stress could trigger gene regulation responses that may
consequently alter the cell metabolism or the cell morphology, the alteration
in the culture environment may also directly or indirectly alter the effec-
tiveness of antimicrobial agents on the bacterial cells. Indeed, whilst some
wide-spectrum antibiotics such as chloramphenicol can be effective against
a large number of Gram positive, Gram negative aerobic, and anaerobic,
bacteria (Corey et al., 2007), some antibiotics such as metronidazole are
useful only in anaerobic conditions (Corey et al., 2007) due to the drug
being specific to the bacterial metabolism which occurs in anaerobiosis. In
fact, many studies have shown that even wide-spectrum antibiotics can have
different efficacy against a single species in different conditions. Suller and
Lloyd (2002) reported that whilst vancomycin gave similar MIC value and
duration of the postantibiotic effect in S. aureus under aerobic and anaerobic
conditions, the death rate was found to be greater in the presence of oxygen
than in anaerobic conditions. Nanavaty et al. (1998) reported that the MIC
of the aminoglycosides for E. coli remained unchanged under various of at-
mospheres (aerobic and anaerobic) and ion concentrations as long as the pH
was above 7, whereas the MIC increased up to 5-fold as the pH decreased
from 8.5 to 5.5. P. aeruginosa seems to be more resistant to environmental
stresses in anaerobic conditions than in aerobic conditions (Field et al., 2005;
Hill et al., 2005). One environment stress may also induce cross-protection in
bacterial cells against other unrelated stresses. It has been reported that after
adaptation to acidic conditions, L. monocytogenes demonstrated increased
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virulence and tolerance to thermal, osmotic or chemical (e. g. crystal violet
and ethanol) stresses (O’Driscoll et al., 1996). Alkaline stress on E. faecalis has
been reported to induce alteration in protein synthesis and cross-protection
to bile salts (Flahaut et al., 1997). Bile acids have been found to induce
biofilm formation in V. cholerae due to vps (Vibrio polysaccharide synthesis)
genes (Hung et al., 2006), which contributes to the possibility of increase
in tolerence to undesirable environments. These reports indicate the com-
plexity that needs to be taken into account when evaluating the efficacy
of an antibacterial agent in vivo solely from the conventional sensitivity
tests in vitro in which the MIC/MBC values are mostly obtained in simplest
conditions.
The findings from this thesis, unfortunately, do not demonstrate whether
or not the gastrointestinal environmental stress responses are likely to be
of any relevance to the efficacy of manuka honey in vivo. It was impossible
to evaluate the efficacy of manuka honey with regards to the alteration in
bacterial metabolism because the mechanism of the antibacterial activity
in manuka honey is not known. For instance, it is not clear in this stage
whether the increase in the MIC values of manuka honey in the presence
of pancreatin or bile is due to the antibacterial activity being decreased by
these substances, or due to cross-protection being induced in the bacterial
cells. Nonetheless, given that most MIC values and MBC values of manuka
honey in all conditions tested in this thesis are lower than those of artificial
honey, it is obvious that the antibacterial efficacy of manuka honey still
remains to some degree under most of the gastrointestinal environmental
conditions. Also, since the antibacterial action in honey is multi-factorial, it
would be more difficult for bacteria to respond and form protection against
honey than against antibiotics.
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8.3 Methylglyoxal in manuka honey
The component(s) responsible for the non-peroxide antibacterial activity in
manuka honey have remained unidentified for decades since the discovery
of this unusual activity. This has been because honey is complex in its
composition. It was not until much of the work in this thesis had been
completed that methylglyoxal (MGO; shown in Fig. 8.1) was identified
as the substance responsible for the non-peroxide antibacterial activity in
manuka honey (Adams et al., 2008; Mavric et al., 2008). However, an as-
yet unidentified synergist is also present which doubles the antibacterial
potency of MGO (Molan, 2008b,a).
Figure 8.1: The chemical structure of methylglyoxal (MGO).
Methylglyoxal, also called 2-oxo-propanal, is formed in organisms as
a side-product of several metabolic pathways, in which glycolysis is the
most important source (Inoue and Kimura, 1995). Methylglyoxal is highly
cytotoxic (Kalapos, 1999), although generally cells may detoxify it through
several mechanisms such as the glyoxalase systems, as shown in Fig. 8.2
(Thornalley, 2003; Vander Jagt, 1993).
The effects of methylglyoxal on living organisms is controversial and
remains to be clarified. While there have been a number of reports regarding
the toxicity of methylglyoxal to living organisms, some other research has
shown that methylglyoxal may not be toxic when used with ascorbic acid
and creatine, and that it may be safely used as an anticancer drug (Ghosh
et al., 2006). The high concentration of methylglyoxal in manuka honey
should not be of concern from a practical point of view. According to Adams
et al. (2008) and Mavric et al. (2008), the amount of methylglyoxal in manuka
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honey varies from 38 to 828 mg/kg. Most reports concerning the cytotoxicity
demonstrated the results by treating plants, mammals, yeasts (Saccharomyces
cerevisiae) and prokaryotes, either in vivo or in vitro, with approximately 10
mmol/l (720 mg/l) or higher concentration of methylglyoxal long-term
(Kalapos, 1999). If we apply this to human ingestion of manuka honey and
also consider that the human body contains about 50 litres of water, this
would mean one needs to take a dose of approximately 50 kg of manuka
honey with a high level of methylglyoxal to reach that cytotoxic amount
of methylglyoxal from the honey. Even then, there is a possibility that not
all of the methylglyoxal will be absorbed from the gut, and that some of
what does get absorbed will be broken down by metabolism. A number
of trials have been conducted in mammals, but the exceptionally high
doses the animals were subjected to in those trials may render questionable
the interpretations. For instance, Kalapos et al. (1991) reported that 800
mg/kg body weight of methylglyoxal was lethal in mice within 4 hours
after intraperitoneal injection. It is questionable if this is of meaning when
applied to humans consuming honey, as it equates to consuming about 50 kg
of honey in a single dose, even if all of the methylglyoxal is absorbed from
the gut. Similarly, Furihata et al. (1985) administered methylglyoxal ranging
300–600 mg/kg body weight by gastric tube to demonstrate an unscheduled
DNA synthesis in male F344 rats. Interestingly, despite the high level of
methylglyoxal being reported by Adams et al. (2008) and Mavric et al. (2008),
toxicity or related disease caused by ingesting manuka honey has never
been reported. Also to be noted is that in published reports on animal trials,
the animals were observed over days and but it is not clear how rapidly nor
how much the methylglyoxal in food would be absorbed in the gut. The
interacting effect of other ingredient (e. g. antioxidants) in food/honey on
the absorption of methylglyoxal and the action of the synergist in manuka
honey also remains to be elucidated.
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8.4 Conclusion
Manuka honey has been shown in published literature and in the work in
this thesis to be effective against a wide range of gastrointestinal pathogens,
although it is too early to conclude from the demonstrated data in this thesis
that the antibacterial activity of manuka honey would still be effective in the
intestine. In the work in this thesis it has been found that manuka honey
with a near median level of antibacterial activity tested against most of the
common enteropathogens inhibits at < 10%, kills at < 16.6%, and stunts the
growth for 2–3 hours at 20% if used in vitro. It was also found that the honey
loses no more than 50% of its antibacterial efficacy when tested in vitro under
most conditions simulating those in the intestine (anaerobiosis and in the
presence of intestinal components). Because acidity itself inhibits bacteria,
it is not known whether or not the honey would work in the stomach.
However, published findings have shown that the activity of honey is not
harmed by exposure to low pH then neutralisation, therefore it should still
be effective once it passes through the stomach to the intestines.
Gastroenteritis has generally been treated with oral rehydration therapy
(ORT) that consists of carbohydrates and electrolytes. In addition to its
antibacterial action, manuka honey could also be used to provide carbohy-
drates in an electrolyte solution to rehydrate patients with gastroenteritis.
Furthermore, because honey also provides additional bioactivities that the
conventional ORS does not have (such as antioxidant, anti-inflammatory
and prebiotic activity), it is likely that a rehydration solution containing
manuka honey and electrolytes would be superior to ORS. With an appro-
priate recipe of honey rehydration solution and further investigation to find
the most appropriate dosage and frequency of doses, a clinical trial may be
warranted.
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8.5 Future work
There is always no end for a research study, and during this project a
number of new questions and interesting topics arose. This section gives
some suggestions on future work that could be done if further research
studies are to be carried out.
8.5.1 Enteropathogens other than common gastrointestinal
pathogens
The gastrointestinal environment is a rather complex reservoir of microor-
ganisms, and it is believed that there are still many species of bacteria
that have not been identified or cannot even be cultured but have shown
potential to cause diseases. Despite the fact that Campylobacter is one of the
most predominant causes of gastroenteritis, and also that the majority of
Campylobacter spp. appear to be C. jejuni and C. coli (as identified in Section
2.4), many other “Campylobacter spp., Helicobacter and related organisms”
(CHRO) have been strongly indicated to be involved in human diarrhoea
(Stephen On, ESR, Christchurch; personal communication). Also, an increas-
ing number of bacteria, including Campylobacter spp. and E. coli, are now
known to enter a viable but nonculturable (VBNC) state (Oliver, 2005).
The determination of the sensitivity of the CHRO or VBNC can be
quite challenging because, as described above, these organisms cannot be
cultured with microbiological techniques available today. In other words,
susceptibility assays based on bacterial culture would not be feasible unless
new culturing techniques for these unusual microbes are established. Since
many of these organisms are thought to be clinically important, it would be
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worth considering an investigation into the efficacy of manuka honey against
these microorganisms once ways of testing them have been developed.
8.5.2 The efficacy of honey on viral gastrointestinal disease
Although the focus of this project has been bacterial gastrointestinal disorder,
it should be noted that a large proportion of gastroenteritis is caused by
viruses. Norovirus and rotavirus are the most common causes of viral
gastroenteritis and have caused several notable outbreaks over the world.
There has not been an effective treatment against these viruses other than to
apply oral rehydration therapy.
Although honey has been reported to be effective against bacteria,
relatively little is known about its antiviral activity. Haffejee and Moosa’s
clinical report showed that honey halved the duration of the symptom of
bacterial but not viral diarrhoea (Haffejee and Moosa, 1985). Al-Waili (2004)
reported that honey revealed a better healing result on labial herpes, genital
herpes and lesions than acyclovir did. It would be of much interest to see
whether or not honey would be of some help to treat viral gastroenteritis.
8.5.3 The efficacy of honey on protected enteropathogens
Most food-borne pathogens get into the gastrointestinal system through the
diet. Campylobacter and Salmonella spp., for example, usually exist in chicken
and pork. If the contaminated meat is not well cooked, the organisms are
ingested along with the meat. Bacillus spp. may also exist in rice. When these
organisms get into the body through food, the cells are protected by the
food substrate such as protein or lipid, which may provide the organisms
a protection from the digestive fluid or enzymes in the body. There has
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been a report showing that bacteria inoculated on a food matrix revealed
higher resistance to acid than the ‘naked’ control (Waterman and Small,
1998). In another research study using a simulated gastric fluid to examine
the survival of E. coli O157:H7 and some Shigella, it was reported that the
inactivation rate significantly declined if cooked ground beef was included
(Tamplin, 2005), suggesting that food ingredients can provide bacteria with
a protective matrix against environmental stress.
Forming a biofilm is another way a bacterial species protects itself from
a hostile environment. Many bacteria including Campylobacter spp. and H.
pylori have been reported to form biofilms in the gastrointestinal tract, and
this is thought to be one of the reasons why H. pylori eradication therapy
sometimes fails (Buswell et al., 1998; Carron et al., 2006; Cole et al., 2004).
Although honey has recently been reported to be able to inhibit P. aeruginosa
in biofilms (Cooper and Jenkins, 2008), more research studies are required
because the work done by Cooper and Jenkins (2008) used topical treatment
of the P. aeruginosa biofilm with honey whereas this inhibition may not
occur in the gastrointestinal tract where an enteric biofilm is unlikely to be
persistently exposed to honey. The effect of the state of bacteria e. g. biofilm
versus planktonic on the efficacy of honey will also have to be investigated
in future.
8.5.4 Pharmacodynamics
In Chapter 6 where the postantibiotic effect assay was described, bacteria
were exposed to 20% of manuka honey for 1 h. In the gut, the time bacterial
cells are exposed to honey may be shorter. Therefore in future work it would
be worth studing various conditions of pharmacodynamics, such as finding
if the postantibiotic effect is induced with a very short exposure time (0.5 h
or even shorter) to manuka honey.
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In the preliminary work, 5%, 10%, 15% and 20% solutions of manuka
honey were tested with S. aureus ATCC 15923, and the postantibiotic effect
was found to be 1.15 h, 2.42 h, 2.46 h and 2.53 h, respectively. It is of interest
that whereas the postantibiotic effect of 5% honey was shorter than that of
20%, that of 10% and 15% were almost equivalent to that of 20%, suggesting
that the postantibiotic effect of manuka honey on S. aureus may not be
concentration-dependant once the concentration of the honey is above the
MIC. It would be of interest to see if this is applicable to other organisms.
The determination of the pharmacodynamic parameters can go one
step further, so that the sub-MIC effect (SME) and the postantibiotic-sub
MIC effect (PA-SME) can also be determined. The sub-MIC effect is defined
by the formula SME = Ts −C, where Ts is the time it takes for the culture
exposed only to sub-MICs to increase 1 log10 unit above the counts ob-
served immediately after washing and C is the corresponding time for the
unexposed culture (Odenholt-Tornqvist et al., 1991; Odenholt, 2001). The
PA-SME, on the other hand, is defined by the formula PA− SME = Tpa −C,
where Tpa is the time for the previously antibiotic-exposed cultures, which
thereafter had been exposed to different sub-MICs, to increase by 1 log10
unit above the counts observed immediately after washing and C is the
corresponding time for the unexposed culture (Odenholt-Tornqvist et al.,
1991; Odenholt, 2001).
In Chapter 6 it was noted that an improved yet standardised method for
pharmacodynamics assays needs to be developed, because otherwise it is
not feasible to examine the pharmacodynamics property for a large number
of samples.
8.5.4.1 The mechanisms of PAE induced by honey in microorganisms
Stubbings et al. (2006) carried out an interesting research using E. coli to
observe the recovery in macromolecular synthesis during the postantibiotic
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effect stage induced by rifampicin and gentamicin, and found that the length
of the postantibiotic effect coincided with the recovery of synthesis of either
RNA, protein or both, depending on which antibiotics were used. Examining
the recovery of the synthesis of macromolecules (DNA, RNA and protein)
in different microorganisms during the honey-induced postantibiotic effect
stage may be of some help in understanding the mechanism of the action of
the non-peroxide antibacterial activity in manuka honey.
8.5.5 The effect of honey on probiotics
Probiotics, or beneficial bacteria, are considered to be competing against
other organisms, which may be pathogenic, by means of colonization and se-
creting antibacterial component such as lactate, lantibiotics, etc. From the sus-
ceptibility tests done in this thesis project, it was realized that the MIC/MBC
of manuka honey for probiotics are higher than those for pathogens.
Several probiotics are known to produce antimicrobial substances to
help compete with other organism. Nisin is one of the well known examples
and its synthesis and mechanisms of action have been investigated in
many research studies (Chatterjee et al., 2005; Cheigh and Pyun, 2005;
Bernbom et al., 2006; Joerger, 2003). However the relationship between
the production of nisin and the effect of honey on stimulating the growth
of probiotics is unknown. As nisin or Lactobacillus-produced antibiotics
(lantibiotics) are produced primarily for competing with other organisms,
the amount of production may not be relevant to the number of the cells
or the growth rate. Honey has been reported to reveal a potential prebiotic
activity (Chick et al., 2001; Ezz El-Arab et al., 2006; Rosendale et al., 2008;
Sanz et al., 2005; Shamala et al., 2000; Shin and Ustunol, 2005) and this
is thought to be due to oligosaccharides in the honey. Understanding the
relationship between honey, probiotics and lantibiotics would be useful
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for either treating or preventing gastrointestinal disorders without using
antibiotics. One significant example is protection of the gut from antibiotic-
associated diarrhoea (AAD) such as C. difficile-associated diarrhoea (CDAD)
that has been described previously in Sections 1.3.5 and 1.4.2. If the beneficial
bacteria are stimulated or strengthened, it would increase the protection of
the body from infection. Even if one is infected by an enteropathogen, the
dosage of antibiotics could be reduced or even omitted if proper use of the
microflora is made.
In Chapter 6 it was found that probiotics are not only relatively resistant
to the antibacterial activity of the manuka honey than are enteropathogens,
but also their growth is stimulated by the honey compared with the control
group in a plain medium. This suggests the possibility that honey may
stimulate the ability of probiotics to compete with pathogens. If this hy-
pothesis is true then humans may strengthen their resistance to bacterial
gastrointestinal diseases by taking honeys, even though the reachable con-
centration may be lower than the MIC for the causative enteropathogens.
To investigate this, several experiments will need to be done. The first is
to co-culture probiotics with enteropathogens in broth medium and ob-
serve their growth so that, based on the growth profile, we may compare
the effect of honey on both probiotics and enteropathogens. The second
is to investigate the effect of honey on the attachment of organisms on
intestinal cells. As attachment on intestinal epithelial cells is the first step of
bacterial infection, the prevention of attachment of pathogenic organisms
would reduce the possibility of the disease. Some research has revealed
the usefulness of honey regarding this (Alnaqdy et al., 2005; George et al.,
1978a). Alnaqdy et al. (2005) co-incubated Salmonella spp. with intestinal
epithelial cells, and the authors observed that the Salmonella spp. treated
with 12.5% honey had lower adherence than those not treated with honey.
George et al. (1978a) did not state the floral source of the honey nor the
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species of the rat’s oral flora they had used, but they observed that honey
reduced the thickness of epithelial attachment. It is not known whether
these results are because the honey treatment caused the loss of the viability
and thus the activity of the bacterial cells or because the honey affected
components of the bacterial cell walls or the epithelial cell membranes so
that the organisms are less likely to adhere to the receptors on the epithelial
cells. It would be of interest to see if this phenomenon can be observed with
other gastrointestinal microorganisms, as the same effect of honey may also
reduce the adherence of probiotics to epithelial cells. The last trial would be
to treat both epithelial cells and bacteria with honey, wash it off, and then
investigate if honey has any effect on the interaction between epithelial and
bacterial cells.
8.5.6 The mechanism of the non-peroxide antibacterial activity
in manuka honey
The lack of a detailed understanding of the nature of the non-peroxide
antibacterial component in manuka honey has made it difficult to explore the
mechanism of action of the antibacterial property of manuka honey over the
decades since its discovery. The recent discovery that methylglyoxal (MGO)
is responsible for the non-peroxide antibacterial activity of manuka honey
(Adams et al., 2008; Mavric et al., 2008) and the identification of its source
being dihydroxyacetone abundantly contained in the nectar from manuka
trees (Adams et al., 2009) gives some clues on the long-lasting mysteries on
the antibacterial properties of the honey. However, several puzzles that have
existed for years now turn into the following paradoxes - how and why does
the methylglyoxal in manuka honey inhibit or even kill bacteria, without
causing any emergence of resistant species (Blair et al., 2009; Cooper et al.,
2009) like most other antibacterial agents do? Since methylglyoxal is largely
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responsible for the non-peroxide antibacterial activity of manuka honey,
would any bacteria that are resistant to methylglyoxal also be resistant
to, or at least tolerate, the antibacterial activity of manuka honey? Why
does the synergy in the potency of antibacterial activity occur only when
methylglyoxal is added to manuka honey but not to other types of honey?
Now that the non-peroxide antibacterial substance has been unveiled,
investigating how methylglyoxal works in manuka honey should be the
next research topic to be focused on, so that this therapeutic property of
honey can be yet further understood and utilised. More research needs
to be done on the mechanism by which pure methylglyoxal kills bacteria,
since little has been published on this. Then the mechanism of action of
methylglyoxal in manuka honey needs to be studied in comparison to gain
an understanding of how the synergist in manuka honey works.
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Abstract We report the antimicrobial effect of manuka
honey against Campylobacter spp. isolated by a diagnostic
laboratory from specimens from a community in New
Zealand. The isolates were differentiated according to
species level using multiplex PCR. C. jejuni (20 strains)
and C. coli (7 strains) were identified. The clinical isolates
identified and type culture collection strains of these species
were subjected to testing to determine the minimum
inhibitory concentration (MIC) of manuka honey using a
microdilution technique. The MIC of the manuka honey
against all of the Campylobacter tested was found to be
around 1% (v/v) honey. The low MIC values suggest that
honey might still inhibit the growth of campylobacteria
after dilution by fluid in the gut, but the actual concentration
of honey that can be achieved in the intestine is unknown.
Therefore, clinical investigation is required to establish the
efficacy of honey against Campylobacter spp. in the gut
environment.
Introduction
Campylobacter spp. is a widespread zoonotic pathogen and
has been recognised as a leading cause of gastroenteritis
worldwide. The prevalence of campylobacteriosis has been
reported to outnumber that of enteritis caused by other
common food-borne pathogens such as Salmonella spp. or
Escherichia coli in several developed and developing
countries [1, 2]. New Zealand has the highest prevalence
of campylobacteriosis in the developed world [3].
Campylobacter spp. is fastidious in respect of nutrition
and atmosphere; therefore, strict growth conditions are
required for survival, although Campylobacter spp. have an
extremely low infectious dose of 500 cells [4, 5]. Mostly,
campylobacteriosis is self-limited, and it can be treated with
antibiotics such as fluoroquinolones. However, deaths have
been reported occasionally [6, 7] and its linkage to
Guillain-Barré syndrome [8] and abortion [9] is also of
great concern. Furthermore, although not reported yet in New
Zealand, antibiotic-resistant strains have been reported in
developed and developing countries [10–12]. The increasing
rate of resistance to antibiotics is thought to be due to the
over-use of antibiotics in veterinary treatment [13].
A clinical trial has been conducted in which it was found
that administration of honey halved the duration of bacterial
diarrhoea [14] and although in that clinical report the
function of re-hydration was emphasised, the easing of the
symptoms may also have been due to the antibacterial
activity of honey, since honey shortened the duration of
bacterial diarrhoea, but not that of viral diarrhoea. Honey
has been used as a treatment for wound infections since
ancient times [15], and has been found to inhibit the growth
of a wide range of bacterial species in vitro [16]. However,
there have been very few studies testing the efficacy of
honey against the widespread Campylobacter spp. Al-
though Adebolu reported the effect of two types of African
honey on diarrhoea-causing bacteria, including one strain of
C. jejuni [17], there were several shortcomings in that
report that may cast doubt upon the reliability of the results
published. From that report it is not known whether or not
other strains or species of Campylobacter had the same
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sensitivity to honey. Also in that report, Adebolu used the
agar diffusion method with nutrient media [17], which may
not be suitable for testing the sensitivity of slow-growing
bacteria like Campylobacter spp. against honey, as the
honey may have diffused out into the agar to a level below
the MIC by the time the organism had grown. But most
importantly, in that paper tests were carried out with types
of honey whose antimicrobial potency had not yet been
determined; yet, the potency of antibacterial activity in
honey may in fact vary up to 100-fold [18], and the
reported sensitivity of the strain of C. jejuni to Adebolu’s
honey could have been one hundred times higher or lower
than the sensitivity to any other randomly chosen honey on
the market.
A few types of honey, such as manuka honey from
Leptospermum scoparium in New Zealand, are reported to
have particularly high antimicrobial activity against various
bacterial species [19]. Manuka honey is coming into
widespread usage for the treatment of infected wounds
[20]. Therefore, the objectives of this study were to
investigate the antibacterial activity of manuka honey
against a number of clinical isolates of Campylobacter
spp. from clinical patients with diarrhoea using the broth
dilution method. The manuka honey we used had its
antimicrobial activity standardised against a reference
antiseptic, phenol. To distinguish the effect of the antibac-
terial component of honey from any osmotic effects,
artificial honey, which was syrup simulating the sugar
composition of honey, was also used for comparison.
Materials and methods
Honey samples
The manuka honey used in this work had the strength of its
antibacterial activity assayed by the method described by
Allen et al. with catalase added [19]. This is an agar well
diffusion assay that compares the activity of honey with
that of a standard antiseptic phenol. The manuka honey
used had activity equivalent to that of 29.4% phenol when
tested against Staphylococcus aureus ATCC 25923. Artificial
honey was made up, containing 30.5% glucose, 37.5%
fructose and 1.5% sucrose, and was dissolved in distilled
water [21]. The two types of honey were stored in the dark at
4°C until used.
Microbiological materials
Campylobacter spp. is widely known as a fastidious
pathogen and requires strict control of growth conditions.
The National Committee for Clinical Laboratory Standards
(NCCLS) has suggested an outline for investigating the
susceptibility of Campylobacter to antibiotics [22]; none-
theless, a “gold standard” protocol for studying this genus
does still not exist [23]. For instance, the agar dilution
method using Mueller–Hinton agar supplemented with 5%
defibrinated sheep blood is recommended in the outline
where the blood is added to the medium to protect
Campylobacter spp. from damage by oxygen-derived
components such as free radicals and hydrogen peroxide
[24, 25]. However, it is not applicable in this study because
the antibacterial activity of manuka honey may be partially
due to hydrogen peroxide [16, 26], which would be
inactivated by catalase present in blood. Instead, freshly
made Mueller–Hinton broth was used in the susceptibility
test. Blood-free Campylobacter selective agar (Oxoid)
containing amphotericin and cefoperazone (LAB M) as
selective agents was used to culture the isolates. Brain
heart infusion yeast extract broth (BHIYE, with 0.6%
yeast extract) supplemented with FBP (0.025% ferrous
sulfate, 0.025% sodium metabisulfite and 0.025% sodium
pyruvate) [27, 28] was used for enrichment, and that
containing 15% sterile glycerol was used as a cryopre-
servative agent.
Campylobacter samples
Campylobacter clinical isolates were kindly provided by
Chris Picket (Medlab, Hamilton, New Zealand)) and were
stored in fastidious anaerobe transport swabs (Copan Italia,
Brescia, Italy) when transporting them from Medlab to the
Honey Research Unit. The isolates were then streaked on
selective agar plates and cultured at 37°C in a micro-
aerobic atmosphere generated with the spirits burn method
[29] for 2 days. The cultures recovered were enriched in
BHIYE-FBP and incubated overnight micro-aerobically as
above, then dispensed into small vials containing cryopre-
servative agent and stored at −70°C. Type culture collection
strains C. jejuni (ATCC 33560) and C. coli (ATCC 33559)
were also processed in this way as growth controls.
As Medlab only differentiates the isolates to genus level,
extra differentiation work to species level was needed for
investigating the effect of manuka honey on different
species of Campylobacter. In this research the multiplex
polymerase chain reaction was used to do this [30].
Campylobacter DNA extraction
Campylobacter DNAwas extracted by boiling. A loopful of
colony for each isolate was taken from its culture plates,
resuspended in 100 µl of distilled water, heated in a boiling
water bath for 10 min and chilled on ice for another 10 min,
followed by the addition of 100 µl of chloroform and brief
centrifuging. The supernatant was stored at −20°C until the
PCR test was carried out.
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Multiplex PCR
Each PCR mix (20 µl) consisted of 6 µl of DNA templates,
2.4 µl of 20 µmol/l primers mix (Sigma), 8 µl of
HotMasterMix (×2.5; Eppendorf) and 3.6 µl of MilliQ
water. The primers used in this work are shown in Table 1.
The DNA amplification procedure was carried out in a
PTC-100 thermocycler (MJ Research, Waltham, MA,
USA). The cycling conditions used were 94°C for 2 min as
initial denaturation, followed by 30 cycles of amplification
(denaturation at 95°C for 30 s, annealing at 59°C for 20 s,
extension at 68°C for 40 s) and 68°C for 6 min for the final
extension. The amplified products were electrophoresed in
1.5% agarose gel and analysed using the ScionImage system.
Susceptibility test
Inoculum preparation
Each isolate was recovered by rubbing the surface of the
frozen culture with a sterilised cotton swab, then streaking
onto blood-free Campylobacter selective agar and incubating
micro-aerobically for 48 h at 37°C. The colonies recovered
were collected with a cotton swab and suspended in
Mueller–Hinton broth. The optical density at 625 nm was
adjusted to 0.08 with fresh broth and was then further diluted
500-fold. This gave a final culture density of approximately
105 cfu/ml after inoculating the honey solution in the
microplate wells. The inoculum density was confirmed using
the track dilution method [31].
Susceptibility test
A 10% (v/v) solution of manuka honey and 20% (v/v)
artificial honey were prepared with Mueller–Hinton broth
and filter-sterilised with a 0.2-µm filter (Sartorius) before
serial dilution. As the MIC of artificial honey would
presumably be higher than that of manuka honey, 20% (v/v)
solution of artificial honey was used in this test.
Of the 12 columns in a microplate, the first column was
added with 40 µl of manuka honey, the second to the tenth
with 40 µl of Mueller–Hinton broth and the last two with a
growth control (Campylobacter spp. and Mueller–Hinton
broth added) and sterility check (plain Mueller–Hinton
broth). For serial dilution 160 µl of honey was added into
the second column, which was then sequentially transferred
to the following wells up to the tenth well. After that, 80 µl
of inoculum was added into each well except the last well,
in which 80 µl of plain Mueller–Hinton broth was added
instead so that the final concentrations of the honey were
3.33%, 2.66%, 2.13%, 1.70%, 1.36%, 1.09%, 0.87%, 0.7%,
0.56% and 0.45% after inoculation. The final concentra-
tions of artificial honey would be twice of those of manuka
honey.
The plate was incubated micro-aerobically at 37°C for
48 h. The lowest concentration of honey needed to
completely inhibit the growth of the isolate was considered
to be its MIC. After this, from each well, 1 µl was
subcultured onto blood-free Campylobacter-selective agar
to see if the honey was bacteriostatic or bacteriocidal to
Campylobacter spp. The cultures in the growth control
wells were also subcultured as positive controls. The
susceptibility test for each species was replicated up to five
times. The difference between the two types of honey in the
results was analysed using the Wilcoxon test in the
statistical package R (http://www.r-project.org) [32].
Results
Multiplex PCR identification
According to the multiplex PCR, of the 27 clinical isolates
collected from Medlab, 20 were identified as C. jejuni and
the rest as C. coli.
Susceptibility test
The susceptibility test revealed that the growth of all 29
species was largely inhibited by both manuka honey and
artificial honey (Table 2). For both C. jejuni and C. coli, the
MIC of manuka honey was significantly lower than that of
artificial honey (P<0.01). The MIC of manuka honey ranged
from 0.8% to 1.1%, whereas that of artificial honey was 3–4
times higher than that of manuka honey (3.1–4.3%).
The subculturing after determining the MIC showed that
growth occurred when subculturing from concentrations of
honey below the MIC, whereas there was no growth from
Table 1 Oligonucleotide primers and their amplicon sizes used in this study [30]
Species Target gene Sequence (5′-3′) GeneBank accession no. Amplicon size (bp)
C. jejuni C. jejuni hipO Forward: ACTTCTTTATTGCTTGCTGC Z36940 323
Reverse: GCCACAACAAGTAAAGAAGC
C. coli C. coli glyA Forward: GTAAAACCAAAGCTTATCGTG AF136494 126
Reverse: TCCAGCAATGTGTGCAATG
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concentrations at and above the MIC. This revealed that the
MIC of either manuka honey or artificial honey was also
the minimum bacteriocidal concentration for all of the
Campylobacter isolates in this study.
Discussion
Although the manuka honey used in the present study had a
level of activity twice as high as that of the manuka honey
used in other studies published, overall, the average
concentration of manuka honey required to inhibit the
growth of all the Campylobacter spp. tested was still far
lower than that required to inhibit most other micro-
organisms with manuka honey [33–38]. Although the data
obtained from this study cannot fully represent the profile
of the genus Campylobacter, our results establish that the
species tested are susceptible to both the antibacterial
components and the osmolarity of manuka honey. Manuka
honey has been reported to be highly effective against various
pathogens, including methicillin-resistant Staphylococcus
aureus (MRSA) and vancomycin-resistant enterococci
(VRE) [34], and its low pH, low water activity, slowly
released hydrogen peroxide and phytochemical antimicro-
bial components are collectively thought to be responsible
for its high efficacy against bacteria [26]. The result in this
work revealed that the efficacy is also observable on
Campylobacter, regardless of strain.
In this study we also observed that even a low
concentration sugar solution was effective against the
isolates, which may suggest that Campylobacter spp.
would be highly susceptible to osmolarity. Doyle [39]
reported that C. jejuni could grow in brucella broth
containing 1.5% of NaCl, but failed in 2.0% NaCl or
greater, and although a large amount of C. jejuni (105–
106 cfu/ml) may increase the tolerance in 6.5% salt at 4°C,
the viable cells significantly decreased in 4.5% salt at
room temperature. In that report Doyle showed that
nalidixic acid-resistant thermophilic Campylobacter
(NARTC) was generally tolerant to salt concentration;
yet, it was still unable to grow in the presence of 2.5%
NaCl. Doyle also noted that a few strains would adapt to
up to 6.5% NaCl after frequent subculturing and claimed
that osmolarity might not be ideal for inhibiting the
growth of Campylobacter spp., but this increasing toler-
ance against osmotic solution was not observed in our
studies. Interestingly, Reezal et al. [40] noted that the
osmotic effect on Campylobacter was seen regardless of
whether the osmolyte in the medium was glucose or salts.
Accordingly, the high susceptibility of Campylobacter
spp. to honey solutions observed in this study may be due
in part to the osmotic effect of the sugar content as well as
to other antimicrobial factors.
The high susceptibility of Campylobacter spp. to
osmolarity, however, may not be of practical consequence
from an antimicrobial viewpoint. The concentration of
sugar in the gut would decline rapidly down below the
effective dosage through absorption and may not inhibit the
growth of Campylobacter spp. in the gut. Sugar is usually
used for oral rehydration therapy or as immediate treatment
for hypoglycaemia due to its rapid absorption through
intestinal villi [41]. Therefore, dietary sugar is unlikely to
contribute to the inhibition of campylobacteriosis. At this
stage it is not known whether the phytochemical antibac-
terial component of manuka honey [42, 43] would be
absorbed in a short time or would remain in the gut to
inhibit bacterial growth after honey has been ingested. It
Table 2 Minimum inhibitory concentration (percentage v/v) of
manuka honey and artificial honey for each strain
Strains Manuka honey Artificial honey
C. jejuni 1 0.84±0.08 3.13±0.39
C. jejuni 2 1±0.12 3.58±0.38
C. jejuni 3 1±0.12 3.44±0.55
C. jejuni 4 0.8±0.09 3.13±0.39
C. jejuni 5 0.88±0.14 3.58±0.38
C. jejuni 6 1.05±0.1 3.27±0.32
C. jejuni 7 0.92±0.17 3.75±0.47
C. jejuni 8 0.96±0.12 3.75±0.47
C. jejuni 9 1±0.12 3.92±0.47
C. jejuni 10 0.8±0.09 3.58±0.38
C. jejuni 11 0.91±0.1 3.58±0.38
C. jejuni 12 1.05±0.1 3.92±0.47
C. jejuni 13 0.96±0.12 3.92±0.47
C. jejuni 14 0.88±0.14 3.61±0.66
C. jejuni 15 0.96±0.12 3.75±0.47
C. jejuni 16 1.05±0.1 3.75±0.47
C. jejuni 17 0.8±0.09 3.92±0.47
C. jejuni 18 1±0.12 3.92±0.47
C. jejuni 19 0.96±0.12 3.58±0.38
C. jejuni 20 0.92±0.17 3.61±0.66
C. jejuni ATCC 33560 1±0.12 3.58±0.38
C. coli 1 1.05±0.1 4.09±0.38
C. coli 2 1±0.12 4.3±0.68
C. coli 3 1.14±0.12 4.09±0.38
C. coli 4 1.1±0.17 3.92±0.47
C. coli 5 1.2±0.15 3.92±0.47
C. coli 6 1.14±0.12 4.09±0.38
C. coli 7 1.1±0.17 3.92±0.47
C. coli ATCC 33559 1.05±0.1 4.09±0.38
Mean of C. jejuni (n=21) 0.94±0.08 3.63±0.24
Mean of C. coli (n=8) 1.1±0.06 4.05±0.13
The values are represented as means of the replicates ± standard
deviation. The numbers of the replicates are given in parentheses. The
determination of the MIC values for each isolate was replicated five
times
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would be of interest to investigate in the future whether or
not this component is absorbed in the gut.
In short, of the Campylobacter spp. isolates most were
identified as C. jejuni and C. coli, and these were found to
be sensitive to the types of honey used in this work. An
unspecified type of honey with unknown antibacterial
potency [14] has been reported to ease the symptoms of
bacterial diarrhoea, and the findings in the present study on
the susceptibility of Campylobacter spp. to manuka honey
also suggest that honey might be useful for treating
bacterial diarrhoea.
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